<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><front><journal-meta><journal-id journal-id-type="nlm-ta">Microorganisms</journal-id><journal-id journal-id-type="iso-abbrev">Microorganisms</journal-id><journal-id journal-id-type="pmc-domain-id">3054</journal-id><journal-id journal-id-type="pmc-domain">microorg</journal-id><journal-id journal-id-type="publisher-id">microorganisms</journal-id><journal-title-group><journal-title>Microorganisms</journal-title></journal-title-group><issn pub-type="epub">2076-2607</issn><publisher><publisher-name>Multidisciplinary Digital Publishing Institute  (MDPI)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8145166</article-id><article-id pub-id-type="pmcid-ver">PMC8145166.1</article-id><article-id pub-id-type="pmcaid">8145166</article-id><article-id pub-id-type="pmcaiid">8145166</article-id><article-id pub-id-type="pmid">33922370</article-id><article-id pub-id-type="doi">10.3390/microorganisms9050899</article-id><article-id pub-id-type="publisher-id">microorganisms-09-00899</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Insights into Antibody-Mediated Alphavirus Immunity and Vaccine Development Landscape</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0003-0447-3131</contrib-id><name name-style="western"><surname>Torres-Ruesta</surname><given-names initials="A">Anthony</given-names></name><xref ref-type="aff" rid="af1-microorganisms-09-00899">1</xref><xref ref-type="aff" rid="af2-microorganisms-09-00899">2</xref><xref ref-type="author-notes" rid="fn1-microorganisms-09-00899">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chee</surname><given-names initials="RSL">Rhonda Sin-Ling</given-names></name><xref ref-type="aff" rid="af1-microorganisms-09-00899">1</xref><xref ref-type="author-notes" rid="fn1-microorganisms-09-00899">&#8224;</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Ng</surname><given-names initials="LFP">Lisa F.P.</given-names></name><xref ref-type="aff" rid="af1-microorganisms-09-00899">1</xref><xref ref-type="aff" rid="af2-microorganisms-09-00899">2</xref><xref ref-type="aff" rid="af3-microorganisms-09-00899">3</xref><xref rid="c1-microorganisms-09-00899" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Arien</surname><given-names initials="KK">Kevin K.</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-microorganisms-09-00899"><label>1</label>A*STAR Infectious Diseases Labs (A*STAR ID Labs), Agency for Science, Technology and Research (A*STAR), Singapore 138648, Singapore; <email>anthony_torres@IDLabs.a-star.edu.sg</email> (A.T.-R.); <email>rhonda_chee@IDLabs.a-star.edu.sg</email> (R.S.-L.C.)</aff><aff id="af2-microorganisms-09-00899"><label>2</label>Department of Biochemistry, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117596, Singapore</aff><aff id="af3-microorganisms-09-00899"><label>3</label>Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool L69 3BX, UK</aff><author-notes><corresp id="c1-microorganisms-09-00899"><label>*</label>Correspondence: <email>Lisa_Ng@IDLabs.a-star.edu.sg</email>; Tel.: +65-6407-0028</corresp><fn id="fn1-microorganisms-09-00899"><label>&#8224;</label><p>Both authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="epub"><day>22</day><month>4</month><year>2021</year></pub-date><pub-date pub-type="collection"><month>5</month><year>2021</year></pub-date><volume>9</volume><issue>5</issue><issue-id pub-id-type="pmc-issue-id">382426</issue-id><elocation-id>899</elocation-id><history><date date-type="received"><day>19</day><month>3</month><year>2021</year></date><date date-type="accepted"><day>16</day><month>4</month><year>2021</year></date></history><pub-history><event event-type="pmc-release"><date><day>22</day><month>04</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>26</day><month>05</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-05-03 22:25:13.497"><day>03</day><month>05</month><year>2024</year></date></event></pub-history><permissions><copyright-statement>&#169; 2021 by the authors.</copyright-statement><copyright-year>2021</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="microorganisms-09-00899.pdf"/><abstract><p>Alphaviruses are mosquito-borne pathogens distributed worldwide in tropical and temperate areas causing a wide range of symptoms ranging from inflammatory arthritis-like manifestations to the induction of encephalitis in humans. Historically, large outbreaks in susceptible populations have been recorded followed by the development of protective long-lasting antibody responses suggesting a potential advantageous role for a vaccine. Although the current understanding of alphavirus antibody-mediated immunity has been mainly gathered in natural and experimental settings of chikungunya virus (CHIKV) infection, little is known about the humoral responses triggered by other emerging alphaviruses. This knowledge is needed to improve serology-based diagnostic tests and the development of highly effective cross-protective vaccines. Here, we review the role of antibody-mediated immunity upon arthritogenic and neurotropic alphavirus infections, and the current research efforts for the development of vaccines as a tool to control future alphavirus outbreaks.</p></abstract><kwd-group><kwd>alphavirus</kwd><kwd>antibody</kwd><kwd>immunity</kwd><kwd>alphavirus vaccine</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1-microorganisms-09-00899"><title>1. Introduction</title><p>Mosquito-borne alphaviruses are Group IV viruses that belong to the family Togaviridae [<xref rid="B1-microorganisms-09-00899" ref-type="bibr">1</xref>]. They are enveloped, positive-sense, single-stranded RNA viruses with a size of &#8776;70 nm bearing a &#8776;11.7 kilobases genome which encodes four non-structural proteins (nsP1, nsP2, nsP3 and nsP4) that serve as the virus&#8217; replication machinery, and five structural proteins (capsid, E3, E2, 6K and E1) that participate in the envelope assembly process [<xref rid="B1-microorganisms-09-00899" ref-type="bibr">1</xref>]. Clinically, alphavirus infections in humans results in the development of viremia followed by an onset of febrile symptoms [<xref rid="B2-microorganisms-09-00899" ref-type="bibr">2</xref>]. The development of inflammatory conditions compromising joints and muscle tissues has been associated to arthritogenic alphaviruses such as chikungunya virus (CHIKV), O&#8217;nyong nyong virus (ONNV), Mayaro virus (MAYV), Ross River virus (RRV), Semliki Forest virus (SFV) and Sindbis virus (SINV) with records of persistent polyarthralgia in a fraction of patients. Conversely, neurotropic alphaviruses such as Eastern Equine Encephalitis virus (EEEV), Western Equine Encephalitis virus (WEEV) and Venezuelan Equine Encephalitis virus (EEEV) have been linked to the induction of lethal encephalitis in humans and animals [<xref rid="B3-microorganisms-09-00899" ref-type="bibr">3</xref>,<xref rid="B4-microorganisms-09-00899" ref-type="bibr">4</xref>].</p><p>Historically, alphaviruses have a proven record of causing massive outbreaks in susceptible populations [<xref rid="B5-microorganisms-09-00899" ref-type="bibr">5</xref>,<xref rid="B6-microorganisms-09-00899" ref-type="bibr">6</xref>,<xref rid="B7-microorganisms-09-00899" ref-type="bibr">7</xref>,<xref rid="B8-microorganisms-09-00899" ref-type="bibr">8</xref>]. Additionally, the appearance of mutations favoring their ecological fit to new vectors has fueled alphavirus propagation worldwide [<xref rid="B9-microorganisms-09-00899" ref-type="bibr">9</xref>,<xref rid="B10-microorganisms-09-00899" ref-type="bibr">10</xref>]. A clear example of their potential as a health threat is the re-emergence of CHIKV in 2004 after a hiatus of more than 50 years since its discovery [<xref rid="B5-microorganisms-09-00899" ref-type="bibr">5</xref>]. More recently, tropical emerging alphaviruses such as ONNV and MAYV are believed to have the potential to become future major epidemics [<xref rid="B11-microorganisms-09-00899" ref-type="bibr">11</xref>,<xref rid="B12-microorganisms-09-00899" ref-type="bibr">12</xref>,<xref rid="B13-microorganisms-09-00899" ref-type="bibr">13</xref>]. This is due, in part, to the lack of robust diagnostic tests to differentiate alphavirus infections from other febrile tropical diseases and the absence of continuous epidemiological surveillance masking their real potential for spread beyond endemic areas [<xref rid="B14-microorganisms-09-00899" ref-type="bibr">14</xref>,<xref rid="B15-microorganisms-09-00899" ref-type="bibr">15</xref>,<xref rid="B16-microorganisms-09-00899" ref-type="bibr">16</xref>].</p><p>Although alphavirus infections are generally not life threating the economic and social costs incurred during outbreaks are thought to be high [<xref rid="B17-microorganisms-09-00899" ref-type="bibr">17</xref>,<xref rid="B18-microorganisms-09-00899" ref-type="bibr">18</xref>,<xref rid="B19-microorganisms-09-00899" ref-type="bibr">19</xref>]. Moreover, the lack of approved treatments leaves management of alphavirus infections to supportive care [<xref rid="B20-microorganisms-09-00899" ref-type="bibr">20</xref>]. Interestingly, a body of work suggests that the alphavirus infection triggers potent humoral responses in exposed populations which seem to confer protection against re-infection [<xref rid="B21-microorganisms-09-00899" ref-type="bibr">21</xref>]. Therefore, a better understanding of the antibody responses against alphaviruses is crucial for the development of vaccines, which would represent a big advantage in the control of alphavirus infections.</p></sec><sec id="sec2-microorganisms-09-00899"><title>2. Antibody-Mediated Alphavirus Immunity</title><sec id="sec2dot1-microorganisms-09-00899"><title>2.1. Virus-Specific Antibody Kinetics Upon Natural Infection with Alphaviruses</title><p>The current knowledge on the role of antibody-mediated immunity upon viral infection has been gathered from cohort studies following major alphavirus outbreaks. Serological surveys following CHIKV re-emergence in 2004 reported the quick development of IgM responses between five to seven days post-illness onset (PIO) [<xref rid="B22-microorganisms-09-00899" ref-type="bibr">22</xref>,<xref rid="B23-microorganisms-09-00899" ref-type="bibr">23</xref>]. IgM is generally detectable for up to three months post-infection [<xref rid="B24-microorganisms-09-00899" ref-type="bibr">24</xref>,<xref rid="B25-microorganisms-09-00899" ref-type="bibr">25</xref>,<xref rid="B26-microorganisms-09-00899" ref-type="bibr">26</xref>]. However, long-lasting IgM has been often reported in patients with long-term CHIKV-induced polyarthralgia, which might indicate a constant antigenic stimulation due to viral persistence [<xref rid="B27-microorganisms-09-00899" ref-type="bibr">27</xref>]. After the initial detection of IgM antibodies, IgG seroconversion reportedly occurs between 4 to 10 days PIO taking over as the main immunoglobulin detected in serum [<xref rid="B22-microorganisms-09-00899" ref-type="bibr">22</xref>,<xref rid="B28-microorganisms-09-00899" ref-type="bibr">28</xref>]. Notably, IgG3 antibodies become the dominant IgG subtype produced upon infection and have been associated to efficient viral clearance and protection against chronic CHIKV symptoms [<xref rid="B23-microorganisms-09-00899" ref-type="bibr">23</xref>]. Importantly, IgG responses persist for several years and might be potentially lifelong [<xref rid="B29-microorganisms-09-00899" ref-type="bibr">29</xref>].</p><p>ONNV and MAYV, both closely-related to CHIKV, are re-emerging arthritogenic alphaviruses believed to be confined to sub-Saharan Africa, and Latin America, respectively [<xref rid="B6-microorganisms-09-00899" ref-type="bibr">6</xref>,<xref rid="B11-microorganisms-09-00899" ref-type="bibr">11</xref>,<xref rid="B12-microorganisms-09-00899" ref-type="bibr">12</xref>,<xref rid="B15-microorganisms-09-00899" ref-type="bibr">15</xref>]. Following the largest ONNV outbreak in Uganda involving more than two million cases between 1959&#8211;1962 [<xref rid="B6-microorganisms-09-00899" ref-type="bibr">6</xref>,<xref rid="B30-microorganisms-09-00899" ref-type="bibr">30</xref>], the induction of potent neutralizing antibodies was described [<xref rid="B31-microorganisms-09-00899" ref-type="bibr">31</xref>]. The first study cohort that evaluated IgM kinetics upon ONNV infection in Uganda [<xref rid="B32-microorganisms-09-00899" ref-type="bibr">32</xref>] reported the appearance of IgM antibodies during the second week PIO which remained elevated for two months. In contrast, reports from imported ONNV cases in Europe described detectable IgM levels as early as five days PIO [<xref rid="B33-microorganisms-09-00899" ref-type="bibr">33</xref>,<xref rid="B34-microorganisms-09-00899" ref-type="bibr">34</xref>]. ONNV-specific IgG levels are increased in serum after the third week and remain high beyond two months PIO [<xref rid="B11-microorganisms-09-00899" ref-type="bibr">11</xref>,<xref rid="B34-microorganisms-09-00899" ref-type="bibr">34</xref>]. However, whether IgG responses are long-lasting remains unknown. Similarly, endemic MAYV infections are characterized by the early appearance of IgM antibodies (3&#8211;8 days PIO) that might last for one to three months [<xref rid="B35-microorganisms-09-00899" ref-type="bibr">35</xref>,<xref rid="B36-microorganisms-09-00899" ref-type="bibr">36</xref>]. IgG becomes detectable around 4&#8211;10 days PIO [<xref rid="B35-microorganisms-09-00899" ref-type="bibr">35</xref>] and remains elevated after 6&#8211;12 months [<xref rid="B37-microorganisms-09-00899" ref-type="bibr">37</xref>,<xref rid="B38-microorganisms-09-00899" ref-type="bibr">38</xref>]. Interestingly, unlike ONNV and CHIKV infections, persistent arthralgia has been reported in more than half of MAYV-infected individuals and although MAYV-specific antibody responses are critical for disease resolution it is seemingly insufficient to protect patients from the development of chronic joint manifestations [<xref rid="B39-microorganisms-09-00899" ref-type="bibr">39</xref>].</p><p>Other alphaviruses linked to continuous small outbreaks associated with arthritic manifestations in human populations are RRV and SINV. RRV is endemic to Australia and is responsible for approximately 4000&#8211;5000 cases annually [<xref rid="B40-microorganisms-09-00899" ref-type="bibr">40</xref>]. Typically, antibody kinetics upon RRV infection are characterized by the development of IgM titers between 7&#8211;10 days PIO, peaking at two to three weeks and lasting for 1&#8211;3 months [<xref rid="B41-microorganisms-09-00899" ref-type="bibr">41</xref>,<xref rid="B42-microorganisms-09-00899" ref-type="bibr">42</xref>]. IgM response rapidly declines after three weeks PIO as IgG becomes dominant [<xref rid="B42-microorganisms-09-00899" ref-type="bibr">42</xref>,<xref rid="B43-microorganisms-09-00899" ref-type="bibr">43</xref>]. Interestingly, IgM persistence has been reported in some RRV cohorts [<xref rid="B41-microorganisms-09-00899" ref-type="bibr">41</xref>]. In one study [<xref rid="B44-microorganisms-09-00899" ref-type="bibr">44</xref>], 19/116 (16.4%) of participants had detectable IgM levels that lasted between seven months to eight years PIO. Likewise, less prevalent SINV has also been linked to the development of persistent virus-specific IgM levels. Although, generally, the antibody response upon SINV infection generates IgM antibodies after 6&#8211;9 days PIO and IgG antibodies after 9&#8211;14 days, some reports described the presence of detectable IgM levels up to four years suggesting active viral replication [<xref rid="B45-microorganisms-09-00899" ref-type="bibr">45</xref>,<xref rid="B46-microorganisms-09-00899" ref-type="bibr">46</xref>,<xref rid="B47-microorganisms-09-00899" ref-type="bibr">47</xref>]. The clinical relevance of persistent IgM levels following RRV and SINV infection is yet to be determined.</p><p>Neurotropic alphaviruses such as EEEV, WEEV and VEEV cause sporadic cases of human encephalitis in the Americas [<xref rid="B4-microorganisms-09-00899" ref-type="bibr">4</xref>]. While the natural reservoirs for these viruses are primarily birds and equines, humans are susceptible to infection when the enzootic cycle of transmission leaks into mosquito populations with a wide range of hosts [<xref rid="B48-microorganisms-09-00899" ref-type="bibr">48</xref>]. Given that human cases are rare, there is a lack of information regarding the development of antibody responses upon natural infections by neurotropic alphaviruses. In a paired serology study [<xref rid="B49-microorganisms-09-00899" ref-type="bibr">49</xref>], virus-specific antibody responses were profiled in a cohort of 20 EEEV and 17 WEEV-infected patients. IgM antibodies were observed as early as 1 PIO, peaking after 1&#8211;2 weeks and remaining detectable for up to three months. In contrast, IgG responses appeared during the second week PIO and remained elevated until the end of the follow-up period.</p></sec><sec id="sec2dot2-microorganisms-09-00899"><title>2.2. Experimental Evidence of the Role of Antibodies in Alphavirus Immunity</title><p>To better understand the role of antibody-mediated immunity upon alphavirus infection, several animal models have been used allowing the detailed examination of the cellular compartments responsible for the initiation of humoral immunity. The role of B cells in alphavirus immunity has been described in experimental CHIKV infections. Inoculation of &#181;MT mice (lacking mature B cells) with CHIKV resulted in higher viremia that persisted up to 402 days post-infection (DPI). In contrast, infected wild type (WT) mice were able to control the virus during the second week post-inoculation [<xref rid="B50-microorganisms-09-00899" ref-type="bibr">50</xref>]. Similar findings were reported in other studies, where mouse strains lacking B cells (&#181;MT, Rag1, Rag2/IL2rg, NRG) infected with CHIKV displayed increased and persistent viremia for up to 515 DPI [<xref rid="B51-microorganisms-09-00899" ref-type="bibr">51</xref>,<xref rid="B52-microorganisms-09-00899" ref-type="bibr">52</xref>].</p><p>B cells also play an important role in alphavirus-induced encephalitis. Although SINV infections in humans are known to cause arthritic manifestations, SINV has been frequently used as a model of alphavirus-induced encephalomyelitis in adult immunocompetent mice given the virus ability to infect neurons [<xref rid="B53-microorganisms-09-00899" ref-type="bibr">53</xref>]. Intracerebral inoculation of SINV in &#181;MT and severe combined immunodeficiency (SCID) mice resulted in defective viral clearance from the brain, brain stem and lumbar spinal cord, virus persistence and recrudescence compared to WT mice [<xref rid="B54-microorganisms-09-00899" ref-type="bibr">54</xref>]. The individual contributions of IgM and IgG antibodies to SINV clearance from brain tissues were assessed in another study [<xref rid="B55-microorganisms-09-00899" ref-type="bibr">55</xref>] where infection in AID<sup>&#8722;/&#8722;</sup> (unable to produce IgG), sIgM<sup>&#8722;/&#8722;</sup> (unable to produce IgM) and AID<sup>&#8722;/&#8722;</sup> sIgM<sup>&#8722;/&#8722;</sup> double-knockout mice resulted only in AID<sup>&#8722;/&#8722;</sup> sIgM<sup>&#8722;/&#8722;</sup> being unable to control infection efficiently suggesting that either IgM or IgG antibodies are sufficient to clear SINV from the central nervous system (CNS). Similar results were obtained in SFV models of encephalitis where infection of &#181;MT [<xref rid="B56-microorganisms-09-00899" ref-type="bibr">56</xref>], SCID [<xref rid="B57-microorganisms-09-00899" ref-type="bibr">57</xref>] and nude mice with impaired antibody switching [<xref rid="B58-microorganisms-09-00899" ref-type="bibr">58</xref>] led to viral persistence.</p><p>Infiltrating virus-specific B cells were observed in infected tissues in a murine model of SINV-induced encephalitis [<xref rid="B59-microorganisms-09-00899" ref-type="bibr">59</xref>,<xref rid="B60-microorganisms-09-00899" ref-type="bibr">60</xref>]. Following intracranial virus inoculation, expansion of IgM-secreting plasmablasts was reported in the cervical lymph nodes. Infiltration of CD19+ B cells occurred between 3&#8211;7 DPI and coincided with the starting of viral clearance. During the clearance of persistent viral RNA (from 8&#8211;80 DPI), the accumulation of SINV-specific IgG and IgA-secreting B cells was observed being associated with increased SINV antibody titers over time [<xref rid="B60-microorganisms-09-00899" ref-type="bibr">60</xref>]. In a subsequent study, it was reported that the brain microenvironment during the early stages of SINV infection facilitates the migration, differentiation, expansion and long term survival of SINV-specific B cells [<xref rid="B59-microorganisms-09-00899" ref-type="bibr">59</xref>].</p><p>Follicular helper T cells (T<sub>FH</sub>) are a subset of CD4 T cells involved in the activation of B lymphocytes and the establishment of robust antibody responses following antigen stimulation. T<sub>FH</sub> promotes B cell differentiation, isotype switching and affinity maturation. In experimental CHIKV infections, the use of CD4-deficient mice ruled out the role of CD4 T cells in viral clearance from infected tissues [<xref rid="B61-microorganisms-09-00899" ref-type="bibr">61</xref>]. However, one study demonstrated impaired IgM and IgG (IgG2c, IgG1, and IgG2b) production in mice lacking CD4 T cells following CHIKV inoculation [<xref rid="B62-microorganisms-09-00899" ref-type="bibr">62</xref>]. Albeit reduced virus-specific antibody levels, the neutralizing capacity of sera from virus-infected CD4-deficient mice was marginally affected [<xref rid="B62-microorganisms-09-00899" ref-type="bibr">62</xref>]. Likewise, another study showed similar results upon CHIKV inoculation of MHCII<sup>&#916;/&#916;</sup> mice (defective of T<sub>FH</sub>) [<xref rid="B51-microorganisms-09-00899" ref-type="bibr">51</xref>]. MHCII<sup>&#916;/&#916;</sup> animals were unable to generate IgG1 antibodies and produced &#8776;100 fold lower IgG2c levels than WT controls. Nonetheless, MHCII<sup>&#916;/&#916;</sup> mice were still able to control virus infection [<xref rid="B51-microorganisms-09-00899" ref-type="bibr">51</xref>]. The generation of virus-specific neutralizing antibodies in MHCII<sup>&#916;/&#916;</sup> mice suggests a T-cell independent B cell activation characterized by the inability to generate memory B cells. Whether CHIKV-specific antibody responses in mice lacking CD4 T cells are long-lasting remains to be elucidated.</p></sec><sec id="sec2dot3-microorganisms-09-00899"><title>2.3. Viral Antigenic Regions Targeted by Neutralizing Antibodies</title><p>The notion of targeting humoral immunity as a therapy against alphavirus infection has been investigated since the late 1930s following the isolation of EEEV, WEEV and VEEV. In a series of seminal studies involving immunization of guinea pigs [<xref rid="B63-microorganisms-09-00899" ref-type="bibr">63</xref>,<xref rid="B64-microorganisms-09-00899" ref-type="bibr">64</xref>,<xref rid="B65-microorganisms-09-00899" ref-type="bibr">65</xref>,<xref rid="B66-microorganisms-09-00899" ref-type="bibr">66</xref>], the subcutaneous inoculation of live EEEV and WEEV strains protected guinea pigs from lethal intracranial infection [<xref rid="B63-microorganisms-09-00899" ref-type="bibr">63</xref>]. Additionally, it was observed that immunization with formalin-inactivated virus strains induced the production of neutralizing antibodies at a comparable level than animals immunized with live viruses [<xref rid="B64-microorganisms-09-00899" ref-type="bibr">64</xref>,<xref rid="B65-microorganisms-09-00899" ref-type="bibr">65</xref>,<xref rid="B66-microorganisms-09-00899" ref-type="bibr">66</xref>]. Subsequent studies reported that passive transfer of hyperimmune rabbit serum protected mice, guinea pigs and rabbits from WEEV infection [<xref rid="B66-microorganisms-09-00899" ref-type="bibr">66</xref>,<xref rid="B67-microorganisms-09-00899" ref-type="bibr">67</xref>]. Similarly, passive serum transfer was shown to be effective at protecting mice from the development of neurological complications upon infection with a neuroadapted strain of SINV [<xref rid="B68-microorganisms-09-00899" ref-type="bibr">68</xref>,<xref rid="B69-microorganisms-09-00899" ref-type="bibr">69</xref>]. Comparable observations were reported in experimental infection models of VEEV [<xref rid="B70-microorganisms-09-00899" ref-type="bibr">70</xref>], CHIKV [<xref rid="B71-microorganisms-09-00899" ref-type="bibr">71</xref>,<xref rid="B72-microorganisms-09-00899" ref-type="bibr">72</xref>], RRV [<xref rid="B73-microorganisms-09-00899" ref-type="bibr">73</xref>] and SFV [<xref rid="B74-microorganisms-09-00899" ref-type="bibr">74</xref>].</p><p>The first attempts in identifying the exact structural regions, recognized by most neutralizing antibodies produced upon infection, were conducted in experimental infection models of alphavirus encephalitis. Structurally, the envelope of an alphavirus virion has a T = 4 icosahedral symmetry [<xref rid="B75-microorganisms-09-00899" ref-type="bibr">75</xref>]. E1 and E2 are two envelop surface glycoproteins exposed in the viral spike as a heterodimer [<xref rid="B75-microorganisms-09-00899" ref-type="bibr">75</xref>] (<xref ref-type="fig" rid="microorganisms-09-00899-f001">Figure 1</xref>). It is believed that the E1-E2 heterodimer interacts with host receptors thus mediating viral entry [<xref rid="B75-microorganisms-09-00899" ref-type="bibr">75</xref>]. Additionally, the E1 and E2 glycoproteins were postulated as highly immunogenic regions since their location in the spike facilitates antigenic recognition. In line with this, early works mapped antigenic sites involved in VEEV, SINV and SFV neutralization to the E1 and E2 proteins using competitive binding assays but the exact amino acid sequences were not determined [<xref rid="B76-microorganisms-09-00899" ref-type="bibr">76</xref>,<xref rid="B77-microorganisms-09-00899" ref-type="bibr">77</xref>,<xref rid="B78-microorganisms-09-00899" ref-type="bibr">78</xref>]. Later, a major antigenic region involving three epitopes important in the neutralization of RRV was identified in the E2 protein (incorporating residues 216, 232 and 234) [<xref rid="B79-microorganisms-09-00899" ref-type="bibr">79</xref>]. Similarly, analysis of antibody escape variants determined important antigenic regions between amino acids 181 and 216 on the E2 protein of SINV [<xref rid="B80-microorganisms-09-00899" ref-type="bibr">80</xref>]. A major neutralization domain was also identified between residues 182&#8211;207 for VEEV [<xref rid="B81-microorganisms-09-00899" ref-type="bibr">81</xref>].</p><p>Following CHIKV reemergence in 2004 several reports identified major linear antigenic sites in the CHIKV E2 protein that induced the production of potent neutralizing antibodies. Using a CHIKV proteome-wide screening approach, a single linear peptide located at the N-terminus of the E2 glycoprotein, E2EP3, was reported as strongly recognized by convalescent CHIKV patients from different cohorts [<xref rid="B23-microorganisms-09-00899" ref-type="bibr">23</xref>]. Furthermore, experimental CHIKV infection in mice and non-human primates (NHP) validated E2EP3 as an immunodominant linear epitope inducing potent neutralizing antibodies [<xref rid="B23-microorganisms-09-00899" ref-type="bibr">23</xref>,<xref rid="B62-microorganisms-09-00899" ref-type="bibr">62</xref>,<xref rid="B82-microorganisms-09-00899" ref-type="bibr">82</xref>]. Interestingly, mice immunization with E2EP3 alone reduced joint swelling and viremia upon CHIKV challenge [<xref rid="B23-microorganisms-09-00899" ref-type="bibr">23</xref>]. In another study focusing on human antibody responses to SINV in cohort from Finland, 6 linear epitopes, located in the capsid, E2, E1 and PE2 (uncleaved E3-E2) proteins, were reported [<xref rid="B83-microorganisms-09-00899" ref-type="bibr">83</xref>]. Three of these epitopes were located to the glycoprotein spike complex between the residues 209&#8211;226 of E1 (E1-P5), 273&#8211;290 (E2-P3) and 308&#8211;325 (E2-P4) of E2 [<xref rid="B83-microorganisms-09-00899" ref-type="bibr">83</xref>]. Interestingly, the E2EP3 equivalent of SINV remained non-reactive suggesting that antibody kinetics against linear E2EP3 between populations exposed to CHIKV and SINV might differ [<xref rid="B83-microorganisms-09-00899" ref-type="bibr">83</xref>].</p><p>The development of mouse and human monoclonal antibodies against different alphaviruses helped further the understanding of antigenic responses upon infection by the identification of conformational epitopes. Early works have shown the therapeutic value of mouse monoclonal antibodies in models of alphavirus encephalitis by SINV [<xref rid="B84-microorganisms-09-00899" ref-type="bibr">84</xref>,<xref rid="B85-microorganisms-09-00899" ref-type="bibr">85</xref>,<xref rid="B86-microorganisms-09-00899" ref-type="bibr">86</xref>,<xref rid="B87-microorganisms-09-00899" ref-type="bibr">87</xref>,<xref rid="B88-microorganisms-09-00899" ref-type="bibr">88</xref>], SFV [<xref rid="B56-microorganisms-09-00899" ref-type="bibr">56</xref>,<xref rid="B57-microorganisms-09-00899" ref-type="bibr">57</xref>,<xref rid="B89-microorganisms-09-00899" ref-type="bibr">89</xref>] and VEEV [<xref rid="B78-microorganisms-09-00899" ref-type="bibr">78</xref>]. Interestingly, it was observed that neutralizing monoclonal antibodies target antigenic regions in the E2 protein. Whereas, non-neutralizing antibodies bind to the E1 protein, yet both are able to confer protection upon alphavirus infection, thereby suggesting other mechanisms of protection in vivo besides virus neutralization [<xref rid="B48-microorganisms-09-00899" ref-type="bibr">48</xref>]. Several monoclonal antibodies targeting both E1 and E2 proteins have been reported in the context of arthritogenic alphavirus infection. Mouse monoclonal antibodies targeting the A and B domain of E2 and the domain II of E1 [<xref rid="B90-microorganisms-09-00899" ref-type="bibr">90</xref>,<xref rid="B91-microorganisms-09-00899" ref-type="bibr">91</xref>,<xref rid="B92-microorganisms-09-00899" ref-type="bibr">92</xref>] and the capsid protein [<xref rid="B93-microorganisms-09-00899" ref-type="bibr">93</xref>,<xref rid="B94-microorganisms-09-00899" ref-type="bibr">94</xref>] have been reported for CHIKV. Likewise, human anti-CHIKV monoclonal antibodies were found to target conformation epitopes in the E2 glycoprotein A (containing a putative RBD [<xref rid="B95-microorganisms-09-00899" ref-type="bibr">95</xref>]) and B (shielding the fusion loop in E1 [<xref rid="B96-microorganisms-09-00899" ref-type="bibr">96</xref>]) domains and proved therapeutic value in experimental NHP infections [<xref rid="B90-microorganisms-09-00899" ref-type="bibr">90</xref>,<xref rid="B97-microorganisms-09-00899" ref-type="bibr">97</xref>,<xref rid="B98-microorganisms-09-00899" ref-type="bibr">98</xref>]. Monoclonal antibodies recognizing epitopes predominantly between residues 58&#8211;80 (domains A) or residues 180&#8211;215 (domain B) of the E2 glycoprotein have been also reported in the context of SINV [<xref rid="B83-microorganisms-09-00899" ref-type="bibr">83</xref>], VEEV [<xref rid="B81-microorganisms-09-00899" ref-type="bibr">81</xref>], EEEV [<xref rid="B99-microorganisms-09-00899" ref-type="bibr">99</xref>,<xref rid="B100-microorganisms-09-00899" ref-type="bibr">100</xref>,<xref rid="B101-microorganisms-09-00899" ref-type="bibr">101</xref>], RRV [<xref rid="B102-microorganisms-09-00899" ref-type="bibr">102</xref>] and MAYV [<xref rid="B103-microorganisms-09-00899" ref-type="bibr">103</xref>].</p><p>The combined evidence suggested the existence of common antigenic sites in the viral spike across alphaviruses, particularly in the E2 protein. These sites are likely required for interaction with host cell receptors suggesting that antibody binding might inhibit infection during viral attachment, entry, fusion or egress [<xref rid="B90-microorganisms-09-00899" ref-type="bibr">90</xref>]. In line with this, a recent study reported the discovery of Mxra8, a cell adhesion molecule, as a host receptor required for viral entry of multiple arthritogenic alphaviruses [<xref rid="B104-microorganisms-09-00899" ref-type="bibr">104</xref>]. Genetically altering mouse or human Mxra8 resulted in diminished infection, conversely, overexpression of Mxra8 in cell lines increased infection rates by CHIKV, ONNV, MAYV and RRV [<xref rid="B104-microorganisms-09-00899" ref-type="bibr">104</xref>,<xref rid="B105-microorganisms-09-00899" ref-type="bibr">105</xref>]. Interestingly, mutagenesis experiments suggested E2 domains A and B as the putative binding site for Mxra8 [<xref rid="B104-microorganisms-09-00899" ref-type="bibr">104</xref>]. This notion was later confirmed by cryo-electron microscopy images of Mxra8 bound to CHIKV [<xref rid="B106-microorganisms-09-00899" ref-type="bibr">106</xref>,<xref rid="B107-microorganisms-09-00899" ref-type="bibr">107</xref>]. Mxra8 sits onto a cleft formed by two contiguous CHIKV E2-E1 heterodimers in one trimeric spike while engaging a neighboring spike [<xref rid="B106-microorganisms-09-00899" ref-type="bibr">106</xref>]. It is believed that this interaction works against the virus by obstructing viral fusion [<xref rid="B106-microorganisms-09-00899" ref-type="bibr">106</xref>]. Importantly, human neutralizing antibodies that recognize regions of the A domain of E2 inhibited the binding of Mxra8 supporting the interactions determined in the cryo-EM atomic model. Notably, Mxra8 seems to not be a receptor for neurotropic alphaviruses [<xref rid="B104-microorganisms-09-00899" ref-type="bibr">104</xref>]. The alignment of CHIKV residues involved in Mxra8 binding reveled a degree of conservation in arthritogenic alphaviruses (44%), but diverged from neurotropic Alphaviruses (14%) which might explain the negative results in the context of SINV, EEEV, WEEV and VEEV infections [<xref rid="B106-microorganisms-09-00899" ref-type="bibr">106</xref>]. In summary, the characterization of alphavirus antigenic epitopes has proven beneficial to pave the way for the development of antibody therapies and vaccines.</p></sec></sec><sec id="sec3-microorganisms-09-00899"><title>3. Alphavirus Vaccine Development</title><p>Recent decades have seen increased rates of geographic dispersal of arboviral re-emergence, due to factors such as growth of global transportation, urbanization and failure of mosquito control [<xref rid="B108-microorganisms-09-00899" ref-type="bibr">108</xref>,<xref rid="B109-microorganisms-09-00899" ref-type="bibr">109</xref>,<xref rid="B110-microorganisms-09-00899" ref-type="bibr">110</xref>,<xref rid="B111-microorganisms-09-00899" ref-type="bibr">111</xref>]. Given that humans appear to be the only amplification hosts and viral reservoir during urban transmission [<xref rid="B112-microorganisms-09-00899" ref-type="bibr">112</xref>,<xref rid="B113-microorganisms-09-00899" ref-type="bibr">113</xref>], another effective means of controlling the spread of infection is through vaccination. While there are currently no licensed or approved vaccines available for alphaviruses, a multitude of approaches have been used to develop vaccine candidates capable of, not only generating high levels of antibodies, but also providing long-lasting protection, with the ease of administration and production requirements. Multiple methods such as live-attenuated viruses, inactivated viruses, virus-like particles (VLP), recombinant subunit vaccines and chimeric vaccines have been explored for vaccine options (<xref ref-type="fig" rid="microorganisms-09-00899-f002">Figure 2</xref> and <xref rid="microorganisms-09-00899-t001" ref-type="table">Table 1</xref>).</p><sec id="sec3dot1-microorganisms-09-00899"><title>3.1. Live-Attenuated Vaccines</title><p>With the development of alphaviruses in reverse genetic systems, more research has been focused on the rational design of live-attenuated vaccines [<xref rid="B221-microorganisms-09-00899" ref-type="bibr">221</xref>,<xref rid="B222-microorganisms-09-00899" ref-type="bibr">222</xref>] in overcoming potential issues, such as genetic reversion mutations in vaccines [<xref rid="B223-microorganisms-09-00899" ref-type="bibr">223</xref>,<xref rid="B224-microorganisms-09-00899" ref-type="bibr">224</xref>], with highly specific mutations or alterations of the original parental virus genome. In addition, not only are the safety profiles of these vaccines is greatly improved, protection with a only single dose is also achieved [<xref rid="B225-microorganisms-09-00899" ref-type="bibr">225</xref>].</p><p>An engineered live-attenuated option for alphavirus vaccine design involves the rational design of downregulating the expression of particular structural proteins with the introduction of a picornavirus (encephalomyocarditis virus) internal ribosome entry site (IRES) into the viral genome. For example, this is demonstrated in a VEEV vaccine candidate, ZPC/IRES, where the expression of the capsid protein is minimalized by translocating its gene to a separate opening reading frame downstream of the envelope glycoprotein genes and interrupting its expression with the introduction of a IRES [<xref rid="B114-microorganisms-09-00899" ref-type="bibr">114</xref>,<xref rid="B226-microorganisms-09-00899" ref-type="bibr">226</xref>]. However, the highly immunogenic envelope glycoproteins E3-E1 were not manipulated, but the insertion of IRES into the genome would functionally alter the host range as replication of the live virus is restricted in mosquitoes.</p><p>ZPC/IRES is based on a full-length clone of a wild type VEEV subtype ID from Zulia state, Venezuela from a sentinel hamster exposed in a tropical lowland. CD-1 mice immunized with 10<sup>5</sup> PFU of ZPC/IRES developed strongly neutralizing antibodies, with PRNT80 of average reciprocal titer of 324 by 20 weeks post immunization. Subsequently, when immunized mice were challenged with the lethal VEEV subtype IC strain 3908 (10<sup>5</sup> PFU, subcutaneous or 10<sup>4</sup> PFU, aerosol route) 4 weeks after immunization, all mice retained their weight and failed to show any signs of disease and survived, compared to mock-vaccinated mice which succumbed to the lethal infection. Additionally, the study tested the vaccine in a NHP immunization-challenge model in the same study. Vaccinated NHPs had PRNT80 values of 160 to 320, and all vaccinated NHPs were protected against viremia upon challenge with VEEV 3908 strain. Using the VEEV ID strain ZPC738 as the vaccine backbone, which is closely related to subtypes IAB and IC, the authors had aimed to develop an IRES-based, live-attenuated vaccine candidate that could possibly protect against other subtypes of VEEV, given that previous attempts to create a vaccine candidate based on the VEEV subtype IAB V3526 vaccine could not significantly protect against aerosol challenge with a subtype IE VEEV strain [<xref rid="B226-microorganisms-09-00899" ref-type="bibr">226</xref>]. Nonetheless, this hypothesis was not pursued in the study, and it would have been curious to learn whether the ZPC/IRES-immunized animals would be protected from a lethal challenge with VEEV of other subtypes, such as subtypes IA/B and IE.</p></sec><sec id="sec3dot2-microorganisms-09-00899"><title>3.2. Inactivated Vaccines</title><p>The inactivated Ross River virus (RRV) vaccine is the most developed and advanced vaccine candidate, having been rigorously tested in both preclinical and up to Phase 3 clinical trials. The Vero cell culture-derived whole-virus RRV vaccine was first produced from a viral seed derived from an RRV isolate from a serologically confirmed case of RRV disease in Queensland, Australia, and subsequently inactivated by sequential formalin and UV light treatment after harvest [<xref rid="B227-microorganisms-09-00899" ref-type="bibr">227</xref>]. In pre-clinical testing of the RRV vaccine, CD-1 mice were given two doses of the inactivated RRV vaccines at different experimental doses 28 days apart, without the use of an adjuvant in its formulation. Upon challenge with 10<sup>6</sup> TCID50 of the mouse-virulent RRV prototype strain T48 at 42 days post immunization, a vaccine dose beyond 0.625 &#956;g provided almost complete protection against viremia development at 1-day post challenge. Interestingly, the possible antibody-dependent enhancement by RRV vaccination by a closely related alphavirus infection was investigated, where viremia in CHIKV LR2006 OPY-1-infected-RRV vaccinated mice was significantly reduced as compared to the control. In this heterologous situation, partial cross protection was observed, but the presence of sub-protective levels of RRV vaccine-induced antibodies prevented the enhancement of CHIKV replication [<xref rid="B73-microorganisms-09-00899" ref-type="bibr">73</xref>].</p><p>Subsequently, a randomized Phase 3 clinical trial for the RRV vaccine was conducted in Australia to investigate the safety and immunogenicity of the vaccine in a large cohort of 1755 healthy younger adults aged 16 to 59 years and 209 healthy older adults aged &gt; 60 years [<xref rid="B115-microorganisms-09-00899" ref-type="bibr">115</xref>]. The 2.5 &#956;g Al(OH)3-adjuvanted vaccine was given over three doses (subsequent boosts at 3 weeks and 6 months). The majority of participants in the younger and older adult populations had seroprotective uNT titers after three immunizations with the whole-virus RRV vaccine, and titers of serum IgG antibodies after three immunizations were higher than the serological IgG ELISA titer threshold associated with protection after natural infection with RRV [<xref rid="B115-microorganisms-09-00899" ref-type="bibr">115</xref>]. While the RRV vaccine had been brought forward to Phase 3 clinical trials, and despite the vaccine demonstrating safety and efficacy, it was not considered financially viable to manufacture, despite Queensland recording its largest and worst epidemic between 2014 to 2015 [<xref rid="B228-microorganisms-09-00899" ref-type="bibr">228</xref>,<xref rid="B229-microorganisms-09-00899" ref-type="bibr">229</xref>]. In addition, given that the cost of vaccine trials is hard to justify for a disease that occurs only in Australia and Papua New Guinea, and where the disease is never fatal, efforts to further develop the RRV vaccine were unfortunately halted.</p></sec><sec id="sec3dot3-microorganisms-09-00899"><title>3.3. Virus-Like Particles (VLPs)</title><p>The VRC-CHKVLP059-00-VP is one of the first potential new CHIKV vaccines to reach advanced development with human clinical testing [<xref rid="B116-microorganisms-09-00899" ref-type="bibr">116</xref>,<xref rid="B117-microorganisms-09-00899" ref-type="bibr">117</xref>]. The CHIKV envelope gene cassette encoding the native polypeptide, E3-E2-6K-E1, of CHIKV strains 37,997 (West African genotype) and LR2006 OPY-1 were inserted into a cytomegalovirus CMV/R expression vector and subsequently transfected into 293T human kidney cells [<xref rid="B118-microorganisms-09-00899" ref-type="bibr">118</xref>]. The resulting VLP product is a CHIKV VLP that is structurally identical to its infectious counterpart (given that structural genes are intact), but is not infectious as its genetic material is removed. While the CHIKV 37997 strain yielded approximately 100 times more VLPs than that from strain LR2006 OPY-1, the former strain was subsequently used to produce the VLPs. Nonetheless, given that the ECSA lineage was responsible for the ongoing outbreak at the time of development, the high degree of amino acid similarity between the two CHIKV strains suggested that the vaccine would be protective against viruses of other genotypes. However, it would have been curious to characterize a VLP produced from a CHIKV strain of the ECSA lineage, given that it is the strain responsible for recent Chikungunya epidemics all around the world [<xref rid="B119-microorganisms-09-00899" ref-type="bibr">119</xref>,<xref rid="B120-microorganisms-09-00899" ref-type="bibr">120</xref>,<xref rid="B121-microorganisms-09-00899" ref-type="bibr">121</xref>,<xref rid="B122-microorganisms-09-00899" ref-type="bibr">122</xref>,<xref rid="B123-microorganisms-09-00899" ref-type="bibr">123</xref>].</p><p>BALB/c mice immunized with two doses of 19 &#956;g of CHIKV VLPs intramuscularly generated the highest neutralizing titer against both the homologous strain 37,997 and the heterologous strain LR2006 OPY-1. In addition, NHPs immunized with 20 &#956;g of VLPs developed substantial neutralizing activity to both homologous and heterologous strains after primary immunization. Interestingly, even though the VLP was made from CHIKV 27,997 strain, there was slightly better neutralization of LR2006 OPY-1 compared to 37,997 in both mice and NHPs. The study speculated that this is suggestive that the LR2006 OPY-1 virus may present a conserved epitope to the immune system better than the 37,997 virus. When total IgG antibodies were passively transferred from immunized NHPs to defective type 1 interferon signaling immunodeficient mice (Ifnar1<sup>&#8722;/&#8722;</sup>), these recipient mice did not develop detectable viremia and all survived a lethal challenge with CHIKV LR2006 OPY-1. This indicated that the humoral immune responses induced by the CHIKV VLPs confer protection against CHIKV infection [<xref rid="B124-microorganisms-09-00899" ref-type="bibr">124</xref>].</p><p>This promising data eventually led to further testing in clinical trials&#8212;phase 2 studies were concluded and reported in 2020 [<xref rid="B117-microorganisms-09-00899" ref-type="bibr">117</xref>]. The randomized phase 2 clinical trial included 400 healthy adults in outpatient clinics in 6 countries in the Caribbean. Two doses of 20 &#956;g of CHIKV VLP, termed as VRC-CHKVLP059-00-VP in clinical trials, were administered 28 days apart via intramuscular injection. Vaccine-induced humoral immune responses in individuals were comparable with titers from participants vaccinated in the phase 1 trial [<xref rid="B116-microorganisms-09-00899" ref-type="bibr">116</xref>], and serum collected from participants in the phase 1 trial induced neutralizing antibodies against all 3 genotypes of CHIKV. Interestingly, while the phase 2 trial aimed to only enroll CHIKV seronegative participants, 20% of the cohort (in particular, participants from 2 study sites&#8212;Dominican Republic and Haiti) were retrospectively found to be seropositive at baseline on the day of the study enrolment, possibly due to seroconversion between screening and study enrolment. A post-hoc analysis demonstrated that the VLP was immunogenic among these seropositive recipients, but a significant difference was observed between the geometric mean ratio between seropositive and seronegative vaccine recipients. Further studies on this specific group of participants to understand the possible effects of seropositivity and efficacy or protection of the CHIKV VLP administered will be interesting, rendering the need for additional clinical trials [<xref rid="B117-microorganisms-09-00899" ref-type="bibr">117</xref>].</p></sec><sec id="sec3dot4-microorganisms-09-00899"><title>3.4. Chimeric Viruses</title><p>Another option in vaccine development in providing high levels of immunity is the use of a virus-vector system that utilizes an avirulent backbone, but incorporates the expression of viral genetic elements, such as the chimeric vector system for producing foreign gene products.</p><p>The insect-only host-restricted Eilat virus (EILV) has recently also been utilized as a chimeric backbone to replace the structural open reading frame with that of EEEV, VEEV or CHIKV [<xref rid="B125-microorganisms-09-00899" ref-type="bibr">125</xref>]. Given that EILV is unable to replicate in vertebrate cells and in brain tissues of infant mice, this enhances the safety aspect of the vaccine, and thus, also serves as a inactivated vaccine, which enhances the expression of particular immunogenic proteins. Separately, the monovalent EILV/EEEV and EILV/VEEV vaccines were efficacious in their protection against lethal alphavirus challenge&#8212;immunized CD-1 mice had a high seroconversion rate observed post vaccination and were highly protected from lethal EEEV-FL93 or VEEV-3908 challenge. Compared to mock-vaccinated animals, EILV/EEEV or EILV/VEEV immunized animals had little or no weight loss and were protected from disease. More importantly, a trivalent vaccine containing the EILV/EEEV, EILV/VEEV and EILV/CHIKV chimeras was formulated and assessed if the vaccine could provide protection against lethal challenge with multiple alphaviruses. A single trivalent dose of EILV/VEEV, EILV/EEEV, and EILV/CHIKV elicited neutralizing antibodies against all three viruses and provided &gt;80% protection against VEEV and EEEV lethal challenge. Collectively, this work showed safety combined with strong immunogenicity and ease of production, making the use of the EILV alphavirus chimeric vaccine platform promising and attractive [<xref rid="B125-microorganisms-09-00899" ref-type="bibr">125</xref>]. The use of a trivalent vaccine candidate also serves as a proof-of-concept to show practicality and increases its potential as a vaccine against neurotropic alphaviruses.</p></sec><sec id="sec3dot5-microorganisms-09-00899"><title>3.5. Nucleic Acid-Based Vaccines</title><p>Commonly known as the &#8216;third-generation vaccine&#8217;, RNA and DNA vaccines form one of the latest vaccine approaches for alphaviruses. The risk of infection from receiving a vaccine is minimal, given the safety associated with the nucleic acid product [<xref rid="B230-microorganisms-09-00899" ref-type="bibr">230</xref>]. In addition, as some vaccines have been shown to have poor immunogenicity due to the lack of uptake or the need for adjuvants [<xref rid="B231-microorganisms-09-00899" ref-type="bibr">231</xref>], much research over the past decades have explored the design of constructs and novel delivery technologies to overcome these issues. In order to overcome several issues related to traditional vaccine development, such as high cost and difficulty in production, RNA has emerged as an effective platform to deliver vaccines using nanoparticle delivery vehicles, such as liposomes [<xref rid="B232-microorganisms-09-00899" ref-type="bibr">232</xref>,<xref rid="B233-microorganisms-09-00899" ref-type="bibr">233</xref>,<xref rid="B234-microorganisms-09-00899" ref-type="bibr">234</xref>].</p><p>A RNA vaccine against CHIKV involves the delivery of the self-replicating RNA genome of the live attenuated CHIKV-NoLS virus with CAF01 liposomes [<xref rid="B126-microorganisms-09-00899" ref-type="bibr">126</xref>]. The mutation in the nucleolar localization sequence (NoLS) in the capsid protein of CHIK-NoLS was previously shown to significantly attenuate viral replication [<xref rid="B127-microorganisms-09-00899" ref-type="bibr">127</xref>]. In the same study, C57/BL6 mice immunized with one dose of CHIKV-NoLS were fully protected from CHIKV infection [<xref rid="B127-microorganisms-09-00899" ref-type="bibr">127</xref>]. In immunodeficient AG129 mice, a single dose of CHIKV-NoLS RNA delivered with CAF01 generated CHIKV-specific neutralizing antibodies. While these immunized AG129 mice developed disease signs, they eventually recover from the immunization, compared to mock-immunized mice. Importantly, CHIKV-NoLS CAF01-immunized AG129 mice survive from subsequent CHIKV challenge and do not develop CHIKV-induced footpad swelling or disease. On the other hand, in immunocompetent C57/BL6 mice, CHIKV-NoLS CAF01-immunized mice developed delayed viremia at a similar titer compared to CHIKV-WT, and were protected from footpad swelling. However, immunization with either CHIKV-NoLS CAF01 or CHIKV-NoLS RNA produced significantly lower levels of neutralizing antibody compared to CHIKV-WT inoculation [<xref rid="B126-microorganisms-09-00899" ref-type="bibr">126</xref>]. However, this study showed that the RNA-launched self-assembling viral particles generated immunity and protection that were just as strong as those of wild-type viral particles, suggesting the significant potential of this approach.</p><p>While multiple novel approaches have been explored to develop vaccines against alphaviruses, a potential prophylactic strategy that could be the development of a multivalent alphavirus vaccine given the reports of cross-neutralizing antibodies against conserved epitopes in the E2 protein across closely related alphaviruses. This approach would prove useful in endemic areas where alphavirus co-circulation occurs.</p></sec></sec></body><back><fn-group><fn><p><bold>Publisher&#8217;s Note:</bold> MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><app-group><app id="app1-microorganisms-09-00899"><title>Supplementary Materials</title><p>The following are available online at <uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.mdpi.com/article/10.3390/microorganisms9050899/s1">https://www.mdpi.com/article/10.3390/microorganisms9050899/s1</uri>. Supplementary Figure S1. Alignment of E1 and E2 amino acid sequences of arthritogenic and encephalitic alphaviruses.</p><supplementary-material content-type="local-data" id="microorganisms-09-00899-s001" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="microorganisms-09-00899-s001.zip" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></app></app-group><notes><title>Author Contributions</title><p>Data curation and writing, A.T.-R. and R.S.-L.C.; conceptualization and supervision, L.F.P.N. All authors have read and agreed to the published version of the manuscript.</p></notes><notes><title>Funding</title><p>This research received no external funding.</p></notes><notes notes-type="data-availability"><title>Data Availability Statement</title><p>No new data were created or analyzed in this study. Data sharing is not applicable to this article.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflict of interest.</p></notes><ref-list><title>References</title><ref id="B1-microorganisms-09-00899"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atkins</surname><given-names>G.J.</given-names></name></person-group><article-title>The Pathogenesis of Alphaviruses</article-title><source>ISRN Virol.</source><year>2013</year><volume>2013</volume><fpage>22</fpage><pub-id pub-id-type="doi">10.5402/2013/861912</pub-id></element-citation></ref><ref id="B2-microorganisms-09-00899"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zaid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Burt</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Poo</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Zandi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Suhrbier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.</given-names></name><name name-style="western"><surname>Texeira</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mahalingam</surname><given-names>S.</given-names></name></person-group><article-title>Arthritogenic alphaviruses: Epidemiological and clinical perspective on emerging arboviruses</article-title><source>Lancet Infect. Dis.</source><year>2020</year><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30491-6</pub-id><pub-id pub-id-type="pmid">33160445</pub-id></element-citation></ref><ref id="B3-microorganisms-09-00899"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suhrbier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jaffar-Bandjee</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Gasque</surname><given-names>P.</given-names></name></person-group><article-title>Arthritogenic alphaviruses&#8212;An overview</article-title><source>Nat. Rev. Rheumatol.</source><year>2012</year><volume>8</volume><fpage>420</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1038/nrrheum.2012.64</pub-id><pub-id pub-id-type="pmid">22565316</pub-id></element-citation></ref><ref id="B4-microorganisms-09-00899"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zacks</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Paessler</surname><given-names>S.</given-names></name></person-group><article-title>Encephalitic alphaviruses</article-title><source>Vet. Microbiol.</source><year>2010</year><volume>140</volume><fpage>281</fpage><lpage>286</lpage><pub-id pub-id-type="doi">10.1016/j.vetmic.2009.08.023</pub-id><pub-id pub-id-type="pmid">19775836</pub-id><pub-id pub-id-type="pmcid">PMC2814892</pub-id></element-citation></ref><ref id="B5-microorganisms-09-00899"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wahid</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ali</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rafique</surname><given-names>S.</given-names></name><name name-style="western"><surname>Idrees</surname><given-names>M.</given-names></name></person-group><article-title>Global expansion of chikungunya virus: Mapping the 64-year history</article-title><source>Int. J. Infect. Dis.</source><year>2017</year><volume>58</volume><fpage>69</fpage><lpage>76</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2017.03.006</pub-id><pub-id pub-id-type="pmid">28288924</pub-id></element-citation></ref><ref id="B6-microorganisms-09-00899"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Haddow</surname><given-names>A.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Walker</surname><given-names>A.J.</given-names></name></person-group><article-title>O&#8217;nyong-nyong fever: An epidemic virus disease in East Africa 1. Introduction</article-title><source>Trans. R. Soc. Trop. Med. Hyg.</source><year>1960</year><volume>54</volume><fpage>517</fpage><lpage>522</lpage><pub-id pub-id-type="doi">10.1016/0035-9203(60)90025-0</pub-id></element-citation></ref><ref id="B7-microorganisms-09-00899"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bessaud</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peyrefitte</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Pastorino</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Tock</surname><given-names>F.</given-names></name><name name-style="western"><surname>Merle</surname><given-names>O.</given-names></name><name name-style="western"><surname>Colpart</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Dehecq</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Girod</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jaffar-Bandjee</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Glass</surname><given-names>P. J.</given-names></name><etal/></person-group><article-title>Chikungunya virus strains, Reunion Island outbreak</article-title><source>Emerg. Infect. Dis.</source><year>2006</year><volume>12</volume><fpage>1604</fpage><lpage>1606</lpage><pub-id pub-id-type="doi">10.3201/eid1210.060596</pub-id><pub-id pub-id-type="pmid">17176585</pub-id><pub-id pub-id-type="pmcid">PMC3290959</pub-id></element-citation></ref><ref id="B8-microorganisms-09-00899"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aaskov</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Mataika</surname><given-names>J.U.</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Rabukawaqa</surname><given-names>V.</given-names></name><name name-style="western"><surname>Tucker</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Miles</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Dalglish</surname><given-names>D.A.</given-names></name></person-group><article-title>An epidemic of Ross River virus infection in Fiji, 1979</article-title><source>Am. J. Trop. Med. Hyg.</source><year>1981</year><volume>30</volume><fpage>1053</fpage><lpage>1059</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.1981.30.1053</pub-id><pub-id pub-id-type="pmid">7283004</pub-id></element-citation></ref><ref id="B9-microorganisms-09-00899"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsetsarkin</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Vanlandingham</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>McGee</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Higgs</surname><given-names>S.</given-names></name></person-group><article-title>A single mutation in chikungunya virus affects vector specificity and epidemic potential</article-title><source>PLoS Pathog.</source><year>2007</year><volume>3</volume><elocation-id>e201</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.0030201</pub-id><pub-id pub-id-type="pmid">18069894</pub-id><pub-id pub-id-type="pmcid">PMC2134949</pub-id></element-citation></ref><ref id="B10-microorganisms-09-00899"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsetsarkin</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>McGee</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Volk</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Vanlandingham</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Higgs</surname><given-names>S.</given-names></name></person-group><article-title>Epistatic roles of E2 glycoprotein mutations in adaption of chikungunya virus to Aedes albopictus and Ae. aegypti mosquitoes</article-title><source>PLoS ONE</source><year>2009</year><volume>4</volume><elocation-id>e6835</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0006835</pub-id><pub-id pub-id-type="pmid">19718263</pub-id><pub-id pub-id-type="pmcid">PMC2729410</pub-id></element-citation></ref><ref id="B11-microorganisms-09-00899"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rezza</surname><given-names>G.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name></person-group><article-title>O&#8217;nyong-nyong fever: A neglected mosquito-borne viral disease</article-title><source>Pathog. Glob. Health</source><year>2017</year><volume>111</volume><fpage>271</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1080/20477724.2017.1355431</pub-id><pub-id pub-id-type="pmid">28829253</pub-id><pub-id pub-id-type="pmcid">PMC5694854</pub-id></element-citation></ref><ref id="B12-microorganisms-09-00899"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Acosta-Ampudia</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Monsalve</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Rodriguez</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Pacheco</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Anaya</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Ramirez-Santana</surname><given-names>C.</given-names></name></person-group><article-title>Mayaro: An emerging viral threat?</article-title><source>Emerg. Microbe. Infect.</source><year>2018</year><volume>7</volume><fpage>163</fpage><pub-id pub-id-type="doi">10.1038/s41426-018-0163-5</pub-id><pub-id pub-id-type="pmcid">PMC6156602</pub-id><pub-id pub-id-type="pmid">30254258</pub-id></element-citation></ref><ref id="B13-microorganisms-09-00899"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ganjian</surname><given-names>N.</given-names></name><name name-style="western"><surname>Riviere-Cinnamond</surname><given-names>A.</given-names></name></person-group><article-title>Mayaro virus in Latin America and the Caribbean</article-title><source>Rev. Panam. Salud. Publica</source><year>2020</year><volume>44</volume><fpage>14</fpage><pub-id pub-id-type="doi">10.26633/RPSP.2020.14</pub-id><pub-id pub-id-type="pmcid">PMC7008609</pub-id><pub-id pub-id-type="pmid">32051685</pub-id></element-citation></ref><ref id="B14-microorganisms-09-00899"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pezzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>LaBeaud</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Reusken</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Drexler</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Vasilakis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Diallo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Simon</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jaenisch</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gallian</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sall</surname><given-names>A.</given-names></name><etal/></person-group><article-title>GloPID-R report on chikungunya, o&#8217;nyong-nyong and Mayaro virus, part 2: Epidemiological distribution of o&#8217;nyong-nyong virus</article-title><source>Antivir. Res.</source><year>2019</year><volume>172</volume><fpage>104611</fpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2019.104611</pub-id><pub-id pub-id-type="pmid">31545982</pub-id></element-citation></ref><ref id="B15-microorganisms-09-00899"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pezzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rodriguez-Morales</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Reusken</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>G.S.</given-names></name><name name-style="western"><surname>LaBeaud</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Louren&#231;o-de-Oliveira</surname><given-names>R.</given-names></name><name name-style="western"><surname>Brasil</surname><given-names>P.</given-names></name><name name-style="western"><surname>Lecuit</surname><given-names>M.</given-names></name><name name-style="western"><surname>Failloux</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Gallian</surname><given-names>P.</given-names></name><etal/></person-group><article-title>GloPID-R report on chikungunya, o&#8217;nyong-nyong and Mayaro virus, part 3: Epidemiological distribution of Mayaro virus</article-title><source>Antivir. Res.</source><year>2019</year><volume>172</volume><fpage>104610</fpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2019.104610</pub-id><pub-id pub-id-type="pmid">31545981</pub-id></element-citation></ref><ref id="B16-microorganisms-09-00899"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pezzi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Reusken</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Drexler</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Busch</surname><given-names>M.</given-names></name><name name-style="western"><surname>LaBeaud</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Vasilakis</surname><given-names>N.</given-names></name><name name-style="western"><surname>Drebot</surname><given-names>M. A.</given-names></name><name name-style="western"><surname>Siqueira</surname><given-names>A.M.</given-names></name><etal/></person-group><article-title>GloPID-R report on Chikungunya, O&#8217;nyong-nyong and Mayaro virus, part I: Biological diagnostics</article-title><source>Antivir. Res.</source><year>2019</year><volume>166</volume><fpage>66</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.antiviral.2019.03.009</pub-id><pub-id pub-id-type="pmid">30905821</pub-id></element-citation></ref><ref id="B17-microorganisms-09-00899"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Seyler</surname><given-names>T.</given-names></name><name name-style="western"><surname>Hutin</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ramanchandran</surname><given-names>V.</given-names></name><name name-style="western"><surname>Ramakrishnan</surname><given-names>R.</given-names></name><name name-style="western"><surname>Manickam</surname><given-names>P.</given-names></name><name name-style="western"><surname>Murhekar</surname><given-names>M.</given-names></name></person-group><article-title>Estimating the burden of disease and the economic cost attributable to chikungunya, Andhra Pradesh, India, 2005&#8211;2006</article-title><source>Trans. R. Soc. Trop. Med. Hyg.</source><year>2010</year><volume>104</volume><fpage>133</fpage><lpage>138</lpage><pub-id pub-id-type="doi">10.1016/j.trstmh.2009.07.014</pub-id><pub-id pub-id-type="pmid">19709705</pub-id></element-citation></ref><ref id="B18-microorganisms-09-00899"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alvis-Zakzuk</surname><given-names>N.J.</given-names></name><name name-style="western"><surname>Diaz-Jimenez</surname><given-names>D.</given-names></name><name name-style="western"><surname>Castillo-Rodriguez</surname><given-names>L.</given-names></name><name name-style="western"><surname>Castaneda-Orjuela</surname><given-names>C.</given-names></name><name name-style="western"><surname>Paternina-Caicedo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Pinzon-Redondo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Carrasquilla-Sotomayor</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alvis-Guzm&#225;n</surname><given-names>N.</given-names></name><name name-style="western"><surname>De La Hoz-Restrepo</surname><given-names>F.</given-names></name></person-group><article-title>Economic Costs of Chikungunya Virus in Colombia</article-title><source>Value Health Reg. Issues</source><year>2018</year><volume>17</volume><fpage>32</fpage><lpage>37</lpage><pub-id pub-id-type="doi">10.1016/j.vhri.2018.01.004</pub-id><pub-id pub-id-type="pmid">29627722</pub-id></element-citation></ref><ref id="B19-microorganisms-09-00899"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thompson</surname><given-names>R.</given-names></name><name name-style="western"><surname>del Martin Campo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Constenla</surname><given-names>D.</given-names></name></person-group><article-title>A review of the economic evidence of Aedes-borne arboviruses and Aedes-borne arboviral disease prevention and control strategies</article-title><source>Expert Rev. Vaccin.</source><year>2020</year><volume>19</volume><fpage>143</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1080/14760584.2020.1733419</pub-id><pub-id pub-id-type="pmid">32077343</pub-id></element-citation></ref><ref id="B20-microorganisms-09-00899"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cunha</surname><given-names>R.V.D.</given-names></name><name name-style="western"><surname>Trinta</surname><given-names>K.S.</given-names></name></person-group><article-title>Chikungunya virus: Clinical aspects and treatment&#8212;A Review</article-title><source>Mem. Inst. Oswaldo Cruz</source><year>2017</year><volume>112</volume><fpage>523</fpage><lpage>531</lpage><pub-id pub-id-type="doi">10.1590/0074-02760170044</pub-id><pub-id pub-id-type="pmid">28767976</pub-id><pub-id pub-id-type="pmcid">PMC5530543</pub-id></element-citation></ref><ref id="B21-microorganisms-09-00899"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lundstrom</surname><given-names>K.</given-names></name></person-group><article-title>Alphavirus-based vaccines</article-title><source>Viruses</source><year>2014</year><volume>6</volume><fpage>2392</fpage><lpage>2415</lpage><pub-id pub-id-type="doi">10.3390/v6062392</pub-id><pub-id pub-id-type="pmid">24937089</pub-id><pub-id pub-id-type="pmcid">PMC4074933</pub-id></element-citation></ref><ref id="B22-microorganisms-09-00899"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Panning</surname><given-names>M.</given-names></name><name name-style="western"><surname>Grywna</surname><given-names>K.</given-names></name><name name-style="western"><surname>van Esbroeck</surname><given-names>M.</given-names></name><name name-style="western"><surname>Emmerich</surname><given-names>P.</given-names></name><name name-style="western"><surname>Drosten</surname><given-names>C.</given-names></name></person-group><article-title>Chikungunya fever in travelers returning to Europe from the Indian Ocean region, 2006</article-title><source>Emerg. Infect. Dis.</source><year>2008</year><volume>14</volume><fpage>416</fpage><lpage>422</lpage><pub-id pub-id-type="doi">10.3201/eid1403.070906</pub-id><pub-id pub-id-type="pmid">18325256</pub-id><pub-id pub-id-type="pmcid">PMC2570846</pub-id></element-citation></ref><ref id="B23-microorganisms-09-00899"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kam</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Lum</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Teo</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Simarmata</surname><given-names>D.</given-names></name><name name-style="western"><surname>Harjanto</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chua</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Wee</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Chow</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein</article-title><source>EMBO Mol. Med.</source><year>2012</year><volume>4</volume><fpage>330</fpage><lpage>343</lpage><pub-id pub-id-type="doi">10.1002/emmm.201200213</pub-id><pub-id pub-id-type="pmid">22389221</pub-id><pub-id pub-id-type="pmcid">PMC3376860</pub-id></element-citation></ref><ref id="B24-microorganisms-09-00899"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pierro</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rossini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gaibani</surname><given-names>P.</given-names></name><name name-style="western"><surname>Finarelli</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Moro</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Landini</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Sambri</surname><given-names>V.</given-names></name></person-group><article-title>Persistence of anti-chikungunya virus-specific antibodies in a cohort of patients followed from the acute phase of infection after the 2007 outbreak in Italy</article-title><source>New Microbe. New Infect.</source><year>2015</year><volume>7</volume><fpage>23</fpage><lpage>25</lpage><pub-id pub-id-type="doi">10.1016/j.nmni.2015.04.002</pub-id><pub-id pub-id-type="pmcid">PMC4475829</pub-id><pub-id pub-id-type="pmid">26106482</pub-id></element-citation></ref><ref id="B25-microorganisms-09-00899"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chua</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Sam</surname><given-names>I.C.</given-names></name><name name-style="western"><surname>Chiam</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>Y.F.</given-names></name></person-group><article-title>The neutralizing role of IgM during early Chikungunya virus infection</article-title><source>PLoS ONE</source><year>2017</year><volume>12</volume><elocation-id>e0171989</elocation-id><pub-id pub-id-type="pmid">28182795</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0171989</pub-id><pub-id pub-id-type="pmcid">PMC5300252</pub-id></element-citation></ref><ref id="B26-microorganisms-09-00899"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Borgherini</surname><given-names>G.</given-names></name><name name-style="western"><surname>Poubeau</surname><given-names>P.</given-names></name><name name-style="western"><surname>Staikowsky</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lory</surname><given-names>M.</given-names></name><name name-style="western"><surname>Le Moullec</surname><given-names>N.</given-names></name><name name-style="western"><surname>Becquart</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Wengling</surname><given-names>C.</given-names></name><name name-style="western"><surname>Michault</surname><given-names>A.</given-names></name><name name-style="western"><surname>Paganin</surname><given-names>F.</given-names></name></person-group><article-title>Outbreak of chikungunya on Reunion Island: Early clinical and laboratory features in 157 adult patients</article-title><source>Clin. Infect. Dis.</source><year>2007</year><volume>44</volume><fpage>1401</fpage><lpage>1407</lpage><pub-id pub-id-type="doi">10.1086/517537</pub-id><pub-id pub-id-type="pmid">17479933</pub-id></element-citation></ref><ref id="B27-microorganisms-09-00899"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Malvy</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ezzedine</surname><given-names>K.</given-names></name><name name-style="western"><surname>Mamani-Matsuda</surname><given-names>M.</given-names></name><name name-style="western"><surname>Autran</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tolou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Receveur</surname><given-names>M-C.</given-names></name><name name-style="western"><surname>Pistone</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rambert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Moynet</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mossalayi</surname><given-names>D.</given-names></name></person-group><article-title>Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies</article-title><source>BMC Infect. Dis.</source><year>2009</year><volume>9</volume><elocation-id>200</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2334-9-200</pub-id><pub-id pub-id-type="pmid">20003320</pub-id><pub-id pub-id-type="pmcid">PMC2803790</pub-id></element-citation></ref><ref id="B28-microorganisms-09-00899"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bozza</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Moreira-Soto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rockstroh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Nascimento</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Calheiros</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Drosten</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bozza</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Souza</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ulbert</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Differential Shedding and Antibody Kinetics of Zika and Chikungunya Viruses, Brazil</article-title><source>Emerg. Infect. Dis.</source><year>2019</year><volume>25</volume><fpage>311</fpage><lpage>315</lpage><pub-id pub-id-type="doi">10.3201/eid2502.180166</pub-id><pub-id pub-id-type="pmid">30666934</pub-id><pub-id pub-id-type="pmcid">PMC6346451</pub-id></element-citation></ref><ref id="B29-microorganisms-09-00899"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nitatpattana</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kanjanopas</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yoksan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Satimai</surname><given-names>W.</given-names></name><name name-style="western"><surname>Vongba</surname><given-names>N.</given-names></name><name name-style="western"><surname>Langdatsuwan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Nakgoi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Ratchakum</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wauquier</surname><given-names>N.</given-names></name><name name-style="western"><surname>Souris</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Long-term persistence of Chikungunya virus neutralizing antibodies in human populations of North Eastern Thailand</article-title><source>Virol. J.</source><year>2014</year><volume>11</volume><fpage>183</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-11-183</pub-id><pub-id pub-id-type="pmid">25330992</pub-id><pub-id pub-id-type="pmcid">PMC4283153</pub-id></element-citation></ref><ref id="B30-microorganisms-09-00899"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shore</surname><given-names>H.</given-names></name></person-group><article-title>O&#8217;nyong-nyong fever: An epidemic virus disease in East Africa: III Some clinical and epidemiological observations in the Northern Province of Uganda</article-title><source>Trans. R. Soc. Trop. Med. Hyg.</source><year>1961</year><volume>55</volume><fpage>361</fpage><lpage>373</lpage><pub-id pub-id-type="doi">10.1016/0035-9203(61)90106-7</pub-id></element-citation></ref><ref id="B31-microorganisms-09-00899"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Williams</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Woodall</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Corbet</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Gillett</surname><given-names>J.D.</given-names></name></person-group><article-title>O&#8217;nyong-Nyong Fever: An Epidemic Virus Disease in East Africa. 8. Virus Isolations from Anopheles Mosquitoes</article-title><source>Trans. R. Soc. Trop. Med. Hyg.</source><year>1965</year><volume>59</volume><fpage>300</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1016/0035-9203(65)90012-X</pub-id><pub-id pub-id-type="pmid">14298035</pub-id></element-citation></ref><ref id="B32-microorganisms-09-00899"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kiwanuka</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sanders</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Rwaguma</surname><given-names>E.B.</given-names></name><name name-style="western"><surname>Kawamata</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ssengooba</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>Najjemba</surname><given-names>R.</given-names></name><name name-style="western"><surname>Were</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Lamunu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bagambisa</surname><given-names>G.</given-names></name><name name-style="western"><surname>Burkot</surname><given-names>T.R.</given-names></name><etal/></person-group><article-title>O&#8217;nyong-nyong fever in south-central Uganda, 1996&#8211;1997: Clinical features and validation of a clinical case definition for surveillance purposes</article-title><source>Clin. Infect. Dis.</source><year>1999</year><volume>29</volume><fpage>1243</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.1086/313462</pub-id><pub-id pub-id-type="pmid">10524970</pub-id></element-citation></ref><ref id="B33-microorganisms-09-00899"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tappe</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kapaun</surname><given-names>A.</given-names></name><name name-style="western"><surname>Emmerich</surname><given-names>P.</given-names></name><name name-style="western"><surname>de Mendonca Campos</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cadar</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gunther</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schmidt-Chanasit</surname><given-names>J.</given-names></name></person-group><article-title>O&#8217;nyong-nyong virus infection imported to Europe from Kenya by a traveler</article-title><source>Emerg. Infect. Dis.</source><year>2014</year><volume>20</volume><fpage>1766</fpage><lpage>1767</lpage><pub-id pub-id-type="doi">10.3201/eid2010.140823</pub-id><pub-id pub-id-type="pmid">25271361</pub-id><pub-id pub-id-type="pmcid">PMC4193281</pub-id></element-citation></ref><ref id="B34-microorganisms-09-00899"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bessaud</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peyrefitte</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Pastorino</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Gravier</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tock</surname><given-names>F.</given-names></name><name name-style="western"><surname>Boete</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tolou</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Grandadam</surname><given-names>M.</given-names></name></person-group><article-title>O&#8217;nyong-nyong Virus, Chad</article-title><source>Emerg. Infect. Dis.</source><year>2006</year><volume>12</volume><fpage>1248</fpage><lpage>1250</lpage><pub-id pub-id-type="doi">10.3201/eid1208.060199</pub-id><pub-id pub-id-type="pmid">16965706</pub-id><pub-id pub-id-type="pmcid">PMC3291225</pub-id></element-citation></ref><ref id="B35-microorganisms-09-00899"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Diagne</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Bengue</surname><given-names>M.</given-names></name><name name-style="western"><surname>Choumet</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hamel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Pompon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Misse</surname><given-names>D.</given-names></name></person-group><article-title>Mayaro Virus Pathogenesis and Transmission Mechanisms</article-title><source>Pathogens</source><year>2020</year><volume>9</volume><elocation-id>738</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens9090738</pub-id><pub-id pub-id-type="pmcid">PMC7558846</pub-id><pub-id pub-id-type="pmid">32911824</pub-id></element-citation></ref><ref id="B36-microorganisms-09-00899"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mourao</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Bastos</surname><given-names>M.D.S.</given-names></name><name name-style="western"><surname>de Figueiredo</surname><given-names>R.P.</given-names></name><name name-style="western"><surname>Gimaque</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Galusso Edos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>V.M.</given-names></name><name name-style="western"><surname>de Oliveira</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Naveca</surname><given-names>F.G.</given-names></name><name name-style="western"><surname>Figueiredo</surname><given-names>L.T.</given-names></name></person-group><article-title>Mayaro fever in the city of Manaus, Brazil, 2007&#8211;2008</article-title><source>Vector Borne Zoonotic Dis.</source><year>2012</year><volume>12</volume><fpage>42</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1089/vbz.2011.0669</pub-id><pub-id pub-id-type="pmid">21923266</pub-id><pub-id pub-id-type="pmcid">PMC3249893</pub-id></element-citation></ref><ref id="B37-microorganisms-09-00899"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Halsey</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Siles</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guevara</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vilcarromero</surname><given-names>S.</given-names></name><name name-style="western"><surname>Jhonston</surname><given-names>E.J.</given-names></name><name name-style="western"><surname>Ramal</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aguilar</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Ampuero</surname><given-names>J.S.</given-names></name></person-group><article-title>Mayaro virus infection, Amazon Basin region, Peru, 2010&#8211;2013</article-title><source>Emerg. Infect. Dis.</source><year>2013</year><volume>19</volume><fpage>1839</fpage><lpage>1842</lpage><pub-id pub-id-type="doi">10.3201/eid1911.130777</pub-id><pub-id pub-id-type="pmid">24210165</pub-id><pub-id pub-id-type="pmcid">PMC3837653</pub-id></element-citation></ref><ref id="B38-microorganisms-09-00899"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Figueiredo</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Nogueira</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Cavalcanti</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Schatzmayr</surname><given-names>H.</given-names></name><name name-style="western"><surname>da Rosa</surname><given-names>A.T.</given-names></name></person-group><article-title>Study of two different enzyme immunoassays for the detection of Mayaro virus antibodies</article-title><source>Mem. Inst. Oswaldo Cruz</source><year>1989</year><volume>84</volume><fpage>303</fpage><lpage>307</lpage><pub-id pub-id-type="doi">10.1590/S0074-02761989000300003</pub-id><pub-id pub-id-type="pmid">2562487</pub-id></element-citation></ref><ref id="B39-microorganisms-09-00899"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santiago</surname><given-names>F.W.</given-names></name><name name-style="western"><surname>Halsey</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Siles</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vilcarromero</surname><given-names>S.</given-names></name><name name-style="western"><surname>Guevara</surname><given-names>C.</given-names></name><name name-style="western"><surname>Silvas</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Ramal</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ampuero</surname><given-names>J.S.</given-names></name><name name-style="western"><surname>Aguilar</surname><given-names>P.V.</given-names></name></person-group><article-title>Long-Term Arthralgia after Mayaro Virus Infection Correlates with Sustained Pro-inflammatory Cytokine Response</article-title><source>PLoS Negl. Trop. Dis.</source><year>2015</year><volume>9</volume><elocation-id>e0004104</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0004104</pub-id><pub-id pub-id-type="pmid">26496497</pub-id><pub-id pub-id-type="pmcid">PMC4619727</pub-id></element-citation></ref><ref id="B40-microorganisms-09-00899"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harley</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sleigh</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ritchie</surname><given-names>S.</given-names></name></person-group><article-title>Ross River virus transmission, infection, and disease: A cross-disciplinary review</article-title><source>Clin. Microbiol. Rev.</source><year>2001</year><volume>14</volume><fpage>909</fpage><lpage>932</lpage><pub-id pub-id-type="doi">10.1128/CMR.14.4.909-932.2001</pub-id><pub-id pub-id-type="pmid">11585790</pub-id><pub-id pub-id-type="pmcid">PMC89008</pub-id></element-citation></ref><ref id="B41-microorganisms-09-00899"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Farmer</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Suhrbier</surname><given-names>A.</given-names></name></person-group><article-title>Interpreting paired serology for Ross River virus and Barmah Forest virus diseases</article-title><source>Aust. J. Gen. Pract.</source><year>2019</year><volume>48</volume><fpage>645</fpage><lpage>649</lpage><pub-id pub-id-type="doi">10.31128/AJGP-02-19-4845</pub-id><pub-id pub-id-type="pmid">31476825</pub-id></element-citation></ref><ref id="B42-microorganisms-09-00899"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Barton</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Bielefeldt-Ohmann</surname><given-names>H.</given-names></name></person-group><article-title>Clinical Presentation, Progression, and Management of Five Cases of Ross River Virus Infection in Performance Horses Located in Southeast Queensland: A Longitudinal Case Series</article-title><source>J. Equin. Vet. Sci.</source><year>2017</year><volume>51</volume><fpage>34</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1016/j.jevs.2016.12.010</pub-id></element-citation></ref><ref id="B43-microorganisms-09-00899"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Azuolas</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Wishart</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bibby</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ainsworth</surname><given-names>C.</given-names></name></person-group><article-title>Isolation of Ross River virus from mosquitoes and from horses with signs of musculo-skeletal disease</article-title><source>Aust. Vet. J.</source><year>2003</year><volume>81</volume><fpage>344</fpage><lpage>347</lpage><pub-id pub-id-type="doi">10.1111/j.1751-0813.2003.tb11511.x</pub-id><pub-id pub-id-type="pmid">15080456</pub-id></element-citation></ref><ref id="B44-microorganisms-09-00899"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kapeleris</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>P.</given-names></name><name name-style="western"><surname>Phillips</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wyatt</surname><given-names>D.</given-names></name><name name-style="western"><surname>Batham</surname><given-names>M.</given-names></name><name name-style="western"><surname>Devine</surname><given-names>P.</given-names></name></person-group><article-title>IgG avidity in the diagnosis of acute Ross River virus infection</article-title><source>Dis. Marker.</source><year>1996</year><volume>12</volume><fpage>279</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1155/1996/756940</pub-id><pub-id pub-id-type="pmid">8718789</pub-id></element-citation></ref><ref id="B45-microorganisms-09-00899"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calisher</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Meurman</surname><given-names>O.</given-names></name><name name-style="western"><surname>Brummer-Korvenkontio</surname><given-names>M.</given-names></name><name name-style="western"><surname>Halonen</surname><given-names>P.E.</given-names></name><name name-style="western"><surname>Muth</surname><given-names>D.J.</given-names></name></person-group><article-title>Sensitive enzyme immunoassay for detecting immunoglobulin M antibodies to Sindbis virus and further evidence that Pogosta disease is caused by a western equine encephalitis complex virus</article-title><source>J. Clin. Microbiol.</source><year>1985</year><volume>22</volume><fpage>566</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1128/JCM.22.4.566-571.1985</pub-id><pub-id pub-id-type="pmid">3908469</pub-id><pub-id pub-id-type="pmcid">PMC268468</pub-id></element-citation></ref><ref id="B46-microorganisms-09-00899"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kurkela</surname><given-names>S.</given-names></name><name name-style="western"><surname>Manni</surname><given-names>T.</given-names></name><name name-style="western"><surname>Myllynen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vaheri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Vapalahti</surname><given-names>O.</given-names></name></person-group><article-title>Clinical and laboratory manifestations of Sindbis virus infection: Prospective study, Finland, 2002&#8211;2003</article-title><source>J. Infect. Dis.</source><year>2005</year><volume>191</volume><fpage>1820</fpage><lpage>1829</lpage><pub-id pub-id-type="doi">10.1086/430007</pub-id><pub-id pub-id-type="pmid">15871114</pub-id></element-citation></ref><ref id="B47-microorganisms-09-00899"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Niklasson</surname><given-names>B.</given-names></name><name name-style="western"><surname>Espmark</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lundstrom</surname><given-names>J.</given-names></name></person-group><article-title>Occurrence of arthralgia and specific IgM antibodies three to four years after Ockelbo disease</article-title><source>J. Infect. Dis.</source><year>1988</year><volume>157</volume><fpage>832</fpage><lpage>835</lpage><pub-id pub-id-type="doi">10.1093/infdis/157.4.832</pub-id><pub-id pub-id-type="pmid">2831289</pub-id></element-citation></ref><ref id="B48-microorganisms-09-00899"><label>48.</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Griffin</surname><given-names>D.E.</given-names></name></person-group><article-title>Neurotropic Alphaviruses</article-title><source>Neurotropic Viral Infections</source><edition>2nd ed.</edition><person-group person-group-type="editor"><name name-style="western"><surname>Reis</surname><given-names>C.S.</given-names></name></person-group><publisher-name>Springer International Publishing</publisher-name><publisher-loc>Cham, Switzerland</publisher-loc><year>2016</year><fpage>175</fpage><lpage>204</lpage></element-citation></ref><ref id="B49-microorganisms-09-00899"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Calisher</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Berardi</surname><given-names>V.P.</given-names></name><name name-style="western"><surname>Muth</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Buff</surname><given-names>E.E.</given-names></name></person-group><article-title>Specificity of immunoglobulin M and G antibody responses in humans infected with eastern and western equine encephalitis viruses: Application to rapid serodiagnosis</article-title><source>J. Clin. Microbiol.</source><year>1986</year><volume>23</volume><fpage>369</fpage><lpage>372</lpage><pub-id pub-id-type="doi">10.1128/JCM.23.2.369-372.1986</pub-id><pub-id pub-id-type="pmid">3009535</pub-id><pub-id pub-id-type="pmcid">PMC268644</pub-id></element-citation></ref><ref id="B50-microorganisms-09-00899"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gardner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Anraku</surname><given-names>I.</given-names></name><name name-style="western"><surname>Le</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Larcher</surname><given-names>T.</given-names></name><name name-style="western"><surname>Major</surname><given-names>L.</given-names></name><name name-style="western"><surname>Roques</surname><given-names>P.</given-names></name><name name-style="western"><surname>Schroder</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Higgs</surname><given-names>S.</given-names></name><name name-style="western"><surname>Suhrbier</surname><given-names>A.</given-names></name></person-group><article-title>Chikungunya virus arthritis in adult wild-type mice</article-title><source>J. Virol.</source><year>2010</year><volume>84</volume><fpage>8021</fpage><lpage>8032</lpage><pub-id pub-id-type="doi">10.1128/JVI.02603-09</pub-id><pub-id pub-id-type="pmid">20519386</pub-id><pub-id pub-id-type="pmcid">PMC2916516</pub-id></element-citation></ref><ref id="B51-microorganisms-09-00899"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poo</surname><given-names>Y.S.</given-names></name><name name-style="western"><surname>Rudd</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Larcher</surname><given-names>T.</given-names></name><name name-style="western"><surname>Colle</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Le</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Nakaya</surname><given-names>H.I.</given-names></name><name name-style="western"><surname>Warrilow</surname><given-names>D.</given-names></name><name name-style="western"><surname>Allcock</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Multiple immune factors are involved in controlling acute and chronic chikungunya virus infection</article-title><source>PLoS Negl. Trop. Dis.</source><year>2014</year><volume>8</volume><elocation-id>e3354</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0003354</pub-id><pub-id pub-id-type="pmid">25474568</pub-id><pub-id pub-id-type="pmcid">PMC4256279</pub-id></element-citation></ref><ref id="B52-microorganisms-09-00899"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hawman</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Stoermer</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Oko</surname><given-names>L.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>T.E.</given-names></name></person-group><article-title>Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>13878</fpage><lpage>13888</lpage><pub-id pub-id-type="doi">10.1128/JVI.02666-13</pub-id><pub-id pub-id-type="pmid">24131709</pub-id><pub-id pub-id-type="pmcid">PMC3838294</pub-id></element-citation></ref><ref id="B53-microorganisms-09-00899"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johnson</surname><given-names>R.T.</given-names></name></person-group><article-title>Virus Invasion of the Central Nervous System: A Study of Sindbis Virus Infection in the Mouse Using Fluorescent Antibody</article-title><source>Am. J. Pathol.</source><year>1965</year><volume>46</volume><fpage>929</fpage><lpage>943</lpage><pub-id pub-id-type="pmid">14328022</pub-id><pub-id pub-id-type="pmcid">PMC1920389</pub-id></element-citation></ref><ref id="B54-microorganisms-09-00899"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burdeinick-Kerr</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wind</surname><given-names>J.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>D.E.</given-names></name></person-group><article-title>Synergistic roles of antibody and interferon in noncytolytic clearance of Sindbis virus from different regions of the central nervous system</article-title><source>J. Virol.</source><year>2007</year><volume>81</volume><fpage>5628</fpage><lpage>5636</lpage><pub-id pub-id-type="doi">10.1128/JVI.01152-06</pub-id><pub-id pub-id-type="pmid">17376910</pub-id><pub-id pub-id-type="pmcid">PMC1900320</pub-id></element-citation></ref><ref id="B55-microorganisms-09-00899"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nilaratanakul</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tran</surname><given-names>O.</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Troisi</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Yeh</surname><given-names>J.X.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>D.E.</given-names></name></person-group><article-title>Germ Line IgM Is Sufficient, but Not Required, for Antibody-Mediated Alphavirus Clearance from the Central Nervous System</article-title><source>J. Virol.</source><year>2018</year><volume>92</volume><fpage>e02081-17</fpage><pub-id pub-id-type="doi">10.1128/JVI.02081-17</pub-id><pub-id pub-id-type="pmid">29321331</pub-id><pub-id pub-id-type="pmcid">PMC5972861</pub-id></element-citation></ref><ref id="B56-microorganisms-09-00899"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fragkoudis</surname><given-names>R.</given-names></name><name name-style="western"><surname>Ballany</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Boyd</surname><given-names>A.</given-names></name><name name-style="western"><surname>Fazakerley</surname><given-names>J.K.</given-names></name></person-group><article-title>In Semliki Forest virus encephalitis, antibody rapidly clears infectious virus and is required to eliminate viral material from the brain, but is not required to generate lesions of demyelination</article-title><source>J. Gen. Virol.</source><year>2008</year><volume>89</volume><fpage>2565</fpage><lpage>2568</lpage><pub-id pub-id-type="doi">10.1099/vir.0.2008/002238-0</pub-id><pub-id pub-id-type="pmid">18796725</pub-id></element-citation></ref><ref id="B57-microorganisms-09-00899"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Amor</surname><given-names>S.</given-names></name><name name-style="western"><surname>Scallan</surname><given-names>M.F.</given-names></name><name name-style="western"><surname>Morris</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Dyson</surname><given-names>H.</given-names></name><name name-style="western"><surname>Fazakerley</surname><given-names>J.K.</given-names></name></person-group><article-title>Role of immune responses in protection and pathogenesis during Semliki Forest virus encephalitis</article-title><source>J. Gen. Virol.</source><year>1996</year><volume>77</volume><fpage>281</fpage><lpage>291</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-77-2-281</pub-id><pub-id pub-id-type="pmid">8627232</pub-id></element-citation></ref><ref id="B58-microorganisms-09-00899"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fazakerley</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Webb</surname><given-names>H.E.</given-names></name></person-group><article-title>Semliki Forest virus-induced, immune-mediated demyelination: Adoptive transfer studies and viral persistence in nude mice</article-title><source>J. Gen. Virol.</source><year>1987</year><volume>68</volume><fpage>377</fpage><lpage>385</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-68-2-377</pub-id><pub-id pub-id-type="pmid">3029281</pub-id></element-citation></ref><ref id="B59-microorganisms-09-00899"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metcalf</surname><given-names>T.U.</given-names></name><name name-style="western"><surname>Baxter</surname><given-names>V.K.</given-names></name><name name-style="western"><surname>Nilaratanakul</surname><given-names>V.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>D.E.</given-names></name></person-group><article-title>Recruitment and retention of B cells in the central nervous system in response to alphavirus encephalomyelitis</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>2420</fpage><lpage>2429</lpage><pub-id pub-id-type="doi">10.1128/JVI.01769-12</pub-id><pub-id pub-id-type="pmid">23255791</pub-id><pub-id pub-id-type="pmcid">PMC3571404</pub-id></element-citation></ref><ref id="B60-microorganisms-09-00899"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metcalf</surname><given-names>T.U.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>D.E.</given-names></name></person-group><article-title>Alphavirus-induced encephalomyelitis: Antibody-secreting cells and viral clearance from the nervous system</article-title><source>J. Virol.</source><year>2011</year><volume>85</volume><fpage>11490</fpage><lpage>11501</lpage><pub-id pub-id-type="doi">10.1128/JVI.05379-11</pub-id><pub-id pub-id-type="pmid">21865385</pub-id><pub-id pub-id-type="pmcid">PMC3194963</pub-id></element-citation></ref><ref id="B61-microorganisms-09-00899"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teo</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Lum</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Claser</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lulla</surname><given-names>V.</given-names></name><name name-style="western"><surname>Lulla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Merits</surname><given-names>A.</given-names></name><name name-style="western"><surname>Renia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>L. F.</given-names></name></person-group><article-title>A pathogenic role for CD4+ T cells during Chikungunya virus infection in mice</article-title><source>J. Immunol.</source><year>2013</year><volume>190</volume><fpage>259</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1202177</pub-id><pub-id pub-id-type="pmid">23209328</pub-id></element-citation></ref><ref id="B62-microorganisms-09-00899"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lum</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Teo</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Kam</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Renia</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>L.F.</given-names></name></person-group><article-title>An essential role of antibodies in the control of Chikungunya virus infection</article-title><source>J. Immunol.</source><year>2013</year><volume>190</volume><fpage>6295</fpage><lpage>6302</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1300304</pub-id><pub-id pub-id-type="pmid">23670192</pub-id><pub-id pub-id-type="pmcid">PMC3677171</pub-id></element-citation></ref><ref id="B63-microorganisms-09-00899"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olitsky</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>H.R.</given-names></name></person-group><article-title>Active Immunication of Guinea Pigs with the Virus of Equine Encephalomyelitis: I. Quantitative Experiments with Various Preparations of Active Virus</article-title><source>J. Exp. Med.</source><year>1936</year><volume>63</volume><fpage>311</fpage><lpage>324</lpage><pub-id pub-id-type="doi">10.1084/jem.63.3.311</pub-id><pub-id pub-id-type="pmid">19870474</pub-id><pub-id pub-id-type="pmcid">PMC2133342</pub-id></element-citation></ref><ref id="B64-microorganisms-09-00899"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Olitsky</surname><given-names>P.K.</given-names></name></person-group><article-title>Active Immunization of Guinea Pigs with the Virus of Equine Encephalomyelitis: Iii. Quantitative Studies of Serum Antiviral Bodies in Animals Immunized with Active and Inactive Virus</article-title><source>J. Exp. Med.</source><year>1936</year><volume>64</volume><fpage>217</fpage><lpage>222</lpage><pub-id pub-id-type="doi">10.1084/jem.64.2.217</pub-id><pub-id pub-id-type="pmid">19870531</pub-id><pub-id pub-id-type="pmcid">PMC2180313</pub-id></element-citation></ref><ref id="B65-microorganisms-09-00899"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cox</surname><given-names>H.R.</given-names></name><name name-style="western"><surname>Olitsky</surname><given-names>P.K.</given-names></name></person-group><article-title>Active Immunization of Guinea Pigs with the Virus of Equine Encephalomyelitis: Iv. Effect of Immune Serum on Antigenicity of Active and Inactive Virus</article-title><source>J. Exp. Med.</source><year>1936</year><volume>64</volume><fpage>223</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1084/jem.64.2.223</pub-id><pub-id pub-id-type="pmid">19870532</pub-id><pub-id pub-id-type="pmcid">PMC2180312</pub-id></element-citation></ref><ref id="B66-microorganisms-09-00899"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Olitsky</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Harford</surname><given-names>C.G.</given-names></name></person-group><article-title>Intraperitoneal and Intracerebral Routes in Serum Protection Tests with the Virus of Equine Encephalomyelitis: Iii. Comparison of Antiviral Serum Constituents from Guinea Pigs Immunized with Active or Formolized Inactive Virus</article-title><source>J. Exp. Med.</source><year>1938</year><volume>68</volume><fpage>779</fpage><lpage>787</lpage><pub-id pub-id-type="doi">10.1084/jem.68.5.779</pub-id><pub-id pub-id-type="pmid">19870816</pub-id><pub-id pub-id-type="pmcid">PMC2133703</pub-id></element-citation></ref><ref id="B67-microorganisms-09-00899"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morgan</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>Schlesinger</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Olitsky</surname><given-names>P.K.</given-names></name></person-group><article-title>Induced Resistance of the Central Nervous System to Experimental Infection with Equine Encephalomyelitis Virus: I. Neutralizing Antibody in the Central Nervous System in Relation to Cerebral Resistance</article-title><source>J. Exp. Med.</source><year>1942</year><volume>76</volume><fpage>357</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1084/jem.76.4.357</pub-id><pub-id pub-id-type="pmid">19871243</pub-id><pub-id pub-id-type="pmcid">PMC2135315</pub-id></element-citation></ref><ref id="B68-microorganisms-09-00899"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Griffin</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>R.T.</given-names></name></person-group><article-title>Role of the immune response in recovery from Sindbis virus encephalitis in mice</article-title><source>J. Immunol.</source><year>1977</year><volume>118</volume><fpage>1070</fpage><lpage>1075</lpage><pub-id pub-id-type="pmid">845432</pub-id></element-citation></ref><ref id="B69-microorganisms-09-00899"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kimura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>D.E.</given-names></name></person-group><article-title>Extensive immune-mediated hippocampal damage in mice surviving infection with neuroadapted Sindbis virus</article-title><source>Virology</source><year>2003</year><volume>311</volume><fpage>28</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/S0042-6822(03)00110-7</pub-id><pub-id pub-id-type="pmid">12832200</pub-id></element-citation></ref><ref id="B70-microorganisms-09-00899"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rabinowitz</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Adler</surname><given-names>W.H.</given-names></name></person-group><article-title>Host defenses during primary Venezuelan equine encephalomyelitis virus infection in mice. I. Passive transfer of protection with immune serum and immune cells</article-title><source>J. Immunol.</source><year>1973</year><volume>110</volume><fpage>1345</fpage><lpage>1353</lpage><pub-id pub-id-type="pmid">4348975</pub-id></element-citation></ref><ref id="B71-microorganisms-09-00899"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Couderc</surname><given-names>T.</given-names></name><name name-style="western"><surname>Khandoudi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Grandadam</surname><given-names>M.</given-names></name><name name-style="western"><surname>Visse</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gangneux</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bagot</surname><given-names>S.</given-names></name><name name-style="western"><surname>Prost</surname><given-names>J. F.</given-names></name><name name-style="western"><surname>Lecuit</surname><given-names>M.</given-names></name></person-group><article-title>Prophylaxis and therapy for Chikungunya virus infection</article-title><source>J. Infect. Dis.</source><year>2009</year><volume>200</volume><fpage>516</fpage><lpage>523</lpage><pub-id pub-id-type="doi">10.1086/600381</pub-id><pub-id pub-id-type="pmid">19572805</pub-id><pub-id pub-id-type="pmcid">PMC7109959</pub-id></element-citation></ref><ref id="B72-microorganisms-09-00899"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>C.Y.</given-names></name><name name-style="western"><surname>Kam</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Fric</surname><given-names>J.</given-names></name><name name-style="western"><surname>Malleret</surname><given-names>B.</given-names></name><name name-style="western"><surname>Koh</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Prakash</surname><given-names>C.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W. W.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>R. T.</given-names></name></person-group><article-title>Chikungunya virus neutralization antigens and direct cell-to-cell transmission are revealed by human antibody-escape mutants</article-title><source>PLoS Pathog.</source><year>2011</year><volume>7</volume><elocation-id>e1002390</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1002390</pub-id><pub-id pub-id-type="pmid">22144891</pub-id><pub-id pub-id-type="pmcid">PMC3228792</pub-id></element-citation></ref><ref id="B73-microorganisms-09-00899"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Holzer</surname><given-names>G.W.</given-names></name><name name-style="western"><surname>Coulibaly</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aichinger</surname><given-names>G.</given-names></name><name name-style="western"><surname>Savidis-Dacho</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mayrhofer</surname><given-names>J.</given-names></name><name name-style="western"><surname>Brunner</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schmid</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kistner</surname><given-names>O.</given-names></name><name name-style="western"><surname>Aaskov</surname><given-names>J. G.</given-names></name><name name-style="western"><surname>Falkner</surname><given-names>F.G.</given-names></name><etal/></person-group><article-title>Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>4132</fpage><lpage>4141</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.03.089</pub-id><pub-id pub-id-type="pmid">21477673</pub-id></element-citation></ref><ref id="B74-microorganisms-09-00899"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kraaijeveld</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Benaissa-Trouw</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Harmsen</surname><given-names>M.</given-names></name><name name-style="western"><surname>Snippe</surname><given-names>H.</given-names></name></person-group><article-title>Adoptive transfer of immunity against virulent Semliki Forest virus with immune spleen cells from mice infected with avirulent Semliki Forest virus</article-title><source>Arch. Virol.</source><year>1986</year><volume>91</volume><fpage>83</fpage><lpage>92</lpage><pub-id pub-id-type="doi">10.1007/BF01316730</pub-id><pub-id pub-id-type="pmid">3489451</pub-id></element-citation></ref><ref id="B75-microorganisms-09-00899"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jose</surname><given-names>J.</given-names></name><name name-style="western"><surname>Snyder</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>R.J.</given-names></name></person-group><article-title>A structural and functional perspective of alphavirus replication and assembly</article-title><source>Future Microbiol.</source><year>2009</year><volume>4</volume><fpage>837</fpage><lpage>856</lpage><pub-id pub-id-type="doi">10.2217/fmb.09.59</pub-id><pub-id pub-id-type="pmid">19722838</pub-id><pub-id pub-id-type="pmcid">PMC2762864</pub-id></element-citation></ref><ref id="B76-microorganisms-09-00899"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stec</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Waddell</surname><given-names>A.</given-names></name><name name-style="western"><surname>Schmaljohn</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Schmaljohn</surname><given-names>A.L.</given-names></name></person-group><article-title>Antibody-selected variation and reversion in Sindbis virus neutralization epitopes</article-title><source>J. Virol.</source><year>1986</year><volume>57</volume><fpage>715</fpage><lpage>720</lpage><pub-id pub-id-type="doi">10.1128/JVI.57.3.715-720.1986</pub-id><pub-id pub-id-type="pmid">2419586</pub-id><pub-id pub-id-type="pmcid">PMC252797</pub-id></element-citation></ref><ref id="B77-microorganisms-09-00899"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boere</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Harmsen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Vinje</surname><given-names>J.</given-names></name><name name-style="western"><surname>Benaissa-Trouw</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Kraaijeveld</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Snippe</surname><given-names>H.</given-names></name></person-group><article-title>Identification of distinct antigenic determinants on Semliki Forest virus by using monoclonal antibodies with different antiviral activities</article-title><source>J. Virol.</source><year>1984</year><volume>52</volume><fpage>575</fpage><lpage>582</lpage><pub-id pub-id-type="doi">10.1128/JVI.52.2.575-582.1984</pub-id><pub-id pub-id-type="pmid">6208379</pub-id><pub-id pub-id-type="pmcid">PMC254560</pub-id></element-citation></ref><ref id="B78-microorganisms-09-00899"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roehrig</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Mathews</surname><given-names>J.H.</given-names></name></person-group><article-title>The neutralization site on the E2 glycoprotein of Venezuelan equine encephalomyelitis (TC-83) virus is composed of multiple conformationally stable epitopes</article-title><source>Virology</source><year>1985</year><volume>142</volume><fpage>347</fpage><lpage>356</lpage><pub-id pub-id-type="doi">10.1016/0042-6822(85)90343-5</pub-id><pub-id pub-id-type="pmid">2414905</pub-id></element-citation></ref><ref id="B79-microorganisms-09-00899"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vrati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fernon</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Dalgarno</surname><given-names>L.</given-names></name><name name-style="western"><surname>Weir</surname><given-names>R.C.</given-names></name></person-group><article-title>Location of a major antigenic site involved in Ross River virus neutralization</article-title><source>Virology</source><year>1988</year><volume>162</volume><fpage>346</fpage><lpage>353</lpage><pub-id pub-id-type="doi">10.1016/0042-6822(88)90474-6</pub-id><pub-id pub-id-type="pmid">2448952</pub-id></element-citation></ref><ref id="B80-microorganisms-09-00899"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Navaratnarajah</surname><given-names>C.K.</given-names></name><name name-style="western"><surname>Kuhn</surname><given-names>R.J.</given-names></name></person-group><article-title>Functional characterization of the Sindbis virus E2 glycoprotein by transposon linker-insertion mutagenesis</article-title><source>Virology</source><year>2007</year><volume>363</volume><fpage>134</fpage><lpage>147</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2007.01.006</pub-id><pub-id pub-id-type="pmid">17306321</pub-id><pub-id pub-id-type="pmcid">PMC1959473</pub-id></element-citation></ref><ref id="B81-microorganisms-09-00899"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hunt</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Frederickson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Maruyama</surname><given-names>T.</given-names></name><name name-style="western"><surname>Roehrig</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Blair</surname><given-names>C.D.</given-names></name></person-group><article-title>The first human epitope map of the alphaviral E1 and E2 proteins reveals a new E2 epitope with significant virus neutralizing activity</article-title><source>PLoS Negl. Trop. Dis.</source><year>2010</year><volume>4</volume><elocation-id>e739</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0000739</pub-id><pub-id pub-id-type="pmid">20644615</pub-id><pub-id pub-id-type="pmcid">PMC2903468</pub-id></element-citation></ref><ref id="B82-microorganisms-09-00899"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kam</surname><given-names>Y.W.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>W.W.</given-names></name><name name-style="western"><surname>Simarmata</surname><given-names>D.</given-names></name><name name-style="western"><surname>Le Grand</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tolou</surname><given-names>H.</given-names></name><name name-style="western"><surname>Merits</surname><given-names>A.</given-names></name><name name-style="western"><surname>Roques</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>L. F.</given-names></name></person-group><article-title>Unique epitopes recognized by antibodies induced in Chikungunya virus-infected non-human primates: Implications for the study of immunopathology and vaccine development</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e95647</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0095647</pub-id><pub-id pub-id-type="pmid">24755730</pub-id><pub-id pub-id-type="pmcid">PMC3995782</pub-id></element-citation></ref><ref id="B83-microorganisms-09-00899"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Adouchief</surname><given-names>S.</given-names></name><name name-style="western"><surname>Smura</surname><given-names>T.</given-names></name><name name-style="western"><surname>Vapalahti</surname><given-names>O.</given-names></name><name name-style="western"><surname>Hepojoki</surname><given-names>J.</given-names></name></person-group><article-title>Mapping of human B-cell epitopes of Sindbis virus</article-title><source>J. Gen. Virol.</source><year>2016</year><volume>97</volume><fpage>2243</fpage><lpage>2254</lpage><pub-id pub-id-type="doi">10.1099/jgv.0.000531</pub-id><pub-id pub-id-type="pmid">27339177</pub-id></element-citation></ref><ref id="B84-microorganisms-09-00899"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chanas</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Gould</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Clegg</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Varma</surname><given-names>M.G.</given-names></name></person-group><article-title>Monoclonal antibodies to Sindbis virus glycoprotein E1 can neutralize, enhance infectivity, and independently inhibit haemagglutination or haemolysis</article-title><source>J. Gen. Virol.</source><year>1982</year><volume>58</volume><fpage>37</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-58-1-37</pub-id><pub-id pub-id-type="pmid">7142968</pub-id></element-citation></ref><ref id="B85-microorganisms-09-00899"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Despres</surname><given-names>P.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>D.E.</given-names></name></person-group><article-title>Antiviral activity of alpha interferon in Sindbis virus-infected cells is restored by anti-E2 monoclonal antibody treatment</article-title><source>J. Virol.</source><year>1995</year><volume>69</volume><fpage>7345</fpage><lpage>7348</lpage><pub-id pub-id-type="doi">10.1128/JVI.69.11.7345-7348.1995</pub-id><pub-id pub-id-type="pmid">7474167</pub-id><pub-id pub-id-type="pmcid">PMC189667</pub-id></element-citation></ref><ref id="B86-microorganisms-09-00899"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Despres</surname><given-names>P.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>D.E.</given-names></name></person-group><article-title>Effects of anti-E2 monoclonal antibody on sindbis virus replication in AT3 cells expressing bcl-2</article-title><source>J. Virol.</source><year>1995</year><volume>69</volume><fpage>7006</fpage><lpage>7014</lpage><pub-id pub-id-type="doi">10.1128/JVI.69.11.7006-7014.1995</pub-id><pub-id pub-id-type="pmid">7474120</pub-id><pub-id pub-id-type="pmcid">PMC189620</pub-id></element-citation></ref><ref id="B87-microorganisms-09-00899"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendoza</surname><given-names>Q.P.</given-names></name><name name-style="western"><surname>Stanley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>D.E.</given-names></name></person-group><article-title>Monoclonal antibodies to the E1 and E2 glycoproteins of Sindbis virus: Definition of epitopes and efficiency of protection from fatal encephalitis</article-title><source>J. Gen. Virol.</source><year>1988</year><volume>69</volume><fpage>3015</fpage><lpage>3022</lpage><pub-id pub-id-type="doi">10.1099/0022-1317-69-12-3015</pub-id><pub-id pub-id-type="pmid">2462014</pub-id></element-citation></ref><ref id="B88-microorganisms-09-00899"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stanley</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cooper</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>D.E.</given-names></name></person-group><article-title>Monoclonal antibody cure and prophylaxis of lethal Sindbis virus encephalitis in mice</article-title><source>J. Virol.</source><year>1986</year><volume>58</volume><fpage>107</fpage><lpage>115</lpage><pub-id pub-id-type="doi">10.1128/JVI.58.1.107-115.1986</pub-id><pub-id pub-id-type="pmid">2419592</pub-id><pub-id pub-id-type="pmcid">PMC252882</pub-id></element-citation></ref><ref id="B89-microorganisms-09-00899"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boere</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Benaissa-Trouw</surname><given-names>B.J.</given-names></name><name name-style="western"><surname>Harmsen</surname><given-names>T.</given-names></name><name name-style="western"><surname>Erich</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kraaijeveld</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Snippe</surname><given-names>H.</given-names></name></person-group><article-title>Mechanisms of monoclonal antibody-mediated protection against virulent Semliki Forest virus</article-title><source>J. Virol.</source><year>1985</year><volume>54</volume><fpage>546</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1128/JVI.54.2.546-551.1985</pub-id><pub-id pub-id-type="pmid">2985817</pub-id><pub-id pub-id-type="pmcid">PMC254827</pub-id></element-citation></ref><ref id="B90-microorganisms-09-00899"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Smith</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Flyak</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Kose</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sapparapu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Khomandiak</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ashbrook</surname><given-names>A. W.</given-names></name><name name-style="western"><surname>Kahle</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Fong</surname><given-names>R. H</given-names></name><etal/></person-group><article-title>Isolation and Characterization of Broad and Ultrapotent Human Monoclonal Antibodies with Therapeutic Activity against Chikungunya Virus</article-title><source>Cell Host Microbe</source><year>2015</year><volume>18</volume><fpage>86</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2015.06.009</pub-id><pub-id pub-id-type="pmid">26159721</pub-id><pub-id pub-id-type="pmcid">PMC4501771</pub-id></element-citation></ref><ref id="B91-microorganisms-09-00899"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chua</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>Y.F.</given-names></name><name name-style="western"><surname>Sam</surname><given-names>I.C.</given-names></name></person-group><article-title>Characterisation of mouse monoclonal antibodies targeting linear epitopes on Chikungunya virus E2 glycoprotein</article-title><source>J. Virol. Method.</source><year>2014</year><volume>195</volume><fpage>126</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2013.10.015</pub-id><pub-id pub-id-type="pmid">24134938</pub-id></element-citation></ref><ref id="B92-microorganisms-09-00899"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Dowd</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Brien</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Edeling</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Gorlatov</surname><given-names>S.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>I.</given-names></name><name name-style="western"><surname>Akahata</surname><given-names>W.</given-names></name><name name-style="western"><surname>Nabel</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Richter</surname><given-names>M. K.</given-names></name><etal/></person-group><article-title>Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus</article-title><source>PLoS Pathog.</source><year>2013</year><volume>9</volume><elocation-id>e1003312</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003312</pub-id><pub-id pub-id-type="pmid">23637602</pub-id><pub-id pub-id-type="pmcid">PMC3630103</pub-id></element-citation></ref><ref id="B93-microorganisms-09-00899"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goh</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Hobson-Peters</surname><given-names>J.</given-names></name><name name-style="western"><surname>Prow</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Baker</surname><given-names>K.</given-names></name><name name-style="western"><surname>Piyasena</surname><given-names>T.B.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Rana</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hastie</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Gorman</surname><given-names>J. J.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>R. A.</given-names></name></person-group><article-title>The Chikungunya Virus Capsid Protein Contains Linear B Cell Epitopes in the N- and C-Terminal Regions that are Dependent on an Intact C-Terminus for Antibody Recognition</article-title><source>Viruses</source><year>2015</year><volume>7</volume><fpage>2943</fpage><lpage>2964</lpage><pub-id pub-id-type="doi">10.3390/v7062754</pub-id><pub-id pub-id-type="pmid">26061335</pub-id><pub-id pub-id-type="pmcid">PMC4488721</pub-id></element-citation></ref><ref id="B94-microorganisms-09-00899"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goh</surname><given-names>L.Y.H.</given-names></name><name name-style="western"><surname>Hobson-Peters</surname><given-names>J.</given-names></name><name name-style="western"><surname>Prow</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Bielefeldt-Ohmann</surname><given-names>H.</given-names></name><name name-style="western"><surname>Suhrbier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>R. A.</given-names></name></person-group><article-title>Monoclonal antibodies specific for the capsid protein of chikungunya virus suitable for multiple applications</article-title><source>J. Gen. Virol.</source><year>2015</year><volume>96</volume><fpage>507</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1099/jgv.0.000002</pub-id><pub-id pub-id-type="pmid">25480927</pub-id></element-citation></ref><ref id="B95-microorganisms-09-00899"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Akahata</surname><given-names>W.</given-names></name><name name-style="western"><surname>Holdaway</surname><given-names>H.</given-names></name><name name-style="western"><surname>Pal</surname><given-names>P.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>M. S.</given-names></name><name name-style="western"><surname>Nabel</surname><given-names>G. J.</given-names></name><name name-style="western"><surname>Rossmann</surname><given-names>M. G.</given-names></name></person-group><article-title>Structural analyses at pseudo atomic resolution of Chikungunya virus and antibodies show mechanisms of neutralization</article-title><source>eLife</source><year>2013</year><volume>2</volume><fpage>e00435</fpage><pub-id pub-id-type="doi">10.7554/eLife.00435</pub-id><pub-id pub-id-type="pmid">23577234</pub-id><pub-id pub-id-type="pmcid">PMC3614025</pub-id></element-citation></ref><ref id="B96-microorganisms-09-00899"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Voss</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Vaney</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Duquerroy</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vonrhein</surname><given-names>C.</given-names></name><name name-style="western"><surname>Girard-Blanc</surname><given-names>C.</given-names></name><name name-style="western"><surname>Crublet</surname><given-names>E.</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bricogne</surname><given-names>G.</given-names></name><name name-style="western"><surname>Rey</surname><given-names>F. A.</given-names></name></person-group><article-title>Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography</article-title><source>Nature</source><year>2010</year><volume>468</volume><fpage>709</fpage><lpage>712</lpage><pub-id pub-id-type="doi">10.1038/nature09555</pub-id><pub-id pub-id-type="pmid">21124458</pub-id></element-citation></ref><ref id="B97-microorganisms-09-00899"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Broeckel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Haese</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kreklywich</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Sukulpovi-Petty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Legasse</surname><given-names>A.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>P. P.</given-names></name><name name-style="western"><surname>Denton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Corvey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Krishnan</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Therapeutic administration of a recombinant human monoclonal antibody reduces the severity of chikungunya virus disease in rhesus macaques</article-title><source>PLoS Negl. Trop. Dis.</source><year>2017</year><volume>11</volume><elocation-id>e0005637</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0005637</pub-id><pub-id pub-id-type="pmid">28628616</pub-id><pub-id pub-id-type="pmcid">PMC5491320</pub-id></element-citation></ref><ref id="B98-microorganisms-09-00899"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fox</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Long</surname><given-names>F.</given-names></name><name name-style="western"><surname>Edeling</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.</given-names></name><name name-style="western"><surname>van Duijl-Richter</surname><given-names>M.K.S.</given-names></name><name name-style="western"><surname>Fong</surname><given-names>R.H.</given-names></name><name name-style="western"><surname>Kahle</surname><given-names>K. M.</given-names></name><name name-style="western"><surname>Smit</surname><given-names>J. M.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Broadly Neutralizing Alphavirus Antibodies Bind an Epitope on E2 and Inhibit Entry and Egress</article-title><source>Cell</source><year>2015</year><volume>163</volume><fpage>1095</fpage><lpage>1107</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2015.10.050</pub-id><pub-id pub-id-type="pmid">26553503</pub-id><pub-id pub-id-type="pmcid">PMC4659373</pub-id></element-citation></ref><ref id="B99-microorganisms-09-00899"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Austin</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Zuiani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Trobaugh</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C.</given-names></name><name name-style="western"><surname>Basore</surname><given-names>K.</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>L. E.</given-names></name><name name-style="western"><surname>Crowe</surname><given-names>J. E</given-names></name><etal/></person-group><article-title>Protective antibodies against Eastern equine encephalitis virus bind to epitopes in domains A and B of the E2 glycoprotein</article-title><source>Nat. Microbiol.</source><year>2019</year><volume>4</volume><fpage>187</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1038/s41564-018-0286-4</pub-id><pub-id pub-id-type="pmid">30455470</pub-id><pub-id pub-id-type="pmcid">PMC6294662</pub-id></element-citation></ref><ref id="B100-microorganisms-09-00899"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q.Y.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y. H.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D. L.</given-names></name></person-group><article-title>Phage display identifies an Eastern equine encephalitis virus glycoprotein E2-specific B cell epitope</article-title><source>Vet. Immunol. Immunopathol.</source><year>2012</year><volume>148</volume><fpage>364</fpage><lpage>368</lpage><pub-id pub-id-type="doi">10.1016/j.vetimm.2012.06.021</pub-id><pub-id pub-id-type="pmid">22824180</pub-id></element-citation></ref><ref id="B101-microorganisms-09-00899"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Q.Y.</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>D.L.</given-names></name></person-group><article-title>Analysis of murine B-cell epitopes on Eastern equine encephalitis virus glycoprotein E2</article-title><source>Appl. Microbiol. Biotechnol.</source><year>2013</year><volume>97</volume><fpage>6359</fpage><lpage>6372</lpage><pub-id pub-id-type="pmid">23512478</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s00253-013-4819-8</pub-id></element-citation></ref><ref id="B102-microorganisms-09-00899"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Powell</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Kose</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Majedi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Bombardi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Carnahan</surname><given-names>R. H.</given-names></name><name name-style="western"><surname>Slaughter</surname><given-names>J. C.</given-names></name><name name-style="western"><surname>Morrison</surname><given-names>T. E.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Human monoclonal antibodies against Ross River virus target epitopes within the E2 protein and protect against disease</article-title><source>PLoS Pathog.</source><year>2020</year><volume>16</volume><elocation-id>e1008517</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1008517</pub-id><pub-id pub-id-type="pmid">32365139</pub-id><pub-id pub-id-type="pmcid">PMC7252634</pub-id></element-citation></ref><ref id="B103-microorganisms-09-00899"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Earnest</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Basore</surname><given-names>K.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bailey</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Alter</surname><given-names>G.</given-names></name><name name-style="western"><surname>Fremont</surname><given-names>D. H.</given-names></name><name name-style="western"><surname>Diamond</surname><given-names>M. S.</given-names></name></person-group><article-title>Neutralizing antibodies against Mayaro virus require Fc effector functions for protective activity</article-title><source>J. Exp. Med.</source><year>2019</year><volume>216</volume><fpage>2282</fpage><lpage>2301</lpage><pub-id pub-id-type="doi">10.1084/jem.20190736</pub-id><pub-id pub-id-type="pmid">31337735</pub-id><pub-id pub-id-type="pmcid">PMC6781005</pub-id></element-citation></ref><ref id="B104-microorganisms-09-00899"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Nair</surname><given-names>S.</given-names></name><name name-style="western"><surname>Basore</surname><given-names>K.</given-names></name><name name-style="western"><surname>Klimstra</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Rimkunas</surname><given-names>R.</given-names></name><name name-style="western"><surname>Fong</surname><given-names>R. H.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Poddar</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Mxra8 is a receptor for multiple arthritogenic alphaviruses</article-title><source>Nature</source><year>2018</year><volume>557</volume><fpage>570</fpage><lpage>574</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0121-3</pub-id><pub-id pub-id-type="pmid">29769725</pub-id><pub-id pub-id-type="pmcid">PMC5970976</pub-id></element-citation></ref><ref id="B105-microorganisms-09-00899"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Earnest</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Winkler</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Desai</surname><given-names>P.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bullock</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gold</surname><given-names>B.</given-names></name><name name-style="western"><surname>Cherry</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Expression of the Mxra8 Receptor Promotes Alphavirus Infection and Pathogenesis in Mice and Drosophila</article-title><source>Cell Rep.</source><year>2019</year><volume>28</volume><fpage>2647</fpage><lpage>2658.e5</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.07.105</pub-id><pub-id pub-id-type="pmid">31484075</pub-id><pub-id pub-id-type="pmcid">PMC6745702</pub-id></element-citation></ref><ref id="B106-microorganisms-09-00899"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Basore</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Nelson</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Uranga</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vang</surname><given-names>L.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gross</surname><given-names>M. L.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Cryo-EM Structure of Chikungunya Virus in Complex with the Mxra8 Receptor</article-title><source>Cell</source><year>2019</year><volume>177</volume><fpage>1725</fpage><lpage>1737.e16</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.04.006</pub-id><pub-id pub-id-type="pmid">31080061</pub-id><pub-id pub-id-type="pmcid">PMC7227486</pub-id></element-citation></ref><ref id="B107-microorganisms-09-00899"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Song</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Chai</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>X.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>F.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Song</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Molecular Basis of Arthritogenic Alphavirus Receptor MXRA8 Binding to Chikungunya Virus Envelope Protein</article-title><source>Cell</source><year>2019</year><volume>177</volume><fpage>1714</fpage><lpage>1724.e12</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2019.04.008</pub-id><pub-id pub-id-type="pmid">31080063</pub-id></element-citation></ref><ref id="B108-microorganisms-09-00899"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gould</surname><given-names>E.</given-names></name><name name-style="western"><surname>Pettersson</surname><given-names>J.</given-names></name><name name-style="western"><surname>Higgs</surname><given-names>S.</given-names></name><name name-style="western"><surname>Charrel</surname><given-names>R.</given-names></name><name name-style="western"><surname>de Lamballerie</surname><given-names>X.</given-names></name></person-group><article-title>Emerging arboviruses: Why today?</article-title><source>One Health</source><year>2017</year><volume>4</volume><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1016/j.onehlt.2017.06.001</pub-id><pub-id pub-id-type="pmid">28785601</pub-id><pub-id pub-id-type="pmcid">PMC5501887</pub-id></element-citation></ref><ref id="B109-microorganisms-09-00899"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name></person-group><article-title>Urbanization and geographic expansion of zoonotic arboviral diseases: Mechanisms and potential strategies for prevention</article-title><source>Trends Microbiol.</source><year>2013</year><volume>21</volume><fpage>360</fpage><lpage>363</lpage><pub-id pub-id-type="doi">10.1016/j.tim.2013.03.003</pub-id><pub-id pub-id-type="pmid">23910545</pub-id><pub-id pub-id-type="pmcid">PMC5193003</pub-id></element-citation></ref><ref id="B110-microorganisms-09-00899"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zahouli</surname><given-names>J.B.Z.</given-names></name><name name-style="western"><surname>Koudou</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>P.</given-names></name><name name-style="western"><surname>Malone</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tano</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Utzinger</surname><given-names>J.</given-names></name></person-group><article-title>Urbanization is a main driver for the larval ecology of Aedes mosquitoes in arbovirus-endemic settings in south-eastern Cote d&#8217;Ivoire</article-title><source>PLoS Negl. Trop. Dis.</source><year>2017</year><volume>11</volume><elocation-id>e0005751</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0005751</pub-id><pub-id pub-id-type="pmid">28704434</pub-id><pub-id pub-id-type="pmcid">PMC5526600</pub-id></element-citation></ref><ref id="B111-microorganisms-09-00899"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kilpatrick</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Randolph</surname><given-names>S.E.</given-names></name></person-group><article-title>Drivers, dynamics, and control of emerging vector-borne zoonotic diseases</article-title><source>Lancet</source><year>2012</year><volume>380</volume><fpage>1946</fpage><lpage>1955</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(12)61151-9</pub-id><pub-id pub-id-type="pmid">23200503</pub-id><pub-id pub-id-type="pmcid">PMC3739480</pub-id></element-citation></ref><ref id="B112-microorganisms-09-00899"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vazeille</surname><given-names>M.</given-names></name><name name-style="western"><surname>Moutailler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pages</surname><given-names>F.</given-names></name><name name-style="western"><surname>Jarjaval</surname><given-names>F.</given-names></name><name name-style="western"><surname>Failloux</surname><given-names>A.B.</given-names></name></person-group><article-title>Introduction of Aedes albopictus in Gabon: What consequences for dengue and chikungunya transmission?</article-title><source>Trop. Med. Int. Health</source><year>2008</year><volume>13</volume><fpage>1176</fpage><lpage>1179</lpage><pub-id pub-id-type="doi">10.1111/j.1365-3156.2008.02123.x</pub-id><pub-id pub-id-type="pmid">18631309</pub-id></element-citation></ref><ref id="B113-microorganisms-09-00899"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Naish</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mengersen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>S.</given-names></name></person-group><article-title>Spatio-temporal patterns of Barmah Forest virus disease in Queensland, Australia</article-title><source>PLoS ONE</source><year>2011</year><volume>6</volume><elocation-id>e25688</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0025688</pub-id><pub-id pub-id-type="pmid">22022430</pub-id><pub-id pub-id-type="pmcid">PMC3192738</pub-id></element-citation></ref><ref id="B114-microorganisms-09-00899"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reed</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Glass</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Bakken</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Barth</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Lind</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>da Silva</surname><given-names>L.</given-names></name><name name-style="western"><surname>Hart</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Rayner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alterson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Custer</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Combined alphavirus replicon particle vaccine induces durable and cross-protective immune responses against equine encephalitis viruses</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>12077</fpage><lpage>12086</lpage><pub-id pub-id-type="doi">10.1128/JVI.01406-14</pub-id><pub-id pub-id-type="pmid">25122801</pub-id><pub-id pub-id-type="pmcid">PMC4178741</pub-id></element-citation></ref><ref id="B115-microorganisms-09-00899"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wressnigg</surname><given-names>N.</given-names></name><name name-style="western"><surname>van der Velden</surname><given-names>M.V.</given-names></name><name name-style="western"><surname>Portsmouth</surname><given-names>D.</given-names></name><name name-style="western"><surname>Draxler</surname><given-names>W.</given-names></name><name name-style="western"><surname>O&#8217;Rourke</surname><given-names>M.</given-names></name><name name-style="western"><surname>Richmond</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>S.</given-names></name><name name-style="western"><surname>McBride</surname><given-names>W.J.H.</given-names></name><name name-style="western"><surname>Redfern</surname><given-names>A.</given-names></name><name name-style="western"><surname>Aaskvo</surname><given-names>J.</given-names></name><etal/></person-group><article-title>An inactivated Ross River virus vaccine is well tolerated and immunogenic in an adult population in a randomized phase 3 trial</article-title><source>Clin. Vaccine Immunol.</source><year>2015</year><volume>22</volume><fpage>267</fpage><lpage>273</lpage><pub-id pub-id-type="doi">10.1128/CVI.00546-14</pub-id><pub-id pub-id-type="pmid">25540268</pub-id><pub-id pub-id-type="pmcid">PMC4340901</pub-id></element-citation></ref><ref id="B116-microorganisms-09-00899"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chang</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Dowd</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Mendoza</surname><given-names>F.H.</given-names></name><name name-style="western"><surname>Saunders</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Sitar</surname><given-names>S.</given-names></name><name name-style="western"><surname>Plummer</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Yamshchikov</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sarwar</surname><given-names>U.N.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Enama</surname><given-names>M.E.</given-names></name><etal/></person-group><article-title>Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: A phase 1 dose-escalation trial</article-title><source>Lancet</source><year>2014</year><volume>384</volume><fpage>2046</fpage><lpage>2052</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(14)61185-5</pub-id><pub-id pub-id-type="pmid">25132507</pub-id></element-citation></ref><ref id="B117-microorganisms-09-00899"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Coates</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Plummer</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Berkowitz</surname><given-names>N.</given-names></name><name name-style="western"><surname>Conan-Cibotti</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cox</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Beck</surname><given-names>A.</given-names></name><name name-style="western"><surname>O&#8217;Callahan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Effect of a Chikungunya Virus-Like Particle Vaccine on Safety and Tolerability Outcomes: A Randomized Clinical Trial</article-title><source>JAMA</source><year>2020</year><volume>323</volume><fpage>1369</fpage><lpage>1377</lpage><pub-id pub-id-type="doi">10.1001/jama.2020.2477</pub-id><pub-id pub-id-type="pmid">32286643</pub-id><pub-id pub-id-type="pmcid">PMC7156994</pub-id></element-citation></ref><ref id="B118-microorganisms-09-00899"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akahata</surname><given-names>W.</given-names></name><name name-style="western"><surname>Nabel</surname><given-names>G.J.</given-names></name></person-group><article-title>A specific domain of the Chikungunya virus E2 protein regulates particle formation in human cells: Implications for alphavirus vaccine design</article-title><source>J. Virol.</source><year>2012</year><volume>86</volume><fpage>8879</fpage><lpage>8883</lpage><pub-id pub-id-type="doi">10.1128/JVI.00370-12</pub-id><pub-id pub-id-type="pmid">22647698</pub-id><pub-id pub-id-type="pmcid">PMC3421714</pub-id></element-citation></ref><ref id="B119-microorganisms-09-00899"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Puri</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fedorova</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lin</surname><given-names>D.</given-names></name><name name-style="western"><surname>Hari</surname><given-names>K.L.</given-names></name><name name-style="western"><surname>Jain</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rodas</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Das</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Shabman</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name></person-group><article-title>Comprehensive Genome Scale Phylogenetic Study Provides New Insights on the Global Expansion of Chikungunya Virus</article-title><source>J. Virol.</source><year>2016</year><volume>90</volume><fpage>10600</fpage><lpage>10611</lpage><pub-id pub-id-type="doi">10.1128/JVI.01166-16</pub-id><pub-id pub-id-type="pmid">27654297</pub-id><pub-id pub-id-type="pmcid">PMC5110187</pub-id></element-citation></ref><ref id="B120-microorganisms-09-00899"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xavier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>V.</given-names></name><name name-style="western"><surname>Bezerra</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>do Monte Alves</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mares-Guia</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Claro</surname><given-names>I.M.</given-names></name><name name-style="western"><surname>de Jesus</surname><given-names>R.</given-names></name><name name-style="western"><surname>Adelino</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ara&#250;jo</surname><given-names>E.</given-names></name><name name-style="western"><surname>Cavalcante</surname><given-names>K.R.L.J</given-names></name><etal/></person-group><article-title>Chikungunya virus ECSA lineage reintroduction in the northeasternmost region of Brazil</article-title><source>Int. J. Infect. Dis.</source><year>2021</year><volume>105</volume><fpage>120</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.ijid.2021.01.026</pub-id><pub-id pub-id-type="pmid">33476757</pub-id></element-citation></ref><ref id="B121-microorganisms-09-00899"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phadungsombat</surname><given-names>J.</given-names></name><name name-style="western"><surname>Imad</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nakayama</surname><given-names>E.E.</given-names></name><name name-style="western"><surname>Kludkleeb</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ponam</surname><given-names>T.</given-names></name><name name-style="western"><surname>Rahim</surname><given-names>R.</given-names></name><name name-style="western"><surname>Hasan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Poltep</surname><given-names>K.</given-names></name><name name-style="western"><surname>Yamanaka</surname><given-names>A.</given-names></name><etal/></person-group><article-title>A Novel Sub-Lineage of Chikungunya Virus East/Central/South African Genotype Indian Ocean Lineage Caused Sequential Outbreaks in Bangladesh and Thailand</article-title><source>Viruses</source><year>2020</year><volume>12</volume><elocation-id>1319</elocation-id><pub-id pub-id-type="doi">10.3390/v12111319</pub-id><pub-id pub-id-type="pmcid">PMC7698486</pub-id><pub-id pub-id-type="pmid">33213040</pub-id></element-citation></ref><ref id="B122-microorganisms-09-00899"><label>122.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fabri</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Rodrigues</surname><given-names>C.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>C.C.D.</given-names></name><name name-style="western"><surname>Chalhoub</surname><given-names>F.L.L.</given-names></name><name name-style="western"><surname>Sampaio</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Faria</surname><given-names>N.</given-names></name><name name-style="western"><surname>Torres</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Fonseca</surname><given-names>V.</given-names></name><name name-style="western"><surname>Brasil</surname><given-names>P.</given-names></name><name name-style="western"><surname>Calvet</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Co-Circulation of Two Independent Clades and Persistence of CHIKV-ECSA Genotype during Epidemic Waves in Rio de Janeiro, Southeast Brazil</article-title><source>Pathogens</source><year>2020</year><volume>9</volume><elocation-id>984</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens9120984</pub-id><pub-id pub-id-type="pmid">33255865</pub-id><pub-id pub-id-type="pmcid">PMC7759993</pub-id></element-citation></ref><ref id="B123-microorganisms-09-00899"><label>123.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Harsha</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>D.</given-names></name><name name-style="western"><surname>Pattabiraman</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mani</surname><given-names>R.S.</given-names></name></person-group><article-title>Continual circulation of ECSA genotype and identification of a novel mutation I317V in the E1 gene of Chikungunya viral strains in southern India during 2015&#8211;2016</article-title><source>J. Med. Virol.</source><year>2020</year><volume>92</volume><fpage>1007</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1002/jmv.25662</pub-id><pub-id pub-id-type="pmid">31900943</pub-id></element-citation></ref><ref id="B124-microorganisms-09-00899"><label>124.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akahata</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Z.Y.</given-names></name><name name-style="western"><surname>Andersen</surname><given-names>H.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>S.</given-names></name><name name-style="western"><surname>Holdaway</surname><given-names>H.A.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>W.P</given-names></name><name name-style="western"><surname>Lewis</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Higgs</surname><given-names>S.</given-names></name><name name-style="western"><surname>Rossmann</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>S.</given-names></name><etal/></person-group><article-title>A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection</article-title><source>Nat. Med.</source><year>2010</year><volume>16</volume><fpage>334</fpage><lpage>338</lpage><pub-id pub-id-type="doi">10.1038/nm.2105</pub-id><pub-id pub-id-type="pmid">20111039</pub-id><pub-id pub-id-type="pmcid">PMC2834826</pub-id></element-citation></ref><ref id="B125-microorganisms-09-00899"><label>125.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erasmus</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Kaelber</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Leal</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sherman</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Frolov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Nasar</surname><given-names>F.</given-names></name></person-group><article-title>Novel Insect-Specific Eilat Virus-Based Chimeric Vaccine Candidates Provide Durable, Mono- and Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge</article-title><source>J. Virol.</source><year>2018</year><volume>92</volume><fpage>e01274-17</fpage><pub-id pub-id-type="pmid">29187545</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01274-17</pub-id><pub-id pub-id-type="pmcid">PMC5790933</pub-id></element-citation></ref><ref id="B126-microorganisms-09-00899"><label>126.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Abeyratne</surname><given-names>E.</given-names></name><name name-style="western"><surname>Tharmarajah</surname><given-names>K.</given-names></name><name name-style="western"><surname>Freitas</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Mostafavi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mahalingam</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zaid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zaman</surname><given-names>M.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>A.</given-names></name></person-group><article-title>Liposomal Delivery of the RNA Genome of a Live-Attenuated Chikungunya Virus Vaccine Candidate Provides Local, but Not Systemic Protection After One Dose</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>304</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.00304</pub-id><pub-id pub-id-type="pmid">32194557</pub-id><pub-id pub-id-type="pmcid">PMC7066069</pub-id></element-citation></ref><ref id="B127-microorganisms-09-00899"><label>127.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Taylor</surname><given-names>A.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zaid</surname><given-names>A.</given-names></name><name name-style="western"><surname>Goh</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Hobson-Peters</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Merits</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mahalingam</surname><given-names>S.</given-names></name></person-group><article-title>Mutation of the N-Terminal Region of Chikungunya Virus Capsid Protein: Implications for Vaccine Design</article-title><source>mBio</source><year>2017</year><volume>8</volume><fpage>e01970-16</fpage><pub-id pub-id-type="doi">10.1128/mBio.01970-16</pub-id><pub-id pub-id-type="pmid">28223458</pub-id><pub-id pub-id-type="pmcid">PMC5358915</pub-id></element-citation></ref><ref id="B128-microorganisms-09-00899"><label>128.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kistner</surname><given-names>O.</given-names></name><name name-style="western"><surname>Barrett</surname><given-names>N.</given-names></name><name name-style="western"><surname>Bruhmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Reiter</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mundt</surname><given-names>W.</given-names></name><name name-style="western"><surname>Savidis-Dacho</surname><given-names>H.</given-names></name><name name-style="western"><surname>Schober-Bendixen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Dorner</surname><given-names>F.</given-names></name><name name-style="western"><surname>Aaskov</surname><given-names>J.</given-names></name></person-group><article-title>The preclinical testing of a formaldehyde inactivated Ross River virus vaccine designed for use in humans</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>4845</fpage><lpage>4852</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.01.103</pub-id><pub-id pub-id-type="pmid">17509734</pub-id></element-citation></ref><ref id="B129-microorganisms-09-00899"><label>129.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aichinger</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ehrlich</surname><given-names>H.J.</given-names></name><name name-style="western"><surname>Aaskov</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>Fritsch</surname><given-names>S.</given-names></name><name name-style="western"><surname>Thomasser</surname><given-names>C.</given-names></name><name name-style="western"><surname>Draxler</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wolzt</surname><given-names>M.</given-names></name><name name-style="western"><surname>Muller</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pinl</surname><given-names>F.</given-names></name><name name-style="western"><surname>Van Damme</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of an inactivated whole virus Vero cell-derived Ross River virus vaccine: A randomized trial</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>9376</fpage><lpage>9384</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.09.125</pub-id><pub-id pub-id-type="pmid">22001875</pub-id></element-citation></ref><ref id="B130-microorganisms-09-00899"><label>130.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chan</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Teo</surname><given-names>T.H.</given-names></name><name name-style="western"><surname>Utt</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Amrun</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Abu Bakar</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yee</surname><given-names>W.-X.</given-names></name><name name-style="western"><surname>Becht</surname><given-names>E.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>C.Y.-P.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Mutating chikungunya virus non-structural protein produces potent live-attenuated vaccine candidate</article-title><source>EMBO Mol. Med.</source><year>2019</year><volume>11</volume><fpage>e10092</fpage><pub-id pub-id-type="doi">10.15252/emmm.201810092</pub-id><pub-id pub-id-type="pmid">31015278</pub-id><pub-id pub-id-type="pmcid">PMC6554673</pub-id></element-citation></ref><ref id="B131-microorganisms-09-00899"><label>131.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hallengard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kakoulidou</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lulla</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kummerer</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>D.X.</given-names></name><name name-style="western"><surname>Mutso</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lulla</surname><given-names>V.</given-names></name><name name-style="western"><surname>Fazakerley</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Roques</surname><given-names>P.</given-names></name><name name-style="western"><surname>Le Grand</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>2858</fpage><lpage>2866</lpage><pub-id pub-id-type="doi">10.1128/JVI.03453-13</pub-id><pub-id pub-id-type="pmid">24371047</pub-id><pub-id pub-id-type="pmcid">PMC3958085</pub-id></element-citation></ref><ref id="B132-microorganisms-09-00899"><label>132.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roques</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ljungberg</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kummerer</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Gosse</surname><given-names>L.</given-names></name><name name-style="western"><surname>Dereuddre-Bosquet</surname><given-names>N.</given-names></name><name name-style="western"><surname>Tchitchek</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hallengard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Garcia-Arriaza</surname><given-names>J.</given-names></name><name name-style="western"><surname>Meinke</surname><given-names>A.</given-names></name><name name-style="western"><surname>Esteban</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Attenuated and vectored vaccines protect nonhuman primates against Chikungunya virus</article-title><source>JCI Insight</source><year>2017</year><volume>2</volume><fpage>e83527</fpage><pub-id pub-id-type="doi">10.1172/jci.insight.83527</pub-id><pub-id pub-id-type="pmid">28352649</pub-id><pub-id pub-id-type="pmcid">PMC5358498</pub-id></element-citation></ref><ref id="B133-microorganisms-09-00899"><label>133.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wressnigg</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hochreiter</surname><given-names>R.</given-names></name><name name-style="western"><surname>Zoihsl</surname><given-names>O.</given-names></name><name name-style="western"><surname>Fritzer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bezay</surname><given-names>N.</given-names></name><name name-style="western"><surname>Klingler</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lingnau</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lundberg</surname><given-names>U.</given-names></name><name name-style="western"><surname>Meinke</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Single-shot live-attenuated chikungunya vaccine in healthy adults: A phase 1, randomised controlled trial</article-title><source>Lancet Infect. Dis.</source><year>2020</year><volume>20</volume><fpage>1193</fpage><lpage>1203</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(20)30238-3</pub-id><pub-id pub-id-type="pmid">32497524</pub-id></element-citation></ref><ref id="B134-microorganisms-09-00899"><label>134.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Carrau</surname><given-names>L.</given-names></name><name name-style="western"><surname>Rezelj</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Noval</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Levi</surname><given-names>L.I.</given-names></name><name name-style="western"><surname>Megrian</surname><given-names>D.</given-names></name><name name-style="western"><surname>Blanc</surname><given-names>H.</given-names></name><name name-style="western"><surname>Weger-Lucarelli</surname><given-names>J.</given-names></name><name name-style="western"><surname>Moratorio</surname><given-names>G.</given-names></name><name name-style="western"><surname>Stapleford</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Vignuzzi</surname><given-names>M.</given-names></name></person-group><article-title>Chikungunya Virus Vaccine Candidates with Decreased Mutational Robustness Are Attenuated In Vivo and Have Compromised Transmissibility</article-title><source>J. Virol.</source><year>2019</year><volume>93</volume><fpage>e00775-19</fpage><pub-id pub-id-type="doi">10.1128/JVI.00775-19</pub-id><pub-id pub-id-type="pmid">31270226</pub-id><pub-id pub-id-type="pmcid">PMC6714818</pub-id></element-citation></ref><ref id="B135-microorganisms-09-00899"><label>135.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Piper</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>M.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Briggs</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Huitt</surname><given-names>E.</given-names></name><name name-style="western"><surname>Nanda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Spears</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Quiles</surname><given-names>M.</given-names></name><name name-style="western"><surname>Cullen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>M.E.</given-names></name><etal/></person-group><article-title>Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL/6J mice</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>6748</fpage><lpage>6757</lpage><pub-id pub-id-type="doi">10.1128/JVI.03357-12</pub-id><pub-id pub-id-type="pmid">23552427</pub-id><pub-id pub-id-type="pmcid">PMC3676113</pub-id></element-citation></ref><ref id="B136-microorganisms-09-00899"><label>136.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gardner</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Hritz</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C.</given-names></name><name name-style="western"><surname>Vanlandingham</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Song</surname><given-names>T.Y.</given-names></name><name name-style="western"><surname>Ghedin</surname><given-names>E.</given-names></name><name name-style="western"><surname>Higgs</surname><given-names>S.</given-names></name><name name-style="western"><surname>Klimstra</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Ryman</surname><given-names>K.D.</given-names></name></person-group><article-title>Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: A model for rational arboviral vaccine design</article-title><source>PLoS Negl. Trop. Dis.</source><year>2014</year><volume>8</volume><elocation-id>e2719</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0002719</pub-id><pub-id pub-id-type="pmid">24587470</pub-id><pub-id pub-id-type="pmcid">PMC3930508</pub-id></element-citation></ref><ref id="B137-microorganisms-09-00899"><label>137.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ludwig</surname><given-names>G.V.</given-names></name><name name-style="western"><surname>Turell</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Vogel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kondig</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Kell</surname><given-names>W.K.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Pratt</surname><given-names>W.D.</given-names></name></person-group><article-title>Comparative neurovirulence of attenuated and non-attenuated strains of Venezuelan equine encephalitis virus in mice</article-title><source>Am. J. Trop. Med. Hyg.</source><year>2001</year><volume>64</volume><fpage>49</fpage><lpage>55</lpage><pub-id pub-id-type="doi">10.4269/ajtmh.2001.64.49</pub-id><pub-id pub-id-type="pmid">11425162</pub-id></element-citation></ref><ref id="B138-microorganisms-09-00899"><label>138.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reed</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Lind</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Lackemeyer</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Sullivan</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Pratt</surname><given-names>W.D.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>M.D.</given-names></name></person-group><article-title>Genetically engineered, live, attenuated vaccines protect nonhuman primates against aerosol challenge with a virulent IE strain of Venezuelan equine encephalitis virus</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>3139</fpage><lpage>3147</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.12.023</pub-id><pub-id pub-id-type="pmid">15837213</pub-id></element-citation></ref><ref id="B139-microorganisms-09-00899"><label>139.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fine</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Terpening</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Mott</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vasconcelos</surname><given-names>D.</given-names></name><name name-style="western"><surname>House</surname><given-names>R.V.</given-names></name></person-group><article-title>Neurovirulence evaluation of Venezuelan equine encephalitis (VEE) vaccine candidate V3526 in nonhuman primates</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>3497</fpage><lpage>3506</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.04.044</pub-id><pub-id pub-id-type="pmid">18508163</pub-id></element-citation></ref><ref id="B140-microorganisms-09-00899"><label>140.</label><element-citation publication-type="confproc"><person-group person-group-type="author"><name name-style="western"><surname>Main</surname><given-names>C.F.D.</given-names></name><name name-style="western"><surname>Snow</surname><given-names>D.</given-names></name><name name-style="western"><surname>Mallory</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Helber</surname><given-names>S.</given-names></name><name name-style="western"><surname>Terpening</surname><given-names>S.</given-names></name><name name-style="western"><surname>Holley</surname><given-names>H.P.</given-names></name></person-group><article-title>Safety of an Attenuated Venezuelan Equine Encephalitis Virus (VEEV) Vaccine in Humans</article-title><source>Proceedings of the America Infectious Diseases Society of America 2008 Annual Meeting</source><conf-loc>Washington, DC, USA</conf-loc><conf-date>25&#8211;28 October 2008</conf-date></element-citation></ref><ref id="B141-microorganisms-09-00899"><label>141.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tretyakova</surname><given-names>I.</given-names></name><name name-style="western"><surname>Tibbens</surname><given-names>A.</given-names></name><name name-style="western"><surname>Jokinen</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Lukashevich</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Pushko</surname><given-names>P.</given-names></name></person-group><article-title>Novel DNA-launched Venezuelan equine encephalitis virus vaccine with rearranged genome</article-title><source>Vaccine</source><year>2019</year><volume>37</volume><fpage>3317</fpage><lpage>3325</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2019.04.072</pub-id><pub-id pub-id-type="pmid">31072736</pub-id></element-citation></ref><ref id="B142-microorganisms-09-00899"><label>142.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tretyakova</surname><given-names>I.</given-names></name><name name-style="western"><surname>Plante</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Peel</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Gudjohnsen</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Mirchandani</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tibbens</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lamichhane</surname><given-names>T.N.</given-names></name><etal/></person-group><article-title>Venezuelan equine encephalitis vaccine with rearranged genome resists reversion and protects non-human primates from viremia after aerosol challenge</article-title><source>Vaccine</source><year>2020</year><volume>38</volume><fpage>3378</fpage><lpage>3386</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2020.02.007</pub-id><pub-id pub-id-type="pmid">32085953</pub-id></element-citation></ref><ref id="B143-microorganisms-09-00899"><label>143.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Trobaugh</surname><given-names>D.W.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dunn</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>D.S.</given-names></name><name name-style="western"><surname>Klimstra</surname><given-names>W.B.</given-names></name></person-group><article-title>Rational design of a live-attenuated eastern equine encephalitis virus vaccine through informed mutation of virulence determinants</article-title><source>PLoS Pathog.</source><year>2019</year><volume>15</volume><elocation-id>e1007584</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1007584</pub-id><pub-id pub-id-type="pmid">30742691</pub-id><pub-id pub-id-type="pmcid">PMC6386422</pub-id></element-citation></ref><ref id="B144-microorganisms-09-00899"><label>144.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plante</surname><given-names>K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Partidos</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Weger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gorchakov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tsetsarkin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Borland</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Powers</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>R.</given-names></name><name name-style="western"><surname>Stinchcomb</surname><given-names>D.T.</given-names></name><etal/></person-group><article-title>Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism</article-title><source>PLoS Pathog.</source><year>2011</year><volume>7</volume><elocation-id>e1002142</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1002142</pub-id><pub-id pub-id-type="pmid">21829348</pub-id><pub-id pub-id-type="pmcid">PMC3145802</pub-id></element-citation></ref><ref id="B145-microorganisms-09-00899"><label>145.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Roy</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Plante</surname><given-names>K.</given-names></name><name name-style="western"><surname>Gorchakov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Vinet-Oliphant</surname><given-names>H.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name></person-group><article-title>Chikungunya vaccine candidate is highly attenuated and protects nonhuman primates against telemetrically monitored disease following a single dose</article-title><source>J. Infect. Dis.</source><year>2014</year><volume>209</volume><fpage>1891</fpage><lpage>1899</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu014</pub-id><pub-id pub-id-type="pmid">24403555</pub-id><pub-id pub-id-type="pmcid">PMC4038141</pub-id></element-citation></ref><ref id="B146-microorganisms-09-00899"><label>146.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Partidos</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Paykel</surname><given-names>J.</given-names></name><name name-style="western"><surname>Weger</surname><given-names>J.</given-names></name><name name-style="western"><surname>Borland</surname><given-names>E.M.</given-names></name><name name-style="western"><surname>Powers</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>R.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Stinchcomb</surname><given-names>D.T.</given-names></name><name name-style="western"><surname>Osorio</surname><given-names>J.E.</given-names></name></person-group><article-title>Cross-protective immunity against o&#8217;nyong-nyong virus afforded by a novel recombinant chikungunya vaccine</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>4638</fpage><lpage>4643</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.04.099</pub-id><pub-id pub-id-type="pmid">22583812</pub-id><pub-id pub-id-type="pmcid">PMC3372665</pub-id></element-citation></ref><ref id="B147-microorganisms-09-00899"><label>147.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pandya</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gorchakov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Leal</surname><given-names>G.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name></person-group><article-title>A vaccine candidate for eastern equine encephalitis virus based on IRES-mediated attenuation</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>1276</fpage><lpage>1282</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.12.121</pub-id><pub-id pub-id-type="pmid">22222869</pub-id><pub-id pub-id-type="pmcid">PMC3283035</pub-id></element-citation></ref><ref id="B148-microorganisms-09-00899"><label>148.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossi</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Guerbois</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gorchakov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Plante</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Forrester</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name></person-group><article-title>IRES-based Venezuelan equine encephalitis vaccine candidate elicits protective immunity in mice</article-title><source>Virology</source><year>2013</year><volume>437</volume><fpage>81</fpage><lpage>88</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2012.11.013</pub-id><pub-id pub-id-type="pmid">23351391</pub-id><pub-id pub-id-type="pmcid">PMC3767167</pub-id></element-citation></ref><ref id="B149-microorganisms-09-00899"><label>149.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossi</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Russell-Lodrigue</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Killeen</surname><given-names>S.Z.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Leal</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bergren</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Vinet-Oliphant</surname><given-names>H.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name></person-group><article-title>IRES-Containing VEEV Vaccine Protects Cynomolgus Macaques from IE Venezuelan Equine Encephalitis Virus Aerosol Challenge</article-title><source>PLoS Negl. Trop. Dis.</source><year>2015</year><volume>9</volume><elocation-id>e0003797</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0003797</pub-id><pub-id pub-id-type="pmid">26020513</pub-id><pub-id pub-id-type="pmcid">PMC4447396</pub-id></element-citation></ref><ref id="B150-microorganisms-09-00899"><label>150.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guerbois</surname><given-names>M.</given-names></name><name name-style="western"><surname>Volkova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Forrester</surname><given-names>N.L.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Frolov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name></person-group><article-title>IRES-driven expression of the capsid protein of the Venezuelan equine encephalitis virus TC-83 vaccine strain increases its attenuation and safety</article-title><source>PLoS Negl. Trop. Dis.</source><year>2013</year><volume>7</volume><elocation-id>e2197</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0002197</pub-id><pub-id pub-id-type="pmid">23675542</pub-id><pub-id pub-id-type="pmcid">PMC3649961</pub-id></element-citation></ref><ref id="B151-microorganisms-09-00899"><label>151.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mota</surname><given-names>M.T.O.</given-names></name><name name-style="western"><surname>Costa</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Sugimoto</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Guimaraes</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Queiroz</surname><given-names>C.M.</given-names><suffix>Jr.</suffix></name><name name-style="western"><surname>Moreira</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>de Sousa</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Santos</surname><given-names>F.M.</given-names></name><name name-style="western"><surname>Queiroz</surname><given-names>V.F.</given-names></name><name name-style="western"><surname>Passos</surname><given-names>I.</given-names></name><etal/></person-group><article-title>In-depth characterization of a novel live-attenuated Mayaro virus vaccine candidate using an immunocompetent mouse model of Mayaro disease</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>5306</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-62084-x</pub-id><pub-id pub-id-type="pmid">32210270</pub-id><pub-id pub-id-type="pmcid">PMC7093544</pub-id></element-citation></ref><ref id="B152-microorganisms-09-00899"><label>152.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weise</surname><given-names>W.J.</given-names></name><name name-style="western"><surname>Hermance</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Forrester</surname><given-names>N.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Langsjoen</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gorchakov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Alcorn</surname><given-names>M.D.H.</given-names></name><name name-style="western"><surname>Tsetsarkin</surname><given-names>K.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name></person-group><article-title>A novel live-attenuated vaccine candidate for mayaro Fever</article-title><source>PLoS Negl. Trop. Dis.</source><year>2014</year><volume>8</volume><elocation-id>e2969</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0002969</pub-id><pub-id pub-id-type="pmid">25101995</pub-id><pub-id pub-id-type="pmcid">PMC4125120</pub-id></element-citation></ref><ref id="B153-microorganisms-09-00899"><label>153.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tiwari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Parida</surname><given-names>M.</given-names></name><name name-style="western"><surname>Santhosh</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dash</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>P.V.</given-names></name></person-group><article-title>Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>2513</fpage><lpage>2522</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.02.062</pub-id><pub-id pub-id-type="pmid">19368794</pub-id></element-citation></ref><ref id="B154-microorganisms-09-00899"><label>154.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sudeep</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Arankalle</surname><given-names>V.A.</given-names></name></person-group><article-title>Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus</article-title><source>Vaccine</source><year>2012</year><volume>30</volume><fpage>6142</fpage><lpage>6149</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.07.072</pub-id><pub-id pub-id-type="pmid">22884660</pub-id></element-citation></ref><ref id="B155-microorganisms-09-00899"><label>155.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Mohan</surname><given-names>K.</given-names></name></person-group><article-title>Phase-I Open Label, Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability and Immunogenicity of Chikungunya Vaccine in Healthy Adults of 18 to 50 Years Age: U.S National Library of Medicine</article-title><year>2020</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT04603131">https://clinicaltrials.gov/ct2/show/NCT04603131</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-03-18">(accessed on 18 March 2021)</date-in-citation></element-citation></ref><ref id="B156-microorganisms-09-00899"><label>156.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pittman</surname><given-names>P.R.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.T.</given-names></name><name name-style="western"><surname>Cannon</surname><given-names>T.L.</given-names></name><name name-style="western"><surname>Mangiafico</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Gibbs</surname><given-names>P.H.</given-names></name></person-group><article-title>Immune interference after sequential alphavirus vaccine vaccinations</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>4879</fpage><lpage>4882</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.02.090</pub-id><pub-id pub-id-type="pmid">19576665</pub-id></element-citation></ref><ref id="B157-microorganisms-09-00899"><label>157.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maryam</surname><given-names>K.-J.</given-names></name><name name-style="western"><surname>Reisler</surname><given-names>R.B.</given-names></name><name name-style="western"><surname>Purcell</surname><given-names>B.K.</given-names></name><name name-style="western"><surname>Rivard</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Cardile</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Liggett</surname><given-names>D.</given-names></name><name name-style="western"><surname>Norris</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pitttman</surname><given-names>P.R.</given-names></name></person-group><article-title>2773. Safety and Immunogenicity Study of Eastern Equine Encephalitis Vaccine</article-title><source>Open Forum Infect. Dis.</source><year>2019</year><volume>6</volume><fpage>978</fpage><lpage>979</lpage><pub-id pub-id-type="doi">10.1093/ofid/ofz360.2450</pub-id></element-citation></ref><ref id="B158-microorganisms-09-00899"><label>158.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Rivard</surname><given-names>R.</given-names></name></person-group><article-title>Phase 2 Open-Label Safety and Immunogenicity Study of the Eastern Equine Encephalitis (EEE) Vaccine, Inactivated, Dried, TSI-GSD 104, Lot 2-1-89, in Healthy Adult Subjects at Risk of Exposure to Eastern Equine Encephalitis Virus: U.S. National Library of Medicine</article-title><year>2016</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov/ct2/show/NCT02654509">https://www.clinicaltrials.gov/ct2/show/NCT02654509</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-03-18">(accessed on 18 March 2021)</date-in-citation></element-citation></ref><ref id="B159-microorganisms-09-00899"><label>159.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Honnold</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Bakken</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Fisher</surname><given-names>D.</given-names></name><name name-style="western"><surname>Lind</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Eccleston</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Spurgers</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Maheshwari</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Glass</surname><given-names>P.J.</given-names></name></person-group><article-title>Second generation inactivated eastern equine encephalitis virus vaccine candidates protect mice against a lethal aerosol challenge</article-title><source>PLoS ONE</source><year>2014</year><volume>9</volume><elocation-id>e104708</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0104708</pub-id><pub-id pub-id-type="pmid">25116127</pub-id><pub-id pub-id-type="pmcid">PMC4130539</pub-id></element-citation></ref><ref id="B160-microorganisms-09-00899"><label>160.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Martin</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Bakken</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Lind</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>P.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>E.</given-names></name><name name-style="western"><surname>Glass</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Hart</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Fine</surname><given-names>D.L.</given-names></name></person-group><article-title>Evaluation of formalin inactivated V3526 virus with adjuvant as a next generation vaccine candidate for Venezuelan equine encephalitis virus</article-title><source>Vaccine</source><year>2010</year><volume>28</volume><fpage>3143</fpage><lpage>3151</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.02.056</pub-id><pub-id pub-id-type="pmid">20193792</pub-id><pub-id pub-id-type="pmcid">PMC2857980</pub-id></element-citation></ref><ref id="B161-microorganisms-09-00899"><label>161.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gupta</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Spurgers</surname><given-names>K.B.</given-names></name><name name-style="western"><surname>Bakken</surname><given-names>R.R.</given-names></name><name name-style="western"><surname>Eccleston</surname><given-names>L.T.</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Honnold</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Glass</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Maheshwari</surname><given-names>R.K.</given-names></name></person-group><article-title>1,5-Iodonaphthyl azide-inactivated V3526 protects against aerosol challenge with virulent venezuelan equine encephalitis virus</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>2762</fpage><lpage>2765</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.04.049</pub-id><pub-id pub-id-type="pmid">27129427</pub-id></element-citation></ref><ref id="B162-microorganisms-09-00899"><label>162.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fine</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Jenkins</surname><given-names>E.</given-names></name><name name-style="western"><surname>Martin</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Glass</surname><given-names>P.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Grimm</surname><given-names>B.</given-names></name></person-group><article-title>A multisystem approach for development and evaluation of inactivated vaccines for Venezuelan equine encephalitis virus (VEEV)</article-title><source>J. Virol. Method.</source><year>2010</year><volume>163</volume><fpage>424</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1016/j.jviromet.2009.11.006</pub-id><pub-id pub-id-type="pmcid">PMC2815040</pub-id><pub-id pub-id-type="pmid">19903494</pub-id></element-citation></ref><ref id="B163-microorganisms-09-00899"><label>163.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>McCarty</surname><given-names>J.</given-names></name></person-group><article-title>A Phase 2 Parallel-Group, Randomized, Double-Blind Study to Assess the Safety and Immunogenicity of PXVX0317 (Chikungunya Virus Virus-Like Particle Vaccine [CHIKV-VLP], Unadjuvanted or Alum-adjuvanted): U.S. National Library of Medicine</article-title><year>2018</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03483961">https://clinicaltrials.gov/ct2/show/NCT03483961</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-03-18">(accessed on 18 March 2021)</date-in-citation></element-citation></ref><ref id="B164-microorganisms-09-00899"><label>164.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metz</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Martina</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>van den Doel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Geertsema</surname><given-names>C.</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Vlak</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Pijlman</surname><given-names>G.P.</given-names></name></person-group><article-title>Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>6092</fpage><lpage>6096</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.09.045</pub-id><pub-id pub-id-type="pmid">24099875</pub-id></element-citation></ref><ref id="B165-microorganisms-09-00899"><label>165.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metz</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Geertsema</surname><given-names>C.</given-names></name><name name-style="western"><surname>Le</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Goh</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vlak</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Pijlman</surname><given-names>G.P.</given-names></name></person-group><article-title>Effective chikungunya virus-like particle vaccine produced in insect cells</article-title><source>PLoS Negl. Trop. Dis.</source><year>2013</year><volume>7</volume><elocation-id>e2124</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0002124</pub-id><pub-id pub-id-type="pmid">23516657</pub-id><pub-id pub-id-type="pmcid">PMC3597470</pub-id></element-citation></ref><ref id="B166-microorganisms-09-00899"><label>166.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saraswat</surname><given-names>S.</given-names></name><name name-style="western"><surname>Athmaram</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Parida</surname><given-names>M.</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>A.</given-names></name><name name-style="western"><surname>Saha</surname><given-names>A.</given-names></name><name name-style="western"><surname>Dash</surname><given-names>P.K.</given-names></name></person-group><article-title>Expression and Characterization of Yeast Derived Chikungunya Virus Like Particles (CHIK-VLPs) and Its Evaluation as a Potential Vaccine Candidate</article-title><source>PLoS Negl. Trop. Dis.</source><year>2016</year><volume>10</volume><elocation-id>e0004782</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0004782</pub-id><pub-id pub-id-type="pmid">27399001</pub-id><pub-id pub-id-type="pmcid">PMC4939942</pub-id></element-citation></ref><ref id="B167-microorganisms-09-00899"><label>167.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Goonewardena</surname><given-names>S.</given-names></name></person-group><article-title>A Phase 1 Dose Escalation Study to Assess the Safety and Immunogenicity of a Monovalent Virus-Like Particle (VLP) Venezuelan Equine Encephalitis Vaccine in Healthy Adults: U.S. National Library of Medicine</article-title><year>2017</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03776994">https://clinicaltrials.gov/ct2/show/NCT03776994</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-03-18">(accessed on 18 March 2021)</date-in-citation></element-citation></ref><ref id="B168-microorganisms-09-00899"><label>168.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ko</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Akahata</surname><given-names>W.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Kong</surname><given-names>W.P.</given-names></name><name name-style="western"><surname>Burke</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Honnold</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Nichols</surname><given-names>D.K.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Y.-J.S.</given-names></name><name name-style="western"><surname>Schieber</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Carlton</surname><given-names>K.</given-names></name><etal/></person-group><article-title>A virus-like particle vaccine prevents equine encephalitis virus infection in nonhuman primates</article-title><source>Sci. Transl. Med.</source><year>2019</year><volume>11</volume><fpage>492</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.aav3113</pub-id><pub-id pub-id-type="pmid">31092692</pub-id></element-citation></ref><ref id="B169-microorganisms-09-00899"><label>169.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Ledgerwood</surname><given-names>J.C.G.</given-names></name></person-group><article-title>A Phase 1 Open Label, Dose-Escalation Clinical Trial to Evaluate the Safety and Immunogenicity of a Trivalent Virus-Like Particle (VLP) Encephalitis Vaccine, VRC-WEVVLP073-00-VP, in Healthy Adults: U.S. National Library of Medicine</article-title><year>2019</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03879603">https://clinicaltrials.gov/ct2/show/NCT03879603</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-03-18">(accessed on 18 March 2021)</date-in-citation></element-citation></ref><ref id="B170-microorganisms-09-00899"><label>170.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riemenschneider</surname><given-names>J.</given-names></name><name name-style="western"><surname>Garrison</surname><given-names>A.</given-names></name><name name-style="western"><surname>Geisbert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Jahrling</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hevey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Negley</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schmaljohn</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hart</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Vanderzanden</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Comparison of individual and combination DNA vaccines for B. anthracis, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus</article-title><source>Vaccine</source><year>2003</year><volume>21</volume><fpage>4071</fpage><lpage>4080</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(03)00362-1</pub-id><pub-id pub-id-type="pmid">12922144</pub-id></element-citation></ref><ref id="B171-microorganisms-09-00899"><label>171.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hart</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Pratt</surname><given-names>W.</given-names></name><name name-style="western"><surname>Panelo</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tammariello</surname><given-names>R.</given-names></name><name name-style="western"><surname>Dertzbaugh</surname><given-names>M.</given-names></name></person-group><article-title>Venezuelan equine encephalitis virus vaccines induce mucosal IgA responses and protection from airborne infection in BALB/c, but not C3H/HeN mice</article-title><source>Vaccine</source><year>1997</year><volume>15</volume><fpage>363</fpage><lpage>369</lpage><pub-id pub-id-type="doi">10.1016/S0264-410X(96)00204-6</pub-id><pub-id pub-id-type="pmid">9141206</pub-id></element-citation></ref><ref id="B172-microorganisms-09-00899"><label>172.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perkins</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>O&#8216;Brien</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Phillpotts</surname><given-names>R.J.</given-names></name></person-group><article-title>Boosting with an adenovirus-based vaccine improves protective efficacy against Venezuelan equine encephalitis virus following DNA vaccination</article-title><source>Vaccine</source><year>2006</year><volume>24</volume><fpage>3440</fpage><lpage>3445</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2006.02.020</pub-id><pub-id pub-id-type="pmid">16527377</pub-id></element-citation></ref><ref id="B173-microorganisms-09-00899"><label>173.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dupuy</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Locher</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Paidhungat</surname><given-names>M.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lind</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Bakken</surname><given-names>R.</given-names></name><name name-style="western"><surname>Parker</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Wahlen</surname><given-names>R.G.</given-names></name><name name-style="western"><surname>Schmaljohn</surname><given-names>C.S.</given-names></name></person-group><article-title>Directed molecular evolution improves the immunogenicity and protective efficacy of a Venezuelan equine encephalitis virus DNA vaccine</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>4152</fpage><lpage>4160</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.04.049</pub-id><pub-id pub-id-type="pmid">19406186</pub-id></element-citation></ref><ref id="B174-microorganisms-09-00899"><label>174.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tretyakova</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lukashevich</surname><given-names>I.S.</given-names></name><name name-style="western"><surname>Glass</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pushko</surname><given-names>P.</given-names></name></person-group><article-title>Novel vaccine against Venezuelan equine encephalitis combines advantages of DNA immunization and a live attenuated vaccine</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>1019</fpage><lpage>1025</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2012.12.050</pub-id><pub-id pub-id-type="pmid">23287629</pub-id><pub-id pub-id-type="pmcid">PMC3556218</pub-id></element-citation></ref><ref id="B175-microorganisms-09-00899"><label>175.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gauci</surname><given-names>P.J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.Q.</given-names></name><name name-style="western"><surname>Rayner</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Barabe</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Nagata</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Proll</surname><given-names>D.F.</given-names></name></person-group><article-title>Identification of Western equine encephalitis virus structural proteins that confer protection after DNA vaccination</article-title><source>Clin. Vaccine Immunol.</source><year>2010</year><volume>17</volume><fpage>176</fpage><lpage>179</lpage><pub-id pub-id-type="doi">10.1128/CVI.00377-09</pub-id><pub-id pub-id-type="pmid">19923571</pub-id><pub-id pub-id-type="pmcid">PMC2812089</pub-id></element-citation></ref><ref id="B176-microorganisms-09-00899"><label>176.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muthumani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lankaraman</surname><given-names>K.M.</given-names></name><name name-style="western"><surname>Laddy</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Sundaram</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>C.W.</given-names></name><name name-style="western"><surname>Sako</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Khan</surname><given-names>A.</given-names></name><name name-style="western"><surname>Sardesai</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.J.</given-names></name><etal/></person-group><article-title>Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>5128</fpage><lpage>5134</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.03.060</pub-id><pub-id pub-id-type="pmid">18471943</pub-id><pub-id pub-id-type="pmcid">PMC2582145</pub-id></element-citation></ref><ref id="B177-microorganisms-09-00899"><label>177.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Ramanathan</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Kawalakar</surname><given-names>O.</given-names></name><name name-style="western"><surname>Sundaram</surname><given-names>S.G.</given-names></name><name name-style="western"><surname>Tingey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Bian</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Muruganandam</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vijauachari</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sardesai</surname><given-names>N.Y.</given-names></name><name name-style="western"><surname>Weiner</surname><given-names>D.B.</given-names></name><etal/></person-group><article-title>Nonstructural protein 2 (nsP2) of Chikungunya virus (CHIKV) enhances protective immunity mediated by a CHIKV envelope protein expressing DNA Vaccine</article-title><source>Viral Immunol.</source><year>2013</year><volume>26</volume><fpage>75</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1089/vim.2012.0061</pub-id><pub-id pub-id-type="pmid">23409931</pub-id><pub-id pub-id-type="pmcid">PMC4845693</pub-id></element-citation></ref><ref id="B178-microorganisms-09-00899"><label>178.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mallilankaraman</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shedlock</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kawalekar</surname><given-names>O.U.</given-names></name><name name-style="western"><surname>Fagone</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ramanathan</surname><given-names>A.A.</given-names></name><name name-style="western"><surname>Ferraro</surname><given-names>B.</given-names></name><name name-style="western"><surname>Stabenow</surname><given-names>J.</given-names></name><name name-style="western"><surname>Vijayachari</surname><given-names>P.</given-names></name><name name-style="western"><surname>Sundaran</surname><given-names>S.G.</given-names></name><etal/></person-group><article-title>A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates</article-title><source>PLoS Negl. Trop. Dis.</source><year>2011</year><volume>5</volume><elocation-id>e928</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0000928</pub-id><pub-id pub-id-type="pmid">21264351</pub-id><pub-id pub-id-type="pmcid">PMC3019110</pub-id></element-citation></ref><ref id="B179-microorganisms-09-00899"><label>179.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dupuy</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Livingston</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Hannaman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Schmaljohn</surname><given-names>C.S.</given-names></name></person-group><article-title>A Multiagent Alphavirus DNA Vaccine Delivered by Intramuscular Electroporation Elicits Robust and Durable Virus-Specific Immune Responses in Mice and Rabbits and Completely Protects Mice against Lethal Venezuelan, Western, and Eastern Equine Encephalitis Virus Aerosol Challenges</article-title><source>J. Immunol. Res.</source><year>2018</year><volume>2018</volume><fpage>8521060</fpage><pub-id pub-id-type="pmid">29967804</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1155/2018/8521060</pub-id><pub-id pub-id-type="pmcid">PMC6008678</pub-id></element-citation></ref><ref id="B180-microorganisms-09-00899"><label>180.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Choi</surname><given-names>H.</given-names></name><name name-style="western"><surname>Kudchodkar</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Reuschel</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Asija</surname><given-names>K.</given-names></name><name name-style="western"><surname>Borole</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>M.</given-names></name><name name-style="western"><surname>Wojtak</surname><given-names>K.</given-names></name><name name-style="western"><surname>Reed</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ramos</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bopp</surname><given-names>N.E.</given-names></name><etal/></person-group><article-title>Protective immunity by an engineered DNA vaccine for Mayaro virus</article-title><source>PLoS Negl. Trop. Dis.</source><year>2019</year><volume>13</volume><elocation-id>e0007042</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0007042</pub-id><pub-id pub-id-type="pmid">30730897</pub-id><pub-id pub-id-type="pmcid">PMC6366747</pub-id></element-citation></ref><ref id="B181-microorganisms-09-00899"><label>181.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tretyakova</surname><given-names>I.</given-names></name><name name-style="western"><surname>Hearn</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pushko</surname><given-names>P.</given-names></name></person-group><article-title>DNA vaccine initiates replication of live attenuated chikungunya virus in vitro and elicits protective immune response in mice</article-title><source>J. Infect. Dis.</source><year>2014</year><volume>209</volume><fpage>1882</fpage><lpage>1890</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiu114</pub-id><pub-id pub-id-type="pmid">24585894</pub-id><pub-id pub-id-type="pmcid">PMC4038148</pub-id></element-citation></ref><ref id="B182-microorganisms-09-00899"><label>182.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muthumani</surname><given-names>K.</given-names></name><name name-style="western"><surname>Block</surname><given-names>P.</given-names></name><name name-style="western"><surname>Flingai</surname><given-names>S.</given-names></name><name name-style="western"><surname>Muruganantham</surname><given-names>N.</given-names></name><name name-style="western"><surname>Chaaithanya</surname><given-names>I.K.</given-names></name><name name-style="western"><surname>Tingey</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wise</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reuschel</surname><given-names>E.L.</given-names></name><name name-style="western"><surname>Chung</surname><given-names>C.</given-names></name><name name-style="western"><surname>Muthumani</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus</article-title><source>J. Infect. Dis.</source><year>2016</year><volume>214</volume><fpage>369</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiw111</pub-id><pub-id pub-id-type="pmid">27001960</pub-id><pub-id pub-id-type="pmcid">PMC4936642</pub-id></element-citation></ref><ref id="B183-microorganisms-09-00899"><label>183.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Szurgot</surname><given-names>I.</given-names></name><name name-style="western"><surname>Ljungberg</surname><given-names>K.</given-names></name><name name-style="western"><surname>Kummerer</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Liljestrom</surname><given-names>P.</given-names></name></person-group><article-title>Infectious RNA vaccine protects mice against chikungunya virus infection</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><fpage>21076</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-78009-7</pub-id><pub-id pub-id-type="pmid">33273501</pub-id><pub-id pub-id-type="pmcid">PMC7712826</pub-id></element-citation></ref><ref id="B184-microorganisms-09-00899"><label>184.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dupuy</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Richards</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Ellefsen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Chau</surname><given-names>L.</given-names></name><name name-style="western"><surname>Luxembourg</surname><given-names>A.</given-names></name><name name-style="western"><surname>Hannaman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Livingston</surname><given-names>B.D.</given-names></name><name name-style="western"><surname>Schmaljohn</surname><given-names>C.S.</given-names></name></person-group><article-title>A DNA vaccine for venezuelan equine encephalitis virus delivered by intramuscular electroporation elicits high levels of neutralizing antibodies in multiple animal models and provides protective immunity to mice and nonhuman primates</article-title><source>Clin. Vaccine Immunol.</source><year>2011</year><volume>18</volume><fpage>707</fpage><lpage>716</lpage><pub-id pub-id-type="doi">10.1128/CVI.00030-11</pub-id><pub-id pub-id-type="pmid">21450977</pub-id><pub-id pub-id-type="pmcid">PMC3122536</pub-id></element-citation></ref><ref id="B185-microorganisms-09-00899"><label>185.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hannaman</surname><given-names>D.</given-names></name><name name-style="western"><surname>Dupuy</surname><given-names>L.C.</given-names></name><name name-style="western"><surname>Ellefsen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Schmaljohn</surname><given-names>C.S.</given-names></name></person-group><article-title>A Phase 1 clinical trial of a DNA vaccine for Venezuelan equine encephalitis delivered by intramuscular or intradermal electroporation</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><fpage>3607</fpage><lpage>3612</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2016.04.077</pub-id><pub-id pub-id-type="pmid">27206386</pub-id></element-citation></ref><ref id="B186-microorganisms-09-00899"><label>186.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nagata</surname><given-names>L.P.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>W.G.</given-names></name><name name-style="western"><surname>Masri</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Rayner</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Schmaltz</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>Das</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Long</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Chan</surname><given-names>C.</given-names></name><name name-style="western"><surname>Proll</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Efficacy of DNA vaccination against western equine encephalitis virus infection</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>2280</fpage><lpage>2283</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2005.01.032</pub-id><pub-id pub-id-type="pmid">15755611</pub-id></element-citation></ref><ref id="B187-microorganisms-09-00899"><label>187.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillips</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Schountz</surname><given-names>T.</given-names></name><name name-style="western"><surname>Toth</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Rico</surname><given-names>A.B.</given-names></name><name name-style="western"><surname>Jarvis</surname><given-names>D.L.</given-names></name><name name-style="western"><surname>Powers</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Olson</surname><given-names>K.E.</given-names></name></person-group><article-title>Liposome-antigen-nucleic acid complexes protect mice from lethal challenge with western and eastern equine encephalitis viruses</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>1771</fpage><lpage>1780</lpage><pub-id pub-id-type="doi">10.1128/JVI.02297-13</pub-id><pub-id pub-id-type="pmid">24257615</pub-id><pub-id pub-id-type="pmcid">PMC3911585</pub-id></element-citation></ref><ref id="B188-microorganisms-09-00899"><label>188.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>C.</given-names></name><name name-style="western"><surname>Panther</surname><given-names>L.</given-names></name><name name-style="western"><surname>August</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zaks</surname><given-names>T.</given-names></name><name name-style="western"><surname>Smolenov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Bart</surname><given-names>S.</given-names></name><name name-style="western"><surname>Watson</surname><given-names>M.</given-names></name></person-group><article-title>Safety and immunogenicity of a mRNA-based chikungunya vaccine in a phase 1 dose-ranging trial</article-title><source>Int. J. Infect. Dis.</source><year>2019</year><volume>79</volume><fpage>17</fpage><pub-id pub-id-type="doi">10.1016/j.ijid.2018.11.058</pub-id></element-citation></ref><ref id="B189-microorganisms-09-00899"><label>189.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kose</surname><given-names>N.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Sapparapu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Bombardi</surname><given-names>R.</given-names></name><name name-style="western"><surname>Tennekoon</surname><given-names>R.N.</given-names></name><name name-style="western"><surname>de Silva</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Elbashir</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Theisen</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Humphris-Narayanan</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ciaramella</surname><given-names>G.</given-names></name><etal/></person-group><article-title>A lipid-encapsulated mRNA encoding a potently neutralizing human monoclonal antibody protects against chikungunya infection</article-title><source>Sci. Immunol.</source><year>2019</year><volume>4</volume><fpage>eaaw6647</fpage><pub-id pub-id-type="doi">10.1126/sciimmunol.aaw6647</pub-id><pub-id pub-id-type="pmid">31101672</pub-id><pub-id pub-id-type="pmcid">PMC6629435</pub-id></element-citation></ref><ref id="B190-microorganisms-09-00899"><label>190.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Moderna</surname><given-names>T.X.</given-names></name></person-group><article-title>A Phase 1, Randomized, Placebo-Controlled, Dose Ranging Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944, Encoding for an Anti-Chikungunya Virus Monoclonal Antibody, in Healthy Adults: U.S. National Library of Medicine</article-title><year>2019</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT03829384">https://clinicaltrials.gov/ct2/show/NCT03829384</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-03-18">(accessed on 18 March 2021)</date-in-citation></element-citation></ref><ref id="B191-microorganisms-09-00899"><label>191.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Metz</surname><given-names>S.W.</given-names></name><name name-style="western"><surname>Geertsema</surname><given-names>C.</given-names></name><name name-style="western"><surname>Martina</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Andrade</surname><given-names>P.</given-names></name><name name-style="western"><surname>Heldens</surname><given-names>J.G.</given-names></name><name name-style="western"><surname>van Oers</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Goldbach</surname><given-names>R.W.</given-names></name><name name-style="western"><surname>Vlak</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Pijlman</surname><given-names>G.P.</given-names></name></person-group><article-title>Functional processing and secretion of Chikungunya virus E1 and E2 glycoproteins in insect cells</article-title><source>Virol. J.</source><year>2011</year><volume>8</volume><fpage>353</fpage><pub-id pub-id-type="doi">10.1186/1743-422X-8-353</pub-id><pub-id pub-id-type="pmid">21762510</pub-id><pub-id pub-id-type="pmcid">PMC3162542</pub-id></element-citation></ref><ref id="B192-microorganisms-09-00899"><label>192.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Khan</surname><given-names>M.</given-names></name><name name-style="western"><surname>Dhanwani</surname><given-names>R.</given-names></name><name name-style="western"><surname>Rao</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Parida</surname><given-names>M.</given-names></name></person-group><article-title>Subunit vaccine formulations based on recombinant envelope proteins of Chikungunya virus elicit balanced Th1/Th2 response and virus-neutralizing antibodies in mice</article-title><source>Virus Res.</source><year>2012</year><volume>167</volume><fpage>236</fpage><lpage>246</lpage><pub-id pub-id-type="doi">10.1016/j.virusres.2012.05.004</pub-id><pub-id pub-id-type="pmid">22610133</pub-id></element-citation></ref><ref id="B193-microorganisms-09-00899"><label>193.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brandler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ruffie</surname><given-names>C.</given-names></name><name name-style="western"><surname>Combredet</surname><given-names>C.</given-names></name><name name-style="western"><surname>Brault</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Najburg</surname><given-names>V.</given-names></name><name name-style="western"><surname>Prevost</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Habel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Tauber</surname><given-names>E.</given-names></name><name name-style="western"><surname>Despres</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tangy</surname><given-names>F.</given-names></name></person-group><article-title>A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus</article-title><source>Vaccine</source><year>2013</year><volume>31</volume><fpage>3718</fpage><lpage>3725</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2013.05.086</pub-id><pub-id pub-id-type="pmid">23742993</pub-id></element-citation></ref><ref id="B194-microorganisms-09-00899"><label>194.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gerke</surname><given-names>C.</given-names></name><name name-style="western"><surname>Frantz</surname><given-names>P.N.</given-names></name><name name-style="western"><surname>Ramsauer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Tangy</surname><given-names>F.</given-names></name></person-group><article-title>Measles-vectored vaccine approaches against viral infections: A focus on Chikungunya</article-title><source>Expert Rev. Vaccines</source><year>2019</year><volume>18</volume><fpage>393</fpage><lpage>403</lpage><pub-id pub-id-type="doi">10.1080/14760584.2019.1562908</pub-id><pub-id pub-id-type="pmid">30601074</pub-id></element-citation></ref><ref id="B195-microorganisms-09-00899"><label>195.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossi</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Comer</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Azar</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Lawrence</surname><given-names>W.S.</given-names></name><name name-style="western"><surname>Plante</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Ramsauer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schrauf</surname><given-names>S.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name></person-group><article-title>Immunogenicity and Efficacy of a Measles Virus-Vectored Chikungunya Vaccine in Nonhuman Primates</article-title><source>J. Infect. Dis.</source><year>2019</year><volume>220</volume><fpage>735</fpage><lpage>742</lpage><pub-id pub-id-type="doi">10.1093/infdis/jiz202</pub-id><pub-id pub-id-type="pmid">31053842</pub-id><pub-id pub-id-type="pmcid">PMC6667792</pub-id></element-citation></ref><ref id="B196-microorganisms-09-00899"><label>196.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramsauer</surname><given-names>K.</given-names></name><name name-style="western"><surname>Schwameis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Firbas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Mullner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Putnak</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Despres</surname><given-names>P.</given-names></name><name name-style="western"><surname>Tauber</surname><given-names>E.</given-names></name><name name-style="western"><surname>Jilma</surname><given-names>B.</given-names></name><name name-style="western"><surname>Tangy</surname><given-names>F.</given-names></name></person-group><article-title>Immunogenicity, safety, and tolerability of a recombinant measles-virus-based chikungunya vaccine: A randomised, double-blind, placebo-controlled, active-comparator, first-in-man trial</article-title><source>Lancet Infect. Dis.</source><year>2015</year><volume>15</volume><fpage>519</fpage><lpage>527</lpage><pub-id pub-id-type="doi">10.1016/S1473-3099(15)70043-5</pub-id><pub-id pub-id-type="pmid">25739878</pub-id></element-citation></ref><ref id="B197-microorganisms-09-00899"><label>197.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reisinger</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Tschismarov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Beubler</surname><given-names>E.</given-names></name><name name-style="western"><surname>Wiedermann</surname><given-names>U.</given-names></name><name name-style="western"><surname>Firbas</surname><given-names>C.</given-names></name><name name-style="western"><surname>Loebermann</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pfeiffer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Muellner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Tauber</surname><given-names>E.</given-names></name><name name-style="western"><surname>Ramsauer</surname><given-names>L.</given-names></name></person-group><article-title>Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: A double-blind, randomised, placebo-controlled and active-controlled phase 2 trial</article-title><source>Lancet</source><year>2019</year><volume>392</volume><fpage>2718</fpage><lpage>2727</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(18)32488-7</pub-id><pub-id pub-id-type="pmid">30409443</pub-id></element-citation></ref><ref id="B198-microorganisms-09-00899"><label>198.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Volkova</surname><given-names>E.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Forrester</surname><given-names>N.</given-names></name><name name-style="western"><surname>Xiao</surname><given-names>S.Y.</given-names></name><name name-style="western"><surname>Frolov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name></person-group><article-title>Chimeric alphavirus vaccine candidates for chikungunya</article-title><source>Vaccine</source><year>2008</year><volume>26</volume><fpage>5030</fpage><lpage>5039</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2008.07.054</pub-id><pub-id pub-id-type="pmid">18692107</pub-id><pub-id pub-id-type="pmcid">PMC2571998</pub-id></element-citation></ref><ref id="B199-microorganisms-09-00899"><label>199.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Frolov</surname><given-names>I.</given-names></name></person-group><article-title>Chimeric Chikungunya viruses are nonpathogenic in highly sensitive mouse models but efficiently induce a protective immune response</article-title><source>J. Virol.</source><year>2011</year><volume>85</volume><fpage>9249</fpage><lpage>9252</lpage><pub-id pub-id-type="doi">10.1128/JVI.00844-11</pub-id><pub-id pub-id-type="pmid">21697494</pub-id><pub-id pub-id-type="pmcid">PMC3165793</pub-id></element-citation></ref><ref id="B200-microorganisms-09-00899"><label>200.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Petrakova</surname><given-names>O.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Aguilar</surname><given-names>P.V.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>W.</given-names></name><name name-style="western"><surname>Paessler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Volk</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Frolov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name></person-group><article-title>Chimeric Sindbis/eastern equine encephalitis vaccine candidates are highly attenuated and immunogenic in mice</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>7573</fpage><lpage>7581</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.07.061</pub-id><pub-id pub-id-type="pmid">17904699</pub-id><pub-id pub-id-type="pmcid">PMC2094013</pub-id></element-citation></ref><ref id="B201-microorganisms-09-00899"><label>201.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paessler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fayzulin</surname><given-names>R.Z.</given-names></name><name name-style="western"><surname>Anishchenko</surname><given-names>M.</given-names></name><name name-style="western"><surname>Greene</surname><given-names>I.P.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Frolov</surname><given-names>I.</given-names></name></person-group><article-title>Recombinant sindbis/Venezuelan equine encephalitis virus is highly attenuated and immunogenic</article-title><source>J. Virol.</source><year>2003</year><volume>77</volume><fpage>9278</fpage><lpage>9286</lpage><pub-id pub-id-type="doi">10.1128/JVI.77.17.9278-9286.2003</pub-id><pub-id pub-id-type="pmid">12915543</pub-id><pub-id pub-id-type="pmcid">PMC187387</pub-id></element-citation></ref><ref id="B202-microorganisms-09-00899"><label>202.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Paessler</surname><given-names>S.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>H.</given-names></name><name name-style="western"><surname>Petrakova</surname><given-names>O.</given-names></name><name name-style="western"><surname>Fayzulin</surname><given-names>R.Z.</given-names></name><name name-style="western"><surname>Yun</surname><given-names>N.</given-names></name><name name-style="western"><surname>Anishchenko</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Frolov</surname><given-names>I.</given-names></name></person-group><article-title>Replication and clearance of Venezuelan equine encephalitis virus from the brains of animals vaccinated with chimeric SIN/VEE viruses</article-title><source>J. Virol.</source><year>2006</year><volume>80</volume><fpage>2784</fpage><lpage>2796</lpage><pub-id pub-id-type="doi">10.1128/JVI.80.6.2784-2796.2006</pub-id><pub-id pub-id-type="pmid">16501087</pub-id><pub-id pub-id-type="pmcid">PMC1395430</pub-id></element-citation></ref><ref id="B203-microorganisms-09-00899"><label>203.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atasheva</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Adams</surname><given-names>A.P.</given-names></name><name name-style="western"><surname>Plante</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Ni</surname><given-names>S.</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>K.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Frolov</surname><given-names>I.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name></person-group><article-title>Chimeric alphavirus vaccine candidates protect mice from intranasal challenge with western equine encephalitis virus</article-title><source>Vaccine</source><year>2009</year><volume>27</volume><fpage>4309</fpage><lpage>4319</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2009.05.011</pub-id><pub-id pub-id-type="pmid">19446595</pub-id><pub-id pub-id-type="pmcid">PMC3238384</pub-id></element-citation></ref><ref id="B204-microorganisms-09-00899"><label>204.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Arriaza</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cepeda</surname><given-names>V.</given-names></name><name name-style="western"><surname>Hallengard</surname><given-names>D.</given-names></name><name name-style="western"><surname>Sorzano</surname><given-names>C.O.</given-names></name><name name-style="western"><surname>Kummerer</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Liljestrom</surname><given-names>P.</given-names></name><name name-style="western"><surname>Esteban</surname><given-names>M.</given-names></name></person-group><article-title>A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against chikungunya infection</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>3527</fpage><lpage>3547</lpage><pub-id pub-id-type="doi">10.1128/JVI.03418-13</pub-id><pub-id pub-id-type="pmid">24403588</pub-id><pub-id pub-id-type="pmcid">PMC3957920</pub-id></element-citation></ref><ref id="B205-microorganisms-09-00899"><label>205.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weger-Lucarelli</surname><given-names>J.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Aliota</surname><given-names>M.T.</given-names></name><name name-style="western"><surname>Partidos</surname><given-names>C.D.</given-names></name><name name-style="western"><surname>Osorio</surname><given-names>J.E.</given-names></name></person-group><article-title>A novel MVA vectored Chikungunya virus vaccine elicits protective immunity in mice</article-title><source>PLoS Negl. Trop. Dis.</source><year>2014</year><volume>8</volume><elocation-id>e2970</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0002970</pub-id><pub-id pub-id-type="pmid">25058320</pub-id><pub-id pub-id-type="pmcid">PMC4109897</pub-id></element-citation></ref><ref id="B206-microorganisms-09-00899"><label>206.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van den Doel</surname><given-names>P.</given-names></name><name name-style="western"><surname>Volz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Roose</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Sewbalaksing</surname><given-names>V.D.</given-names></name><name name-style="western"><surname>Pijlman</surname><given-names>G.P.</given-names></name><name name-style="western"><surname>van Middelkoop</surname><given-names>I.</given-names></name><name name-style="western"><surname>Duiverman</surname><given-names>V.</given-names></name><name name-style="western"><surname>van de Wetering</surname><given-names>E.</given-names></name><name name-style="western"><surname>Sutter</surname><given-names>G.</given-names></name><name name-style="western"><surname>Osterhaus</surname><given-names>A.D.M.E.</given-names></name><etal/></person-group><article-title>Recombinant modified vaccinia virus Ankara expressing glycoprotein E2 of Chikungunya virus protects AG129 mice against lethal challenge</article-title><source>PLoS Negl. Trop. Dis.</source><year>2014</year><volume>8</volume><elocation-id>e3101</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pntd.0003101</pub-id><pub-id pub-id-type="pmid">25188230</pub-id><pub-id pub-id-type="pmcid">PMC4154657</pub-id></element-citation></ref><ref id="B207-microorganisms-09-00899"><label>207.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hu</surname><given-names>W.G.</given-names></name><name name-style="western"><surname>Steigerwald</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kalla</surname><given-names>M.</given-names></name><name name-style="western"><surname>Volkmann</surname><given-names>A.</given-names></name><name name-style="western"><surname>Noll</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nagata</surname><given-names>L.P.</given-names></name></person-group><article-title>Protective efficacy of monovalent and trivalent recombinant MVA-based vaccines against three encephalitic alphaviruses</article-title><source>Vaccine</source><year>2018</year><volume>36</volume><fpage>5194</fpage><lpage>5203</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2018.06.064</pub-id><pub-id pub-id-type="pmid">30037666</pub-id></element-citation></ref><ref id="B208-microorganisms-09-00899"><label>208.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Suhrbier</surname><given-names>A.</given-names></name><name name-style="western"><surname>Penn-Nicholson</surname><given-names>A.</given-names></name><name name-style="western"><surname>Woraratanadharm</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gardner</surname><given-names>J.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>M.</given-names></name><name name-style="western"><surname>Le</surname><given-names>T.T.</given-names></name><name name-style="western"><surname>Anraku</surname><given-names>I.</given-names></name><name name-style="western"><surname>Sakalian</surname><given-names>M.</given-names></name><name name-style="western"><surname>Einfeld</surname><given-names>D.</given-names></name><etal/></person-group><article-title>A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>2803</fpage><lpage>2809</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2011.01.108</pub-id><pub-id pub-id-type="pmid">21320541</pub-id><pub-id pub-id-type="pmcid">PMC3061842</pub-id></element-citation></ref><ref id="B209-microorganisms-09-00899"><label>209.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lopez-Camacho</surname><given-names>C.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Blight</surname><given-names>J.</given-names></name><name name-style="western"><surname>Lazaro Moreli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Montoya-Diaz</surname><given-names>E.</given-names></name><name name-style="western"><surname>Huiskonen</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Kummerer</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Reyes-Sandoval</surname><given-names>A.</given-names></name></person-group><article-title>Assessment of Immunogenicity and Neutralisation Efficacy of Viral-Vectored Vaccines Against Chikungunya Virus</article-title><source>Viruses</source><year>2019</year><volume>11</volume><elocation-id>322</elocation-id><pub-id pub-id-type="doi">10.3390/v11040322</pub-id><pub-id pub-id-type="pmid">30987160</pub-id><pub-id pub-id-type="pmcid">PMC6521086</pub-id></element-citation></ref><ref id="B210-microorganisms-09-00899"><label>210.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kroon Campos</surname><given-names>R.</given-names></name><name name-style="western"><surname>Preciado-Llanes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Azar</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>Y.C.</given-names></name><name name-style="western"><surname>Brandon</surname><given-names>O.</given-names></name><name name-style="western"><surname>Lopez-Camacho</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reyes-Sandoval</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>S.L.</given-names></name></person-group><article-title>Adenoviral-Vectored Mayaro and Chikungunya Virus Vaccine Candidates Afford Partial Cross-Protection From Lethal Challenge in A129 Mouse Model</article-title><source>Front. Immunol.</source><year>2020</year><volume>11</volume><fpage>591885</fpage><pub-id pub-id-type="doi">10.3389/fimmu.2020.591885</pub-id><pub-id pub-id-type="pmid">33224148</pub-id><pub-id pub-id-type="pmcid">PMC7672187</pub-id></element-citation></ref><ref id="B211-microorganisms-09-00899"><label>211.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Campos</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Preciado-Llanes</surname><given-names>L.</given-names></name><name name-style="western"><surname>Azar</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Lopez-Camacho</surname><given-names>C.</given-names></name><name name-style="western"><surname>Reyes-Sandoval</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>S.L.</given-names></name></person-group><article-title>A Single and Un-Adjuvanted Dose of a Chimpanzee Adenovirus-Vectored Vaccine against Chikungunya Virus Fully Protects Mice from Lethal Disease</article-title><source>Pathogens</source><year>2019</year><volume>8</volume><elocation-id>231</elocation-id><pub-id pub-id-type="doi">10.3390/pathogens8040231</pub-id><pub-id pub-id-type="pmid">31718104</pub-id><pub-id pub-id-type="pmcid">PMC6963200</pub-id></element-citation></ref><ref id="B212-microorganisms-09-00899"><label>212.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Hill</surname><given-names>A.V.</given-names></name></person-group><article-title>Safety and Immunogenicity of a Candidate CHIKV Vaccine (CHIK001): National Library of Medicine (U.S.)</article-title><year>2018</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/record/NCT03590392">https://clinicaltrials.gov/ct2/show/record/NCT03590392</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-03-18">(accessed on 18 March 2021)</date-in-citation></element-citation></ref><ref id="B213-microorganisms-09-00899"><label>213.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Phillpotts</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>L.</given-names></name><name name-style="western"><surname>Appleton</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Carr</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>A.</given-names></name></person-group><article-title>Intranasal immunisation with defective adenovirus serotype 5 expressing the Venezuelan equine encephalitis virus E2 glycoprotein protects against airborne challenge with virulent virus</article-title><source>Vaccine</source><year>2005</year><volume>23</volume><fpage>1615</fpage><lpage>1623</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2004.06.056</pub-id><pub-id pub-id-type="pmid">15694514</pub-id></element-citation></ref><ref id="B214-microorganisms-09-00899"><label>214.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perkins</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Williams</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>O&#8217;Brien</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Laws</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Phillpotts</surname><given-names>R.J.</given-names></name></person-group><article-title>CpG used as an adjuvant for an adenovirus-based Venezuelan equine encephalitis virus vaccine increases the immune response to the vector, but not to the transgene product</article-title><source>Viral. Immunol.</source><year>2008</year><volume>21</volume><fpage>451</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1089/vim.2008.0052</pub-id><pub-id pub-id-type="pmid">19115934</pub-id></element-citation></ref><ref id="B215-microorganisms-09-00899"><label>215.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>J.Q.</given-names></name><name name-style="western"><surname>Barabe</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Chau</surname><given-names>D.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rayner</surname><given-names>G.R.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>W.G.</given-names></name><name name-style="western"><surname>Nagata</surname><given-names>L.P.</given-names></name></person-group><article-title>Complete protection of mice against a lethal dose challenge of western equine encephalitis virus after immunization with an adenovirus-vectored vaccine</article-title><source>Vaccine</source><year>2007</year><volume>25</volume><fpage>4368</fpage><lpage>4375</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2007.03.042</pub-id><pub-id pub-id-type="pmid">17467858</pub-id></element-citation></ref><ref id="B216-microorganisms-09-00899"><label>216.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Swayze</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Bhogal</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Barabe</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>McLaws</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>J.Q.</given-names></name></person-group><article-title>Envelope protein E1 as vaccine target for western equine encephalitis virus</article-title><source>Vaccine</source><year>2011</year><volume>29</volume><fpage>813</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1016/j.vaccine.2010.11.009</pub-id><pub-id pub-id-type="pmid">21084062</pub-id></element-citation></ref><ref id="B217-microorganisms-09-00899"><label>217.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chattopadhyay</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>E.</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>R.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Rose</surname><given-names>J.K.</given-names></name></person-group><article-title>A chimeric vesiculo/alphavirus is an effective alphavirus vaccine</article-title><source>J. Virol.</source><year>2013</year><volume>87</volume><fpage>395</fpage><lpage>402</lpage><pub-id pub-id-type="doi">10.1128/JVI.01860-12</pub-id><pub-id pub-id-type="pmid">23077320</pub-id><pub-id pub-id-type="pmcid">PMC3536361</pub-id></element-citation></ref><ref id="B218-microorganisms-09-00899"><label>218.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nasar</surname><given-names>F.</given-names></name><name name-style="western"><surname>Matassov</surname><given-names>D.</given-names></name><name name-style="western"><surname>Seymour</surname><given-names>R.L.</given-names></name><name name-style="western"><surname>Latham</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gorchakov</surname><given-names>R.V.</given-names></name><name name-style="western"><surname>Nowak</surname><given-names>R.M.</given-names></name><name name-style="western"><surname>Leal</surname><given-names>G.</given-names></name><name name-style="western"><surname>Hamm</surname><given-names>S.</given-names></name><name name-style="western"><surname>Eldridge</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Tesh</surname><given-names>R.B.</given-names></name><etal/></person-group><article-title>Recombinant Isfahan Virus and Vesicular Stomatitis Virus Vaccine Vectors Provide Durable, Multivalent, Single-Dose Protection against Lethal Alphavirus Challenge</article-title><source>J. Virol.</source><year>2017</year><volume>91</volume><fpage>e01729-16</fpage><pub-id pub-id-type="doi">10.1128/JVI.01729-16</pub-id><pub-id pub-id-type="pmid">28148802</pub-id><pub-id pub-id-type="pmcid">PMC5375677</pub-id></element-citation></ref><ref id="B219-microorganisms-09-00899"><label>219.</label><element-citation publication-type="gov"><person-group person-group-type="author"><name name-style="western"><surname>Fierro</surname><given-names>C.</given-names></name></person-group><article-title>Phase 1 Vaccination Trial to Evaluate Safety, Tolerability and Immunogenicity of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects: National Library of Medicine (U.S.)</article-title><year>2019</year><comment>Available online: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/study/NCT04131595">https://clinicaltrials.gov/ct2/show/study/NCT04131595</ext-link></comment><date-in-citation content-type="access-date" iso-8601-date="2021-03-18">(accessed on 18 March 2021)</date-in-citation></element-citation></ref><ref id="B220-microorganisms-09-00899"><label>220.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erasmus</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Auguste</surname><given-names>A.J.</given-names></name><name name-style="western"><surname>Kaelber</surname><given-names>J.T.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>H.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Fenton</surname><given-names>K.</given-names></name><name name-style="western"><surname>Leal</surname><given-names>G.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>D.Y.</given-names></name><name name-style="western"><surname>Chiu</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>T.</given-names></name><etal/></person-group><article-title>A chikungunya fever vaccine utilizing an insect-specific virus platform</article-title><source>Nat. Med.</source><year>2017</year><volume>23</volume><fpage>192</fpage><lpage>199</lpage><pub-id pub-id-type="doi">10.1038/nm.4253</pub-id><pub-id pub-id-type="pmid">27991917</pub-id><pub-id pub-id-type="pmcid">PMC5296253</pub-id></element-citation></ref><ref id="B221-microorganisms-09-00899"><label>221.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lauring</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>J.O.</given-names></name><name name-style="western"><surname>Andino</surname><given-names>R.</given-names></name></person-group><article-title>Rationalizing the development of live attenuated virus vaccines</article-title><source>Nat. Biotechnol.</source><year>2010</year><volume>28</volume><fpage>573</fpage><lpage>579</lpage><pub-id pub-id-type="doi">10.1038/nbt.1635</pub-id><pub-id pub-id-type="pmid">20531338</pub-id><pub-id pub-id-type="pmcid">PMC2883798</pub-id></element-citation></ref><ref id="B222-microorganisms-09-00899"><label>222.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rueckert</surname><given-names>C.</given-names></name><name name-style="western"><surname>Guzman</surname><given-names>C.A.</given-names></name></person-group><article-title>Vaccines: From empirical development to rational design</article-title><source>PLoS Pathog.</source><year>2012</year><volume>8</volume><elocation-id>e1003001</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1003001</pub-id><pub-id pub-id-type="pmid">23144616</pub-id><pub-id pub-id-type="pmcid">PMC3493475</pub-id></element-citation></ref><ref id="B223-microorganisms-09-00899"><label>223.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Coffey</surname><given-names>L.L.</given-names></name><name name-style="western"><surname>Beeharry</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Borderia</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Blanc</surname><given-names>H.</given-names></name><name name-style="western"><surname>Vignuzzi</surname><given-names>M.</given-names></name></person-group><article-title>Arbovirus high fidelity variant loses fitness in mosquitoes and mice</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2011</year><volume>108</volume><fpage>16038</fpage><lpage>16043</lpage><pub-id pub-id-type="doi">10.1073/pnas.1111650108</pub-id><pub-id pub-id-type="pmid">21896755</pub-id><pub-id pub-id-type="pmcid">PMC3179076</pub-id></element-citation></ref><ref id="B224-microorganisms-09-00899"><label>224.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Plotkin</surname><given-names>S.A.</given-names></name></person-group><article-title>Vaccines: Past, present and future</article-title><source>Nat. Med.</source><year>2005</year><volume>11</volume><fpage>5</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1038/nm1209</pub-id><pub-id pub-id-type="pmcid">PMC7095920</pub-id><pub-id pub-id-type="pmid">15812490</pub-id></element-citation></ref><ref id="B225-microorganisms-09-00899"><label>225.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jang</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Byun</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Park</surname><given-names>E.S.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.H.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>J.H.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>K.H.</given-names></name><name name-style="western"><surname>Seong</surname><given-names>B.L.</given-names></name></person-group><article-title>Host defense mechanism-based rational design of live vaccine</article-title><source>PLoS ONE</source><year>2013</year><volume>8</volume><elocation-id>e75043</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0075043</pub-id><pub-id pub-id-type="pmid">24098364</pub-id><pub-id pub-id-type="pmcid">PMC3788757</pub-id></element-citation></ref><ref id="B226-microorganisms-09-00899"><label>226.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rossi</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Russell-Lodrigue</surname><given-names>K.E.</given-names></name><name name-style="western"><surname>Plante</surname><given-names>K.S.</given-names></name><name name-style="western"><surname>Bergren</surname><given-names>N.A.</given-names></name><name name-style="western"><surname>Gorchakov</surname><given-names>R.</given-names></name><name name-style="western"><surname>Roy</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Weaver</surname><given-names>S.C.</given-names></name></person-group><article-title>Rationally Attenuated Vaccines for Venezuelan Equine Encephalitis Protect Against Epidemic Strains with a Single Dose</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>497</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8030497</pub-id><pub-id pub-id-type="pmcid">PMC7563393</pub-id><pub-id pub-id-type="pmid">32887313</pub-id></element-citation></ref><ref id="B227-microorganisms-09-00899"><label>227.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Aaskov</surname><given-names>J.G.</given-names></name></person-group><article-title>Development of a candidate vaccine against Ross River virus infection</article-title><source>Vaccine</source><year>1994</year><volume>12</volume><fpage>1118</fpage><lpage>1124</lpage><pub-id pub-id-type="doi">10.1016/0264-410X(94)90182-1</pub-id><pub-id pub-id-type="pmid">7998422</pub-id></element-citation></ref><ref id="B228-microorganisms-09-00899"><label>228.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>A.K.</given-names></name><name name-style="western"><surname>Clennon</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Vazquez-Prokopec</surname><given-names>G.</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Frentiu</surname><given-names>F.D.</given-names></name><name name-style="western"><surname>Hafner</surname><given-names>L.M.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>W.B.</given-names></name><name name-style="western"><surname>Devine</surname><given-names>G.J.</given-names></name></person-group><article-title>Spatial and temporal patterns of Ross River virus in south east Queensland, Australia: Identification of hot spots at the rural-urban interface</article-title><source>BMC Infect. Dis.</source><year>2020</year><volume>20</volume><elocation-id>722</elocation-id><pub-id pub-id-type="doi">10.1186/s12879-020-05411-x</pub-id><pub-id pub-id-type="pmid">33008314</pub-id><pub-id pub-id-type="pmcid">PMC7530966</pub-id></element-citation></ref><ref id="B229-microorganisms-09-00899"><label>229.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jansen</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Shivas</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>May</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Pyke</surname><given-names>A.T.</given-names></name><name name-style="western"><surname>Onn</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Lodo</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hall-Mendelin</surname><given-names>S.</given-names></name><name name-style="western"><surname>McMahon</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Montgomery</surname><given-names>B.L.</given-names></name><name name-style="western"><surname>Darbro</surname><given-names>J.M.</given-names></name><etal/></person-group><article-title>Epidemiologic, Entomologic, and Virologic Factors of the 2014&#8211;2015 Ross River Virus Outbreak, Queensland, Australia</article-title><source>Emerg. Infect. Dis.</source><year>2019</year><volume>25</volume><fpage>2243</fpage><lpage>2252</lpage><pub-id pub-id-type="doi">10.3201/eid2512.181810</pub-id><pub-id pub-id-type="pmid">31742522</pub-id><pub-id pub-id-type="pmcid">PMC6874252</pub-id></element-citation></ref><ref id="B230-microorganisms-09-00899"><label>230.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pardi</surname><given-names>N.</given-names></name><name name-style="western"><surname>Hogan</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Porter</surname><given-names>F.W.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name></person-group><article-title>mRNA vaccines&#8212;A new era in vaccinology</article-title><source>Nat. Rev. Drug Discov.</source><year>2018</year><volume>17</volume><fpage>261</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.243</pub-id><pub-id pub-id-type="pmid">29326426</pub-id><pub-id pub-id-type="pmcid">PMC5906799</pub-id></element-citation></ref><ref id="B231-microorganisms-09-00899"><label>231.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hobernik</surname><given-names>D.</given-names></name><name name-style="western"><surname>Bros</surname><given-names>M.</given-names></name></person-group><article-title>DNA Vaccines&#8212;How Far From Clinical Use?</article-title><source>Int. J. Mol. Sci.</source><year>2018</year><volume>19</volume><elocation-id>3605</elocation-id><pub-id pub-id-type="doi">10.3390/ijms19113605</pub-id><pub-id pub-id-type="pmid">30445702</pub-id><pub-id pub-id-type="pmcid">PMC6274812</pub-id></element-citation></ref><ref id="B232-microorganisms-09-00899"><label>232.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reichmuth</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Oberli</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Jaklenec</surname><given-names>A.</given-names></name><name name-style="western"><surname>Langer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Blankschtein</surname><given-names>D.</given-names></name></person-group><article-title>mRNA vaccine delivery using lipid nanoparticles</article-title><source>Ther. Deliv.</source><year>2016</year><volume>7</volume><fpage>319</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.4155/tde-2016-0006</pub-id><pub-id pub-id-type="pmid">27075952</pub-id><pub-id pub-id-type="pmcid">PMC5439223</pub-id></element-citation></ref><ref id="B233-microorganisms-09-00899"><label>233.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwendener</surname><given-names>R.A.</given-names></name></person-group><article-title>Liposomes as vaccine delivery systems: A review of the recent advances</article-title><source>Ther. Adv. Vaccin.</source><year>2014</year><volume>2</volume><fpage>159</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1177/2051013614541440</pub-id><pub-id pub-id-type="pmid">25364509</pub-id><pub-id pub-id-type="pmcid">PMC4212474</pub-id></element-citation></ref><ref id="B234-microorganisms-09-00899"><label>234.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buschmann</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Carrasco</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Alishetty</surname><given-names>S.</given-names></name><name name-style="western"><surname>Paige</surname><given-names>M.</given-names></name><name name-style="western"><surname>Alameh</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>D.</given-names></name></person-group><article-title>Nanomaterial Delivery Systems for mRNA Vaccines</article-title><source>Vaccines</source><year>2021</year><volume>9</volume><elocation-id>65</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines9010065</pub-id><pub-id pub-id-type="pmid">33478109</pub-id><pub-id pub-id-type="pmcid">PMC7836001</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="microorganisms-09-00899-f001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Structure of the alphavirus E1-E2 heterodimer. Ribbon diagram (PDB: 3N41) highlighting (<bold>A</bold>) E1 glycoprotein (domain I: red, domain II: yellow, domain III: blue, fusion loop FL: orange, E2: grey) and (<bold>B</bold>) E2 glycoprotein (domain A: cyan, domain B: green, domain C: pink, beta-ribbons: purple, E1: grey). (<bold>C</bold>) Table summarizing reported antibody binding regions in the E1 and E2 glycoproteins of arthrogenic and neurotropic alphaviruses. Numbers in the table refer to in-text citations describing such binding sites (See Reference list). Background color matches protein doimains depicted in (<bold>A</bold>) and (<bold>B</bold>). To assess for the degree of conservation among common antigenic regions across alphaviruses a sequence aligment analysis was conducted (See <xref ref-type="app" rid="app1-microorganisms-09-00899">Supplementary Figure S1</xref>).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="microorganisms-09-00899-g001.jpg"/></fig><fig id="microorganisms-09-00899-f002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>An outline of the current vaccine options against arthritogenic (left panel) and neurotropic (right panel) alphaviruses. Most of these vaccine candidates are currently under preclinical testing (early preclinical&#8212;vaccine candidates tested in mouse models; late preclinical&#8212;vaccine candidates currently under testing in non-human primates (NHP)), while a minority of them are currently undergoing clinical trials (Phase 1, 2 or 3). LAV; live-attenuated virus; VLP, virus-like particle; SIN, Sindbis virus; ISFV, Isfahan virus; May, Mayaro virus; EILV, Eilat virus, VSV/VSIV, vesicular stomatitis virus; MV, measles virus; MVA, modified vaccinia virus Ankara. Data curated from literature reported through February 2021. Numbers in superscript refer to reference numbers (See Reference list [<xref rid="B23-microorganisms-09-00899" ref-type="bibr">23</xref>,<xref rid="B73-microorganisms-09-00899" ref-type="bibr">73</xref>,<xref rid="B114-microorganisms-09-00899" ref-type="bibr">114</xref>,<xref rid="B115-microorganisms-09-00899" ref-type="bibr">115</xref>,<xref rid="B116-microorganisms-09-00899" ref-type="bibr">116</xref>,<xref rid="B117-microorganisms-09-00899" ref-type="bibr">117</xref>,<xref rid="B118-microorganisms-09-00899" ref-type="bibr">118</xref>,<xref rid="B119-microorganisms-09-00899" ref-type="bibr">119</xref>,<xref rid="B120-microorganisms-09-00899" ref-type="bibr">120</xref>,<xref rid="B121-microorganisms-09-00899" ref-type="bibr">121</xref>,<xref rid="B122-microorganisms-09-00899" ref-type="bibr">122</xref>,<xref rid="B123-microorganisms-09-00899" ref-type="bibr">123</xref>,<xref rid="B124-microorganisms-09-00899" ref-type="bibr">124</xref>,<xref rid="B125-microorganisms-09-00899" ref-type="bibr">125</xref>,<xref rid="B126-microorganisms-09-00899" ref-type="bibr">126</xref>,<xref rid="B127-microorganisms-09-00899" ref-type="bibr">127</xref>,<xref rid="B128-microorganisms-09-00899" ref-type="bibr">128</xref>,<xref rid="B129-microorganisms-09-00899" ref-type="bibr">129</xref>,<xref rid="B130-microorganisms-09-00899" ref-type="bibr">130</xref>,<xref rid="B131-microorganisms-09-00899" ref-type="bibr">131</xref>,<xref rid="B132-microorganisms-09-00899" ref-type="bibr">132</xref>,<xref rid="B133-microorganisms-09-00899" ref-type="bibr">133</xref>,<xref rid="B134-microorganisms-09-00899" ref-type="bibr">134</xref>,<xref rid="B135-microorganisms-09-00899" ref-type="bibr">135</xref>,<xref rid="B136-microorganisms-09-00899" ref-type="bibr">136</xref>,<xref rid="B137-microorganisms-09-00899" ref-type="bibr">137</xref>,<xref rid="B138-microorganisms-09-00899" ref-type="bibr">138</xref>,<xref rid="B139-microorganisms-09-00899" ref-type="bibr">139</xref>,<xref rid="B140-microorganisms-09-00899" ref-type="bibr">140</xref>,<xref rid="B141-microorganisms-09-00899" ref-type="bibr">141</xref>,<xref rid="B142-microorganisms-09-00899" ref-type="bibr">142</xref>,<xref rid="B143-microorganisms-09-00899" ref-type="bibr">143</xref>,<xref rid="B144-microorganisms-09-00899" ref-type="bibr">144</xref>,<xref rid="B145-microorganisms-09-00899" ref-type="bibr">145</xref>,<xref rid="B146-microorganisms-09-00899" ref-type="bibr">146</xref>,<xref rid="B147-microorganisms-09-00899" ref-type="bibr">147</xref>,<xref rid="B148-microorganisms-09-00899" ref-type="bibr">148</xref>,<xref rid="B149-microorganisms-09-00899" ref-type="bibr">149</xref>,<xref rid="B150-microorganisms-09-00899" ref-type="bibr">150</xref>,<xref rid="B151-microorganisms-09-00899" ref-type="bibr">151</xref>,<xref rid="B152-microorganisms-09-00899" ref-type="bibr">152</xref>,<xref rid="B153-microorganisms-09-00899" ref-type="bibr">153</xref>,<xref rid="B154-microorganisms-09-00899" ref-type="bibr">154</xref>,<xref rid="B155-microorganisms-09-00899" ref-type="bibr">155</xref>,<xref rid="B156-microorganisms-09-00899" ref-type="bibr">156</xref>,<xref rid="B157-microorganisms-09-00899" ref-type="bibr">157</xref>,<xref rid="B158-microorganisms-09-00899" ref-type="bibr">158</xref>,<xref rid="B159-microorganisms-09-00899" ref-type="bibr">159</xref>,<xref rid="B160-microorganisms-09-00899" ref-type="bibr">160</xref>,<xref rid="B161-microorganisms-09-00899" ref-type="bibr">161</xref>,<xref rid="B162-microorganisms-09-00899" ref-type="bibr">162</xref>,<xref rid="B163-microorganisms-09-00899" ref-type="bibr">163</xref>,<xref rid="B164-microorganisms-09-00899" ref-type="bibr">164</xref>,<xref rid="B165-microorganisms-09-00899" ref-type="bibr">165</xref>,<xref rid="B166-microorganisms-09-00899" ref-type="bibr">166</xref>,<xref rid="B167-microorganisms-09-00899" ref-type="bibr">167</xref>,<xref rid="B168-microorganisms-09-00899" ref-type="bibr">168</xref>,<xref rid="B169-microorganisms-09-00899" ref-type="bibr">169</xref>,<xref rid="B170-microorganisms-09-00899" ref-type="bibr">170</xref>,<xref rid="B171-microorganisms-09-00899" ref-type="bibr">171</xref>,<xref rid="B172-microorganisms-09-00899" ref-type="bibr">172</xref>,<xref rid="B173-microorganisms-09-00899" ref-type="bibr">173</xref>,<xref rid="B174-microorganisms-09-00899" ref-type="bibr">174</xref>,<xref rid="B175-microorganisms-09-00899" ref-type="bibr">175</xref>,<xref rid="B176-microorganisms-09-00899" ref-type="bibr">176</xref>,<xref rid="B177-microorganisms-09-00899" ref-type="bibr">177</xref>,<xref rid="B178-microorganisms-09-00899" ref-type="bibr">178</xref>,<xref rid="B179-microorganisms-09-00899" ref-type="bibr">179</xref>,<xref rid="B180-microorganisms-09-00899" ref-type="bibr">180</xref>,<xref rid="B181-microorganisms-09-00899" ref-type="bibr">181</xref>,<xref rid="B182-microorganisms-09-00899" ref-type="bibr">182</xref>,<xref rid="B183-microorganisms-09-00899" ref-type="bibr">183</xref>,<xref rid="B184-microorganisms-09-00899" ref-type="bibr">184</xref>,<xref rid="B185-microorganisms-09-00899" ref-type="bibr">185</xref>,<xref rid="B186-microorganisms-09-00899" ref-type="bibr">186</xref>,<xref rid="B187-microorganisms-09-00899" ref-type="bibr">187</xref>,<xref rid="B188-microorganisms-09-00899" ref-type="bibr">188</xref>,<xref rid="B189-microorganisms-09-00899" ref-type="bibr">189</xref>,<xref rid="B190-microorganisms-09-00899" ref-type="bibr">190</xref>,<xref rid="B191-microorganisms-09-00899" ref-type="bibr">191</xref>,<xref rid="B192-microorganisms-09-00899" ref-type="bibr">192</xref>,<xref rid="B193-microorganisms-09-00899" ref-type="bibr">193</xref>,<xref rid="B194-microorganisms-09-00899" ref-type="bibr">194</xref>,<xref rid="B195-microorganisms-09-00899" ref-type="bibr">195</xref>,<xref rid="B196-microorganisms-09-00899" ref-type="bibr">196</xref>,<xref rid="B197-microorganisms-09-00899" ref-type="bibr">197</xref>,<xref rid="B198-microorganisms-09-00899" ref-type="bibr">198</xref>,<xref rid="B199-microorganisms-09-00899" ref-type="bibr">199</xref>,<xref rid="B200-microorganisms-09-00899" ref-type="bibr">200</xref>,<xref rid="B201-microorganisms-09-00899" ref-type="bibr">201</xref>,<xref rid="B202-microorganisms-09-00899" ref-type="bibr">202</xref>,<xref rid="B203-microorganisms-09-00899" ref-type="bibr">203</xref>,<xref rid="B204-microorganisms-09-00899" ref-type="bibr">204</xref>,<xref rid="B205-microorganisms-09-00899" ref-type="bibr">205</xref>,<xref rid="B206-microorganisms-09-00899" ref-type="bibr">206</xref>,<xref rid="B207-microorganisms-09-00899" ref-type="bibr">207</xref>,<xref rid="B208-microorganisms-09-00899" ref-type="bibr">208</xref>,<xref rid="B209-microorganisms-09-00899" ref-type="bibr">209</xref>,<xref rid="B210-microorganisms-09-00899" ref-type="bibr">210</xref>,<xref rid="B211-microorganisms-09-00899" ref-type="bibr">211</xref>,<xref rid="B212-microorganisms-09-00899" ref-type="bibr">212</xref>,<xref rid="B213-microorganisms-09-00899" ref-type="bibr">213</xref>,<xref rid="B214-microorganisms-09-00899" ref-type="bibr">214</xref>,<xref rid="B215-microorganisms-09-00899" ref-type="bibr">215</xref>,<xref rid="B216-microorganisms-09-00899" ref-type="bibr">216</xref>,<xref rid="B217-microorganisms-09-00899" ref-type="bibr">217</xref>,<xref rid="B218-microorganisms-09-00899" ref-type="bibr">218</xref>,<xref rid="B219-microorganisms-09-00899" ref-type="bibr">219</xref>,<xref rid="B220-microorganisms-09-00899" ref-type="bibr">220</xref>]).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="microorganisms-09-00899-g002.jpg"/></fig><table-wrap id="microorganisms-09-00899-t001" orientation="portrait" position="float"><object-id pub-id-type="pii">microorganisms-09-00899-t001_Table 1</object-id><label>Table 1</label><caption><p>List of vaccine candidates against relevant alphaviruses currently under development <sup>1</sup>.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Vaccine Against Virus</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Name</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Strain Vaccine Modelled After</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Phase</th><th colspan="3" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Immunization</th><th colspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" rowspan="1">Challenge</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Humoral Immune Response(s)</th><th rowspan="2" align="center" valign="middle" style="border-top:solid thin;border-bottom:solid thin" colspan="1">Ref</th></tr><tr><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dose</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Route</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Schedule</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dose (Strain, Genotype)</th><th align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Route</th></tr></thead><tbody><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Live-attenuated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV, ONNV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">RH-CHIKV<break/>EV-CHIKV<break/>RHEV-CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LR2006 OPY1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice, 3 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>6</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the ventral side of the right hind footpad</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>6</sup> PFU LR2006 OPY1 or WT-ONNV IMTSSA/5163, 3 mpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the ventral side of the right hind footpad</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC50, 613 (RH-CHIKV), 3407 (EV-CHIKV), 921 (RHEV-CHIKV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B130-microorganisms-09-00899" ref-type="bibr">130</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CHIKV</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">&#916;5nsP3 (VLA1553-301 in clinical trials) and &#916;6K</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LR2006 OPY1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice, 5 to 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> or 10<sup>5</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in both flanks</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>6</sup> PFU LR2006 OPY1, 7 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT50, 100 to 1000</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B131-microorganisms-09-00899" ref-type="bibr">131</xref>,<xref rid="B132-microorganisms-09-00899" ref-type="bibr">132</xref>,<xref rid="B133-microorganisms-09-00899" ref-type="bibr">133</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cynomolgus macaques, 3&#8211;4 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the right upper back side</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 AID50 (corresponding to 7000&#8211;10,000 PFU) LR2006 OPY1, 123 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.v.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT50, &gt;1000</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human clinical trial, Phase 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.2 &#215; 10<sup>3</sup>,<break/>3.2 &#215; 10<sup>4</sup> or 3.2 &#215; 10<sup>5</sup> TCID50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses (0 and 6 months, or 0 and 12 months)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GMT, 592.6 to 686.9</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV-NoLS</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LR2006 OPY1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice, 21 days of age</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU of LR2006 OPY1 or Ross River virus, 30 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&lt;10% cells infected at 10<sup>-1</sup> serum dilution</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B127-microorganisms-09-00899" ref-type="bibr">127</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Stop CHIKV<break/>SuperStop CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LR2006 OPY1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice, 5 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~5&#8211;25 (Stop CHIKV) and ~10&#8211;25 (SuperStop CHIKV) fold reduction compared to mock</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B134-microorganisms-09-00899" ref-type="bibr">134</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChikV HR</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">37997</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice, 28 days of age</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8764;10<sup>3</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. into the left footpad</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>3</sup> PFU CHIKV SL15649, 28 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the footpad</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT50, 5 to ~500</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B135-microorganisms-09-00899" ref-type="bibr">135</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Heparin sulfate cell culture adapted</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LR2006 OPY1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD-1 mice, 21 days old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> GE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the rear footpad</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>3</sup> PFU LR2006 OPY1, 21 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~40 to 1000 fold change compared to mock</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B136-microorganisms-09-00899" ref-type="bibr">136</xref>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">VEEV</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">V3526</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">IA/B Trinidad donkey</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c, 6 to 8 week oldC3H/HeN mice, 6 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> PFU of TrD, 28 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B137-microorganisms-09-00899" ref-type="bibr">137</xref>,<xref rid="B138-microorganisms-09-00899" ref-type="bibr">138</xref>,<xref rid="B139-microorganisms-09-00899" ref-type="bibr">139</xref>,<xref rid="B140-microorganisms-09-00899" ref-type="bibr">140</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cynomolgus macaques (age not specified)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5 &#215; 10<sup>6</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8764;10<sup>8</sup> PFU VEEV IE 68U201, 8 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">aerosol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 28 to 2560</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rhesus macaques (2 to 4 years old)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.3 &#215; 10<sup>5</sup> or 7.5 &#215; 10<sup>4</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. or i.t./i.s.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, ~80 to 300</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human clinical trial, Phase 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 or 125 PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">VEEV</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">V4020</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">IA/B Trinidad donkey</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c mice, 4 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU of VEEV TrD, 28 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 160 to1280</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B141-microorganisms-09-00899" ref-type="bibr">141</xref>,<xref rid="B142-microorganisms-09-00899" ref-type="bibr">142</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cynomolgus macaques (age not specified)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~10<sup>4</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the right leg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose (or second dose at 2 x 10<sup>4</sup> PFU i.m. if did not seroconvert)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>6</sup> to 10<sup>7</sup> PFU of the VEEV TrD, 73 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">aerosol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, &gt;640</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5&#8242;U4&amp;6 C65-69 E71-77 3&#8242;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-nucleotide" xlink:href="U11337">U11337</ext-link> mutants</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FL93-939</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD-1 mice, 5 to 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.5 &#215; 10<sup>5</sup> GE</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in footpad, or i.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> PFU EEEV FL93, 21 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in both footpads</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 16 to ~4000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B143-microorganisms-09-00899" ref-type="bibr">143</xref>]</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Live-attenuated (IRES)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CHIKV</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CHIKV/IRES</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LR2006 OPY1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A129 mice, 3 or 10 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.d.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 PFU LR2006 OPY1, 94 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.d.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, &gt;320</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B144-microorganisms-09-00899" ref-type="bibr">144</xref>,<xref rid="B145-microorganisms-09-00899" ref-type="bibr">145</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice, 3 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the hind leg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>6.5</sup> PFU Ross CHIKV, 21 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean PRNT80, 62</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A129 mice, 8 to 10 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> TCID50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 PFU LR2006 OPY1, 50 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.d.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean PRNT80, 1152</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cynomolgus macaques, &gt;3 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. or i.d.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> PFU LR2006 OPY1, 52 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the upper deltoid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 40 to 640PRNT50, 160 to 1280</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ONNV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV/IRES</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LR2006 OPY1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A129 mice, 6 to 7 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.d.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> PFU ONNV SG650, 38 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.d.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 160</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B146-microorganisms-09-00899" ref-type="bibr">146</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">VEEV</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ZPC/IRESv1, ZPC/IRESv2</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ID ZPC738</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD-1 mice, 6 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the scruff of the back</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> PFU VEEV 3908, 4 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. or aerosol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 40 to 324</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B114-microorganisms-09-00899" ref-type="bibr">114</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cynomologous macaques, age not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the upper deltoid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~ 8 &#215; 10<sup>5</sup> to 9 &#215; 10<sup>6</sup> PFU VEEV 3908, 35 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">aerosol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, &lt;20 to 20PRNT50, &lt;20 to 160</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EEE/IRES</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FL93-939</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NIH Swiss mice, 3 to 4 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the medial thigh</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>3</sup> PFU of FL93-939, 4 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.p.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 160 to 640</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B147-microorganisms-09-00899" ref-type="bibr">147</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">VEEV</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">68U201/IRESv1 68U201/IRESv2</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">IE 68U201</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD1 mice, 6 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in right hind leg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">(Lethal dose, NP) 68U201 at 1, 3, or 12 mpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 64 to ~300</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B148-microorganisms-09-00899" ref-type="bibr">148</xref>,<xref rid="B149-microorganisms-09-00899" ref-type="bibr">149</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cynomolgus macaques (age not specified)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the upper deltoid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 &#215; 10<sup>4</sup> PFU VEEV IE 68U201, 49 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">aerosol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, ~100 to 340</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEEV/IRES/C</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IA/B Trinidad donkey</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD-1 mice, 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU of VEEV 3908, 6 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean PRNT80, 184</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B150-microorganisms-09-00899" ref-type="bibr">150</xref>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">MAYV</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">MAYV/IRES</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">MAYV-CH</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c, 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 &#215; 10<sup>5</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. i.pl. route</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 &#215; 10<sup>5</sup> PFU of WT MAYV, 28 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. i.pl. route</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT50, &gt;640 (at 21dpi)</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B146-microorganisms-09-00899" ref-type="bibr">146</xref>,<xref rid="B151-microorganisms-09-00899" ref-type="bibr">151</xref>,<xref rid="B152-microorganisms-09-00899" ref-type="bibr">152</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AG129</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 &#215; 10<sup>4</sup>, 2 &#215; 10<sup>3</sup> or 2 &#215; 10<sup>2</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. i.pl. route</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 &#215; 10<sup>3</sup> PFU of WT MAYV, 14 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. i.pl. route</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD-1, 28-day old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. over the dorsum</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 160 to &#8805; 640</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AG129, 5 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.d. on the left foot</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU of WT MAYV, 29 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 320 to &#8805; 640</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Inactivated</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Vero cell adapted</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DRDE-06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Swiss albino mice, 3 to 4 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10, 25 or 50 ug</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three doses (0, 14 and 28 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT90, 6400</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B153-microorganisms-09-00899" ref-type="bibr">153</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CHIKV</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">BPL/formalin-inactivated CHIKV<break/>BBV87 (in clinical trials)</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">IND-06-AP3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c mice, 4 to 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10, 20 or 50 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses (0 and 14 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5 x 10<sup>4</sup> TCID50 IND-06-AP3, 4 or 22 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GMT, NT50, 80 to 1280</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B154-microorganisms-09-00899" ref-type="bibr">154</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human clinical trial, Phase 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10, 20 or 30 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three doses (0, 29 and 57 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B155-microorganisms-09-00899" ref-type="bibr">155</xref>]</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">RRV</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Vero cell culture-derived whole-virus RRV vaccine Ross River Virus (RRV) Vaccine</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">T48</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD-1 mice, 7 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.0025, 0.01, 0.039, 0.156, 0.625, 2.5 or 10 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses (0 and 28 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>6</sup> TCID50 RRV T48, 42 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.v.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean NT, &#8804;2.9 to 46.2</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B73-microorganisms-09-00899" ref-type="bibr">73</xref>,<xref rid="B115-microorganisms-09-00899" ref-type="bibr">115</xref>,<xref rid="B128-microorganisms-09-00899" ref-type="bibr">128</xref>,<xref rid="B129-microorganisms-09-00899" ref-type="bibr">129</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A129 mice, 7 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.063, 0.25 or 1 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses (0 and 21 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>2.5</sup> TCID50 T48, 42 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. into left footpad</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mean NT, &#8804;14 to 21</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD-1 mice, age not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses (0 and 28 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>6</sup> TCID50 T48, 6 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.v.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1000 TCID50</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Guinea pigs (Duncan Hartley), age not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single or two doses (0 and 6 weeks)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>6</sup> TCID50 T48, 10 or 34 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.v.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NP</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human clinical trial, Phase 1/2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.25, 2.5, 5, or 10 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three doses in escalation (0, 21 days, 6 months)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GMT, 50 to 520.9</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human clinical trial, Phase 3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5 ug</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three doses (0, 3 weeks, 6 months)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#956;NT GMT, ~0 to 85</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TSI-GSD-104 (formalin inactivated)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
PE-6
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human clinical trial, Phase 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. (0 and 28 days), i.d. (6 months)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three doses (0, 28 days and 6 months)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80 &gt;40 in 60% subjects (primary doses) versus 84% subjects (completed the 2-dose primary series and the 6-month dose)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B156-microorganisms-09-00899" ref-type="bibr">156</xref>,<xref rid="B157-microorganisms-09-00899" ref-type="bibr">157</xref>,<xref rid="B158-microorganisms-09-00899" ref-type="bibr">158</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">fCVEV1219<break/>iCVEV1219<break/>gCVEV1219</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CVEV1219</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c mice, 6 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1 to 5 &#181;g of inactivated EEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.n., s.c. or i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose or two doses (0 and 28 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Lethal dose of EEEV FL93-939, at 28 dpim (single dose) or 56 dpim (two doses)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">aerosol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, ~1 to 1000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B159-microorganisms-09-00899" ref-type="bibr">159</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V3526 virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V3526</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c mice, 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.2 &#956;g (s.c.) or 0.04 &#956;g (i.m.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. or i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses (0 and 28 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU VEEV TrD, 56 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">aerosol or s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GMT PRNT80, ~60 to 2500</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B160-microorganisms-09-00899" ref-type="bibr">160</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">F-iV3526</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">V3526</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c mice, 8 to 10 weeks old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1, 3 or 5 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.n., s.c. (under the skin over the neck) or i.m. (thigh muscle of the hind leg)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">454 (i.n.), 897 (i.m.) or 55 (s.c.) PFU VEEV-TrD, 56 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">aerosol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Microneutralization titer of 100 to 3500</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B161-microorganisms-09-00899" ref-type="bibr">161</xref>,<xref rid="B162-microorganisms-09-00899" ref-type="bibr">162</xref>]</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Virus-like particle</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CHIKV</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">VRC 311<break/>Or<break/>VRC-CHKVLP059-00-VP/ PXVX0317 (in clinical trials)</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">37997</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c mice, 6 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">19 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 doses (2 and 5 weeks)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC50, 10703 to 54600</td><td rowspan="5" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B116-microorganisms-09-00899" ref-type="bibr">116</xref>,<xref rid="B117-microorganisms-09-00899" ref-type="bibr">117</xref>,<xref rid="B118-microorganisms-09-00899" ref-type="bibr">118</xref>,<xref rid="B163-microorganisms-09-00899" ref-type="bibr">163</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cynomolgus macaques, 3 to 4 years old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 doses (0, 4 and 24 weeks)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>10</sup> PFU LR2006 OPY1, 15 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.v.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC50, 10219 to 15072</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human clinical trial, Phase 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10, 20 or 40 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 doses (0, 4 and 24 weeks)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC50, 4525 to 8745</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human, clinical trial Phase 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 doses (0 and 28 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EC50 GMT, 2005</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human clinical trial (Phase 2b, recruitment completed)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6, 10 or 20 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses (0 and 14 or 28 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CHIKV</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Baculovirus-expressed VLP</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">S27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AG129, 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 doses (0 and 21 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1000 TCID50 S27, 6 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.p.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT95, 40 to 80</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B164-microorganisms-09-00899" ref-type="bibr">164</xref>,<xref rid="B165-microorganisms-09-00899" ref-type="bibr">165</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice, 6 to 12 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1 or 1 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> CCID<sub>50</sub> LR2006 OPY1, 6 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT95, ~1,100</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Yeast-expressed VLP</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DRDE06/DRDE07</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c mice, 4 week or 2 days old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10, 20 or 40 ug</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three doses (0, 14 and 28 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT50, 128 to 2048</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B166-microorganisms-09-00899" ref-type="bibr">166</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Venezuelan Equine Encephalitis Monovalent Virus-Like Particle Vaccine (VEEV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human clinical trial (Phase 1, not recruiting)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2, 10, or 20 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dose escalation (0, 28 days, and day 140 booster)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B167-microorganisms-09-00899" ref-type="bibr">167</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">WEEV, EEEV, and VEEV</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">VRC-WEVVLP073-00-VP (Trivalent vaccine)</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
WEEV CBA87, EEEV PE-6 and VEEV TC-83
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c mice, 6 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">monovalent (5 &#956;g) or trivalent (5 &#956;g each)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses (0 and 21 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2.5 &#215; 10<sup>3</sup> PFU WEEV CBA87, 8.9 &#215; 10<sup>3</sup> PFU EEEV FL93-939, and 1.3 &#215; 10<sup>3</sup> PFU VEEV Trinidad donkey, 56 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">aerosol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, ~250 to 100000</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B168-microorganisms-09-00899" ref-type="bibr">168</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cynomolgus macaques, age not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Monovalent (20 &#956;g) or trivalent (20 &#956;g each)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses (0 and 28 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>6</sup> PFU WEEV CBA87, 10<sup>8</sup> PFU EEEV FL93-939, and 10<sup>8</sup> VEEV Trinidad donkey, 56 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">aerosol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, ~1000 to 10000</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human clinical trial, Phase 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6, 30 or 60 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dose escalation (0 and 8 weeks)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B169-microorganisms-09-00899" ref-type="bibr">169</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA/RNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">VEEV</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">VEEV 26S DNA plasmid</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">I/AB TrD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c mice, 6 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8764;3 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA/gene gun, delivered to two sites on the abdomen of each mouse</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three doses (at 3-week intervals)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8764;10<sup>4</sup> PFU of TrD, 9 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c., aerosol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT50, GMT &lt;1.6 to 2.5</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B170-microorganisms-09-00899" ref-type="bibr">170</xref>,<xref rid="B171-microorganisms-09-00899" ref-type="bibr">171</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Hartley guinea pigs, age not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~5 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA/gene gun, delivered to two sites on the abdomen of each mouse</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three doses (0, 4 and 8 weeks)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8764;10<sup>4</sup> PFU of TrD, 21 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">aerosol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT50, 0 to 640</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DNA-Ad</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TC-83</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c mice, 6 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 &#956;g of DNA per dose and 107 PFU of RAd/VEEV #3 per boost</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">gene guni.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">immunised with the DNA vaccines on day 0, 14 and 28 and Ad-based vaccine on day 42</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 LD50 of virulent airborne VEEV, 63 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">aerosol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT50, 160</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B172-microorganisms-09-00899" ref-type="bibr">172</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AG4-1C7<break/>AG4-1G2 AG2-5A7<break/>AG2-5A10 plasmid DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">I/AB TrD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c mice, 6 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">particle-mediated epidermal delivery (i.d.)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three doses (at 3-week intervals)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8764;10<sup>4</sup> PFU of VEEV TrD (&#8805;1000 LD50), 70 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">aerosol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, ~1 to 5.5 log<sub>10</sub> GMT</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B173-microorganisms-09-00899" ref-type="bibr">173</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pTC83 iDNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TC-83</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c mice, 3 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m. electroporation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> PFU VEEV 3908, 21 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 10 to 320</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B174-microorganisms-09-00899" ref-type="bibr">174</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pE3-E2-6K-E1<break/>pE3-E2<break/>P6K-E1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">71V-1658</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c, age not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">gene gun</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three doses (14 days apart)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1500 PFU WEEV 71V-1658,<break/>Fleming, or CBA87, 42 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B175-microorganisms-09-00899" ref-type="bibr">175</xref>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CHIKV</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">pCHIKV-Capsid, pCHIKV-Envelope (pMCE321)</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Consensus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice, 3 to 4 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 &#181;g, 2&#8211;3 times</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Electroporation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses (2 weeks apart)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B176-microorganisms-09-00899" ref-type="bibr">176</xref>,<xref rid="B177-microorganisms-09-00899" ref-type="bibr">177</xref>,<xref rid="B178-microorganisms-09-00899" ref-type="bibr">178</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice, 6 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m. electroporation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three doses (0, 14 and 21 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7log<sub>10</sub> PFU of PC-08, 35 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NP</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c mice</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m. electroporation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses (2 weeks apart)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">7log<sub>10</sub> PFU PC-08</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TCID50, 20 to 320</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Rhesus macaques, age not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m. electroporation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three doses (4 weeks apart)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TCID50, 80 to 1280</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#916;5nsP3 and &#916;6K DNA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LR2006 OPY1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice, 5 to 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">20 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.d. with DermaVax electroporation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose or two doses (0 and 3 weeks)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>6</sup> PFU LR2006 OPY1, 7 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT50, 100 to 10000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B131-microorganisms-09-00899" ref-type="bibr">131</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CHIKV</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CHIKV-NoLS RNA</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LR2006 OPY1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice, 28 days of age</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the ventral/lateral side of the right foot</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU LR2006 OPY1, 30 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the ventral/lateral side of the right (ipsilateral) or left (contralateral)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 0</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B126-microorganisms-09-00899" ref-type="bibr">126</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AG129 mice, 28 days old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the ventral/lateral side of the right foot</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU LR2006 OPY1, 30 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the ventral/lateral side of the right (ipsilateral) or left (contralateral)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEEV, WEEV and EEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3-EEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEEV IAB TrD, WEEV CBA874 and EEEV FL91-46794</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice, 6 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">15 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m. electroporation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses (0 and 21 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU VEEV IAB TrD or 2 &#215; 10<sup>4</sup> PFU WEEV CBA874 or 105 PFU EEEV FL91-46794, 7 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">aerosol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, ~1 to 1000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B179-microorganisms-09-00899" ref-type="bibr">179</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">MAYV</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">scMAYV-E</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice, 5 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m. electroporation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single, two doses or three doses (at 2 week intervals)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT50, 789.8</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B180-microorganisms-09-00899" ref-type="bibr">180</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A129 mice, 4 to 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m. electroporation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single, two doses or three doses (at 2 week intervals)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>2</sup> PFU MAYV 15537</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.p.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">p181/25-7</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TSI-GSD-28</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c mice, 3 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m. electroporation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 &#215; 10<sup>6</sup> PFU CHIKV Ross, 28 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 160 to 1280</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B181-microorganisms-09-00899" ref-type="bibr">181</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">dMaB</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c mice, age not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Electroporation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>7</sup> PFU Del-03</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. or i.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IC50, 3 to 4.5log<sub>10</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B182-microorganisms-09-00899" ref-type="bibr">182</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">iRNA&#916;5nsP3<break/>iDNA&#916;5nsP3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LR2006 OPY1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice, 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.125, 1.25 or 10 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m. in the gastrocnemius muscle of the left hind leg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>6</sup> PFU LR2006 OPY1, 5 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. at the dorsal side of each hind foot</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT50, ~1 to 10<sup>4</sup></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B183-microorganisms-09-00899" ref-type="bibr">183</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pMG4020 DNA plasmid</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TC-83</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c, 4 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5 or 5 ug</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m. electroporation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU VEEV TrD, 28 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 320 to &gt;1280</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B141-microorganisms-09-00899" ref-type="bibr">141</xref>]</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">VEEV</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">VEEV<sub>WT</sub> VEEV<sub>COCAP</sub><break/>VEEV<sub>CO</sub></td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">IAB TrD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c, 6 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25, 5, or 1 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m. electroporation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses (3 weeks apart)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8764;10<sup>4</sup> PFU VEEV IAB strain TrD, 7 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">aerosol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 1 to ~4.5log<sub>10</sub></td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B184-microorganisms-09-00899" ref-type="bibr">184</xref>,<xref rid="B185-microorganisms-09-00899" ref-type="bibr">185</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">New Zealand White rabbits, age not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">500 &#956;g of VEEV<sub>CO</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m. electroporation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three doses (0, 28 and 230 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, ~3log<sub>10</sub> to 5log<sub>10</sub></td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cynomolgus macaques, age not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50 or 500 &#956;g of VEEV<sub>CO</sub></td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m. electroporation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses (0 and 56 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 &#215; 10<sup>8</sup> PFU VEEV IAB TrD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">aerosol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, ~0.8log<sub>10</sub> to 3.5log10</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human clinical trial, Phase 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5 or 2 mg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m. electroporation or i.d. electroporation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three doses (days 0, 28, and 56)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">GMT PRNT80, 7 to 78</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">pVHX-671V-1658<break/>pVHX-6 CBA87<break/>pVHX-6 Fleming</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Fleming, CBA 87 or 71V-1658,</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c mice, age not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 shots &#215; 2.5 &#956;g precipitated on 0.5 mg gold</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">gene gun</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Four doses (2 weeks apart)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.5 &#215; 10<sup>3</sup> PFU WEEV Fleming, CBA 87 or 71V-1658, 8 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B186-microorganisms-09-00899" ref-type="bibr">186</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEEV and EEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LANAC E1ecto</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEEV McMillan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD-1 mice, 4 to 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. injection dorsal to the cervical spine</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses (2 weeks apart)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU WEEV McMillan, Montana-64, or EEEV Florida-93, 4, 5, 9, 11, or 13 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.n. or s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT50, &lt;40 to 200</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B187-microorganisms-09-00899" ref-type="bibr">187</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">mRNA-1388 (or VAL-181388 in clinical trials)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human clinical trial, Phase 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">25, 50 or 100 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dose escalation procedure (0 and 4 weeks)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">&#8216;dose-dependent increase&#8217; in neutralizing and binding antibody titers</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B188-microorganisms-09-00899" ref-type="bibr">188</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CHIKV</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">mRNA-1944</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">
SL15649
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AG129, age not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.4, 1 or 10 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.v. tail vein injection</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>2.5</sup> TCID50 of CHK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">subcutaneous injection in the footpad and hock of the right leg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B189-microorganisms-09-00899" ref-type="bibr">189</xref>,<xref rid="B190-microorganisms-09-00899" ref-type="bibr">190</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cynomolgus macaques, 2 to 3 year old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.5 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.v.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">FRNT50, 5 to 12</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human clinical trial, Phase 1 (active, not recruiting)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">0.1, 0.3 and 0.6 mg/kg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.v.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dose escalation</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT50, &#8216;all participants also showed circulating neutralizing antibody activity&#8217;</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Subunit</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV-sE1 and -sE2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">S27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AG129 mice, 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses (0 and 21 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1000 TCID50 of S27 isolate, 9 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.p.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT95, &lt;25</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B164-microorganisms-09-00899" ref-type="bibr">164</xref>,<xref rid="B165-microorganisms-09-00899" ref-type="bibr">165</xref>,<xref rid="B191-microorganisms-09-00899" ref-type="bibr">191</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rE2p</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IND-06-AP3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c, 6 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10, 20 or 50 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses (2 weeks apart)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Mice immunized with 50 &#956;g challenged with 7 log10 TCID50 /mL, 4 or 22 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT50, 0.25log10 to 2.5log10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B154-microorganisms-09-00899" ref-type="bibr">154</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKE1 and CHIKE2 recombinant proteins</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">DRDE-06</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">40 &#956;g</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three doses (0, 21 and 35 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT90, 32 to 512</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B192-microorganisms-09-00899" ref-type="bibr">192</xref>]</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Chimeric virus</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Measles virus-based chimeras</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CHIKV (VLP)</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">MV-CHIKV</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">06&#8211;49</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD46-IFNAR, 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>3</sup> to 10<sup>5</sup> TCID50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.p.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single or two doses (30 days apart)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 PFU of CHIKV 06-49, 2 mpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.p.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT50, 450 to 4050<break/>PRNT90, 50 to 450</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B193-microorganisms-09-00899" ref-type="bibr">193</xref>,<xref rid="B194-microorganisms-09-00899" ref-type="bibr">194</xref>,<xref rid="B195-microorganisms-09-00899" ref-type="bibr">195</xref>,<xref rid="B196-microorganisms-09-00899" ref-type="bibr">196</xref>,<xref rid="B197-microorganisms-09-00899" ref-type="bibr">197</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cynomolgus macaques, age not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 &#215; 10<sup>5</sup> (&#177; 0.5 log) TCID50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses (28 days apart)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.4 &#215; 10<sup>5</sup> PFU LR2006 OPY1, 56 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 40 to &gt;640</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human clinical trial, Phase 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.5 &#215; 10<sup>4</sup>, 7.5 &#215; 10<sup>4</sup> or 3.0 &#215; 10<sup>5</sup> TCID50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m. or s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dose escalation (0 and 28 days, or 0 and 90 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT50, 5 to 433</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human clinical trial, Phase 2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 &#215; 10<sup>4</sup> or 5 &#215; 10<sup>5</sup> TCID50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three doses (0, 28, and 196 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT50, ~5 to 5000</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Alphavirus-based chimeras</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEE/CHIKV<break/>EEE/CHIKV<break/>SIN/CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LR2006 OPY1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NIH Swiss, C57BL/6, &gt;3 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.8 log<sub>10</sub> PFU (VEE/CHIKV and SIN/CHIKV), 5.3 log<sub>10</sub> PFU (EEE/CHIKV)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the medial thigh</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6.5 log<sub>10</sub> PFU (Ross CHIKV strain), 21 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 20 to 320</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B198-microorganisms-09-00899" ref-type="bibr">198</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEE/IRES-CHIKV<break/>VEE/IRES-C/CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">A129 mice, 6 to 9 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>2</sup> PFU of LR2006 OPY1, 5 weeks post immunization</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, &gt;640</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B199-microorganisms-09-00899" ref-type="bibr">199</xref>]</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CHIKV</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EILV-CHIKV</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CHIKV 996659</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice, 4 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.8 log<sub>10</sub> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 log<sub>10</sub> PFU 99659, 30 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.d.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, &#8805; 80</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B125-microorganisms-09-00899" ref-type="bibr">125</xref>,<xref rid="B220-microorganisms-09-00899" ref-type="bibr">220</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">IFN&#945;/&#946;R&#8722;/&#8722;, 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.8 log<sub>10</sub> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3 log<sub>10</sub> PFU 99659, 292 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.d.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 160 to 1280</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Cynomolgus macaques, 3 to 5 years</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">8.1 log<sub>10</sub> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m. into the right quadriceps</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 log<sub>10</sub> PFU LR2006 OPY1, 31 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 80 to 640</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EILV/EEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EEEV FL-93</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adult CD-1 mice (age not specified)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>8</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> PFU EEEV-FL93, 70 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.p.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 80 to 640</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B125-microorganisms-09-00899" ref-type="bibr">125</xref>,<xref rid="B220-microorganisms-09-00899" ref-type="bibr">220</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trivalent EILV/EEEV EILV/VEEV EILV/CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EEEV FL-93, VEEV IAB TC-83, CHIKV 996659</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adult CD-1 mice (age not specified)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>8</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>5</sup> PFU EEEV-FL93, 70 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.p.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 40 to 640 and 20 to 640 for mono- and trivalent vaccines respectively</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EILV/EEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEEV IAB TC-83</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adult CD-1 mice (age not specified)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>8</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>3</sup> PFU VEEV-IC 3908, 70 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 80 to 1280</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Trivalent EILV/EEEV, EILV/VEEV EILV/CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EEEV FL-93, VEEV IAB TC-83, CHIKV 996659</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Adult CD-1 mice (age not specified)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>8</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>3</sup> PFU VEEV-IC 3908, 70 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 40 to 640 and 20 to 80 for mono- and trivalent vaccines respectively</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">EEEV (Sindbis virus)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SIN/NAEEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EEEV FL93-939</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NIH Swiss mice, 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.7, 4.7 or 5.7 log<sub>10</sub> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 log<sub>10</sub> PFU FL93-939, 28 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.p.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 125 to 660</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B200-microorganisms-09-00899" ref-type="bibr">200</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SIN/SAEEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EEEV BeAr436087</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NIH Swiss mice, 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.8, 4.8 or 5.8 log<sub>10</sub> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">6 log<sub>10</sub> PFU FL93-939, 28 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.p.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 28 to 308</td></tr><tr><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">VEEV</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">SIN-83</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">VEEV IAB TC-83</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Weanling NIH Swiss mice, 6 day old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>3</sup>, 10<sup>4</sup>, 10<sup>5</sup> or 10<sup>6</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>6</sup> PFU VEEV IC ZPC738 IC SH3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.in medial thigh</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 30 to 960</td><td rowspan="6" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B201-microorganisms-09-00899" ref-type="bibr">201</xref>,<xref rid="B202-microorganisms-09-00899" ref-type="bibr">202</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NIH Swiss mice, 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 &#215; 10<sup>5</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 x 10<sup>5</sup> or 10<sup>6</sup> PFU VEEV ZPC738, 8 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c., i.c., or i.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 55 to 73 (single), 100 to 160 (booster)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SAAR/TRD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEEV IAB TrD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NIH Swiss mice, 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 &#215; 10<sup>5</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 x 10<sup>5</sup> or 10<sup>6</sup> PFU VEEV ZPC738, 8 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c., i.c., or i.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 126 to 167 (single), 152 to 160 (booster)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SIN/TRD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEEV IAB TrD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NIH Swiss mice, 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 &#215; 10<sup>5</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 x 10<sup>5</sup> or 10<sup>6</sup> PFU VEEV ZPC738, 8 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c., i.c., or i.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 37 to 57 (single), 50 to 73 (booster)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SIN/ZPC</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEEV ID ZPC738</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NIH Swiss mice, 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 &#215; 10<sup>5</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">2 x 10<sup>5</sup> or 10<sup>6</sup> PFU VEEV ZPC738, 8 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c., i.c., or i.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 187 to 253 (single), 253 to 487 (booster)</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">All the above</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEEV IAB TC-83, IAB TrD, ID ZPC738</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Syrian golden hamsters, 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 &#215; 10<sup>5</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the medial thigh</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>6</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.in medial thigh</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td></tr><tr><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">WEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SIN/CO92</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEEV CO92-1356</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NIH Swiss mice, 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">3.5, 4.5, or 5.0 log<sub>10</sub> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the medial thigh</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.3 log<sub>10</sub> PFU WEEV TBT235, 28 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 20 to 640</td><td rowspan="3" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B203-microorganisms-09-00899" ref-type="bibr">203</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SIN/SIN/McM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEEV McMillan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NIH Swiss mice, 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.8 or 5.8 log<sub>10</sub> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the medial thigh</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.0 log<sub>10</sub> PFU WEEV McMillan, 28 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 600 to 604</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">SIN/EEE/McM</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EEEV 436087 and WEEV McMillan</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NIH Swiss mice, 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">4.6 or 5.6 log<sub>10</sub> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the medial thigh</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5.0 log<sub>10</sub> PFU WEEV McMillan, 28 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 416 to 420</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Vaccinia virus-based chimeras</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MVA-CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LR2006-OPY1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice, 6 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>7</sup> PFU (first dose), 2 &#215; 10<sup>7</sup> PFU (second dose)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.p.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses (2 weeks apart)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>6</sup> PFU LR2006-OPY1, 9 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the dorsal side of each hind foot</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT50, ~100 to 3000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B204-microorganisms-09-00899" ref-type="bibr">204</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">CHIKV</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">MVA-CHIK</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">LR2006-OPY1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c mice, 4 to 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>7</sup> TCID50 units</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.d. injection into the left hind footpad.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single or two doses (28 days apart)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup><break/>LR2006 OPY1 TCID50 units at 39 or 42 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.d.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TCID50, 5 to 15</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B205-microorganisms-09-00899" ref-type="bibr">205</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AG129, 6 to 10 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>7</sup> TCID50 units</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.d. injection into the left hind footpad.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single or two doses (28 days apart)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>2</sup><break/>LR2006 OPY1 TCID50 units at 39 or 42 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.d.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">TCID50, 4 to 8</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MVA-6KE1, MVA-E3E2, MVA-6KE1E3E2</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
CHIKV S27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AG129 mice, 7 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 &#215; 10<sup>6</sup> TCID50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m. into the quadriceps muscles of the left leg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses (3 weeks apart)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>3</sup><break/>TCID50 CHIKV-S27 and CHIKV-IND/NL10, 63 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.p.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT100, 10 to 160</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B206-microorganisms-09-00899" ref-type="bibr">206</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EEEV, VEEV, and WEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MVA-BN-E/V/W (monovalent)<break/>MVA-BN-E + MVA-BN-V + MVA-BN-W (triple mixture of monovalent vaccines)<break/>MVA-BN-WEV (trivalent)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEEV 71 V-1658, EEEV FL93-939NA and VEEV TrD</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c mice, age not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>8</sup> TCID50</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. or i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses (28 days apart)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 &#215; 10<sup>3</sup> or 10<sup>4</sup> PFU of WEEV Fleming, EEEV PE6, or VEEV TrD, 14 days post booster</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT50, ~750 to 3800 (monovalent), ~&lt;60 to 340 (triple mixture of monovalent vaccines) and ~&lt;60 to 380 (trivalent)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B207-microorganisms-09-00899" ref-type="bibr">207</xref>]</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Adenovirus-based chimeras</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CAdVax-CHIK</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">LR2006 OPY1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD-1 or C57BL/6, 6 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>8</sup> IU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.p.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> CCID50 LR2006 OPY1 or QIMR, 6.5 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. into side of each hind foot towards the ankle</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT100, ~2000</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B208-microorganisms-09-00899" ref-type="bibr">208</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">ChAdOx1 Chik<break/></td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c, 6 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>8</sup> IU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NT50, 5.39 &#215; 10<sup>3</sup></td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B209-microorganisms-09-00899" ref-type="bibr">209</xref>,<xref rid="B210-microorganisms-09-00899" ref-type="bibr">210</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AG129, 5 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>8</sup> IU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m. in each leg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.7 &#215; 10<sup>4</sup> PFU LR2006 OPY1, 30 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.d. into the left foot</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChAdOx1 Chik<break/>ChAdOx1 Chik &#916;Cap</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AG129, 5 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>8</sup> IU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m. in each hind leg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">9.7 &#215; 10<sup>4</sup> PFU of LR2006 OPY1, 30 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.d. into the left foot towards the ankle</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 32 to 64 (Chik), 16 to 32 (Chik &#916;Cap)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B211-microorganisms-09-00899" ref-type="bibr">211</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIK001 (in clinical trials)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Human clinical trial, Phase 1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5 &#215; 10<sup>9</sup>, 2.5 &#215; 10<sup>10</sup> or 5 &#215; 10<sup>10</sup> vp</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B212-microorganisms-09-00899" ref-type="bibr">212</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">MAYV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ChAdOx1 May</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">AG129, 5 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.6 &#215; 10<sup>4</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m. in each leg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.6 &#215; 10<sup>4</sup> PFU MAYV-CH, 30 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.d. into the left foot</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT50, 160 to 620</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B210-microorganisms-09-00899" ref-type="bibr">210</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">VEEV</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">Rad/VEEV#3</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">VEEV IAB TC-83</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c, 6 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>7</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three doses (at 0, 7 and 21 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Dose ND, 28 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">aerosol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT50 (NP)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B213-microorganisms-09-00899" ref-type="bibr">213</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c, 6 to 8 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>7</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Two doses (at 0, 21 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">5000 LD50 TrD, 42 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">aerosol</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">ND</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B214-microorganisms-09-00899" ref-type="bibr">214</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ad5-WEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEEV 71V-1658</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c mice, age not specified</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>7</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single or two doses (at 4 weeks)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">1.5 &#215; 10<sup>3</sup> PFU Fleming or 71V-1658, 13 wpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT50, 160</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B215-microorganisms-09-00899" ref-type="bibr">215</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Ad5-E1</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">WEEV 71V-1658</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">BALB/c mice, 6 to 9 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>7</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m. in both leg</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">50 LD50 of 71V-1658, 7 dpim, or<break/>400 LD50 CBA87, 1, 3, 5 or 7 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.n.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT50, &lt;10</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B216-microorganisms-09-00899" ref-type="bibr">216</xref>]</td></tr><tr><td colspan="4" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Vesiculovirus-based chimeras</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rVSV&#916;G-CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV S27</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6, 3 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>6</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m. into the right hind leg muscle</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU LR 2006 OPY1, 30 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the left rear footpad</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 80 to 640</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B217-microorganisms-09-00899" ref-type="bibr">217</xref>]</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rVSIV-VEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">VEEV ZPC738</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD-1, 4 to 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>8</sup>/10<sup>7</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU VEEV ZPC738, 35 or 245 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 288 to 600 at 25 and 35 dpim, 304 to 360 at 245 dpim</td><td rowspan="4" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">[<xref rid="B218-microorganisms-09-00899" ref-type="bibr">218</xref>]</td></tr><tr><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">VEEV</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">rISFV-VEEV</td><td rowspan="2" align="center" valign="middle" style="border-bottom:solid thin" colspan="1">VEEV ZPC738</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD-1, 4 to 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>8</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU VEEV ZPC738, 28 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, &#8805;20</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD-1, 4 to 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>8</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU VEEV ZPC738, 35 or 245 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, 40 to 160 at 25 and 35 dpim, 25 to 64 at 245 dpim</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">rISFV-EEEV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">EEEV FL93-939</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CD-1, 4 to 6 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>8</sup> PFU</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">i.m.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Single dose</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>4</sup> PFU EEEV FL93-939, 28 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c.</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">PRNT80, &#8805;20</td></tr><tr><td colspan="2" align="center" valign="middle" style="border-bottom:solid thin" rowspan="1">Epitope-based</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">
</td></tr><tr><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">CHIKV</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">E2EP3</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">NA</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">C57BL/6 mice, 3 week old</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">100 &#956;g (50 &#956;g for booster doses)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. in the abdominal flank</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">Three doses (0, 14 and 21 days)</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">10<sup>6</sup> PFU CHIKV SGP11, 30 dpim</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">s.c. region at the ventral side of the right hind footpad, towards the ankle</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">~40% reduction from mock control</td><td align="center" valign="middle" style="border-bottom:solid thin" rowspan="1" colspan="1">[<xref rid="B23-microorganisms-09-00899" ref-type="bibr">23</xref>]</td></tr></tbody></table><table-wrap-foot><fn><p><sup>1 </sup>s.c., subcutaneous; i.v., intravenous; i.m., intramuscular; i.d., intradermal; i.p., intraperitoneal; i.n., intranasal; i.t./i.s., intrathalamic/ intraspinal; i.pl., intraplantar; i.c., intracranial; dpim, days post immunization; wpim, weeks post immunization; mpim, months post immunization; IRES, internal ribosome entry site; PFU, plaque forming units; TCID50, 50% tissue culture infective dose; CCID50, 50% cell culture infectious dose; IC50, 50% inhibitory concentration; GE, genomic equivalents; IU, infectious units; AID50, 50% animal infectious dose; PRNT50, 50% plaque reduction neutralizing antibody titer; PRNT80, 80% plaque reduction neutralizing antibody titer; PRNT90, 90% plaque reduction neutralizing antibody titer; LD50, median lethal dose; NT50, 50% neutralizing titer; GMT, geometric mean titer; &#956;NT, neutralizing titer; SIN, Sindbis virus; ISFV, Isfahan virus; May, Mayaro virus; EILV, Eilat virus, VSV/VSIV, vesicular stomatitis virus; MV, measles virus; MVA, modified vaccinia virus Ankara; NP, not provided; NA, not applicable; WT, wild type. Data curated from literature reported through February 2021.</p></fn></table-wrap-foot></table-wrap></floats-group></article></pmc-articleset>